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DIABETES MELLITUS AND THE METABOLIC SYNDROME 
 
Diabetes mellitus is an endocrine disorder, characterized by a chronic elevation of 
blood glucose levels (hyperglycemia). Type 1 diabetes mellitus (less than 10% of all 
diabetes mellitus cases) is caused by an immune mediated destruction of the β-
cells resulting in an absolute insulin deficiency. This is the most prevalent form 
among children and adolescents. In individuals with type 2 diabetes (DM2), 
hyperglycemia is caused by a combination of an impairment of the beta-cells to 
release sufficient insulin (β-cell dysfunction) and an impaired metabolic response of 
peripheral tissues to circulating insulin (insulin resistance) [1,2]. Deficient action of 
insulin on target tissues, either due to insulin resistance or insulin deficiency, not 
only leads to hyperglycemia, but also to other metabolic abnormalities, including 
abnormalities in fasting and postprandial lipid metabolism (dyslipidemia). 
Dyslipidemia associated with DM2 is characterized by hypertriglyceridemia, low 
high-density lipoprotein (HDL)-cholesterol, and small and dense low-density 
lipoprotein (LDL) particles, which are more atherogenic than the more buoyant 
forms [3-5].  
 
In 1988, Reaven described the insulin resistance syndrome or syndrome X [6], now 
called the metabolic syndrome. It was originally defined by the presence of 
hyperinsulinemia (compensatory for the underlying insulin resistance), varying 
degrees of glucose tolerance, hypertriglyceridemia and low plasma HDL cholesterol 
concentration [6]. Remarkably, obesity or waist circumference was not part of the 
original definition. In the most common working definition, as proposed by the 
Adult Treatment Panel III of the National Cholesterol Education Program (NCEP) for 
reasons of unification and clinical utility, the metabolic syndrome is characterized 
by central obesity, hypertriglyceridemia, low plasma HDL-cholesterol, hypertension 
and dysglycemia, i.e. impaired fasting glucose [7]. 
 
The prevalence of diabetes has increased substantially over the last decades. An 
estimated 30 million people worldwide had diabetes in 1985. For the year 2000, 
the World Health Organization has estimated the number of cases of adults with 
diabetes to be 171 million and the total number is projected to rise to 366 million 
by the year 2030 [8]. The most important factors contributing to this increase in 
prevalence are ageing of the population and, in particular, the increasing 
prevalence of obesity [9].  
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Among individuals with DM2, the cardiovascular disease (CVD) morbidity and 
mortality is two to four times higher compared to individuals with normal glucose 
metabolism and the CVD mortality in individuals with DM2 accounts for as much as 
75% of all deaths [10,11]. In the Reykjavik Study, a population-based study with 
over 18000 elderly participants, the relative impact of elevated glucose, 
triglycerides and systolic blood pressure with regard to fatal and non-fatal CHD was 
higher in women than in men [11]. In premenopausal women non-HDL cholesterol 
concentrations are lower than in age-matched men, whereas the reverse is true 
after menopause [12]. Indeed, postmenopausal women have higher fasting and 
postprandial triglyceride levels [13], higher total cholesterol [14,15] and smaller 
LDL particles [16], as compared to premenopausal women. This higher relative CVD 
risk and the paucity of studies in postmenopausal women prompted us to perform 
the postprandial studies described in this thesis in postmenopausal women.  
 
DETERMINANTS OF CARDIOMETABOLIC RISK  
 
New determinants of cardiometabolic risk 
 
There are several conventional risk factors that can explain part of the excess CVD 
risk in individuals with DM2. These include high LDL cholesterol, low HDL 
cholesterol, hypertension, smoking, hyperglycemia, and high triglyceride 
concentrations [17,18]. However, these risk factors, only explain part of the 
increased CVD risk in individuals with DM2 [18]. For that reason additional risk 
factors or determinants have been explored that might contribute to the excess 
CVD risk in individuals with DM2. These include, but are not limited to, 
postprandial dysmetabolism [19,20], endothelial dysfunction [21], low-grade 
inflammation, non-alcoholic fatty liver disease [22], oxidative stress [23,24], and 
advanced glycation end-products [25]. These additional potential determinants are 
introduced in the next sections. A risk determinant is defined as a variable that is 
directly or indirectly associated with outcome, regardless of the postulated 
causality. In case of a risk factor, the association with outcome is presumed to be 
causal and in case of a risk predictor, the variable predicts the outcome without 
necessarily conveying causality. A risk marker reflects not only the presence of a 
risk factor but also some form of susceptibility of the organism to the detrimental 
effects of this risk factor. A risk marker is associated with the disease (statistically) 
but need not be causally linked and it may be a measure of the disease process 
itself [26]. 
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Postprandial glucose and triglycerides 
 
Both fasting triglycerides and glucose are established risk factors of CVD in 
individuals with and without DM2. A meta-regression analysis of 20 studies with 
more than 95 000 people demonstrated a continuous relationship of plasma 
glucose levels with incident CVD events [27], and a meta-analyses in over 57 000 
individuals of 17 studies found that fasting triglyceride levels were associated with 
CVD, also when adjusted for HDL-cholesterol [28]. However, a number of studies 
suggest that postprandial or post-load glucose and postprandial triglyceride 
concentrations are more strongly associated with some of the CVD risk factors and 
mortality than the respective fasting values [29-31]. They debate the causal role of 
postprandial glucose in relation to CVD [32], versus simply reflecting the 
underlying metabolic abnormalities in for example lipid metabolism. It has also 
been suggested that the relation between hyperglycemia and CVD is mediated by 
oxidative stress [33]. Ceriello et al. showed a cumulative effect of postprandial 
hyperglycemia and postprandial hypertriglyceridemia on oxidative stress 
generation in subjects with DM2 [34]. Indeed, specific meal components, such as 
fat and carbohydrates may exert acute effects on endothelial function [35], and 
enhance the production of reactive oxygen species, which may also contribute to 
CVD risk [36]. However, the relative contributions and mechanisms of postprandial 
glucose levels and postprandial triglyceride levels with respect to atherosclerosis 
and CVD risk are not yet clarified [32,37].  
 
Endothelial functions and dysfunctions 
 
The vascular endothelium is a large autocrine, paracrine and endocrine organ, and 
plays an important role in the regulation of vascular homeostasis [21,38,39]. The 
normal, healthy endothelium synthesizes and releases numerous substances in 
response to a myriad of diverse chemical and physical stimuli. These factors are 
important in maintaining and regulating vascular homeostasis, including vascular 
tone, smooth muscle cell proliferation, inflammation, and coagulation and 
fibrinolysis [40,41]. Endothelium derived nitric oxide (NO) is a key molecule in the 
regulation of endothelial functions. NO is synthesized by a stereo-specific reaction 
from L-arginine by the enzyme nitric oxide synthase (eNOS) [42,43]. Shear stress 
increases the expression of eNOS, whereas asymmetrical dimethylarginine (ADMA) 
is an inhibitor of eNOS [44]. The produced NO diffuses through the endothelial cell 
membrane into the adjacent smooth muscle cells, and activates soluble guanylate 
cyclase, that converts guanosine triphospate (GTP) to cyclic 3’5’-guanosine 
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monophophate (cGMP) [45], which ultimately decreases intracellular calcium levels 
leading to relaxation of the smooth muscle cells and causing vasodilatation. In 
addition, NO also inhibits platelet adherence and aggregation, leukocyte adhesion 
and proliferation of smooth muscle cells [46]. A disturbance of the endothelial 
regulatory mechanisms may lead to endothelial dysfunctioning, which can be 
defined as the loss of one or more of these functions [47]. Dysfunctioning of the 
vascular endothelium is recognized to be an early step in the development of 
atherosclerosis [48-51]. Endothelial function is difficult to assess. An optimal 
methodology for studying endothelial function does not exist. Over the last 
decades, multiple biochemical markers and invasive and non-invasive tests have 
been introduced.  
 
A number of biochemical markers have been identified that reflect endothelial 
(dys)function, including soluble adhesion molecules, E-selectin and von Willebrand 
factor (vWF). The soluble adhesion molecules, intercellular adhesion molecule 1 
(ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) facilitate endothelial 
adhesion of circulation leukocytes. These molecules are not endothelium specific; 
also other cell types including smooth muscle cells and monocytes express them. 
The expression of ICAM-1 and VCAM-1 is increased in response to inflammatory 
cytokines [52]. Higher plasma concentrations of VCAM-1 and ICAM-1 have been 
reported in DM2 [53,54]. E-selectin is specifically expressed by stimulated 
endothelial cells and exposed on their surface. The soluble form of E-selectin may 
result from shedding of damaged or activated endothelial cells [55]. High plasma 
levels of E-selectin have been observed in obese individuals [56], in hypertensive 
patients [57] and in individuals with DM2 [58].  Von Willebrand factor (vWF) is an 
endothelial ligand for platelet glycoproteins and is endothelium specific. In case of 
endothelial cell injury vWF is released. Major CVD risk factors, including smoking 
[59], hypertension [60] and DM2 [61] are associated with increased plasma levels of 
vWF. In addition, vWF is a predictor of CVD morbidity and mortality [62,63]. 
 
A non-invasive method for measuring endothelial function using high-resolution 
vascular ultrasound was first described by Celermajer and colleagues [64]. In this 
procedure, the arterial diameter of the brachial artery is subsequently measured in 
rest, during reactive hyperemia (leading to flow mediated vasodilatation (FMD), an 
endothelium-dependent response) and following sublingual administration of 
nitroglycerin (an endothelium independent, nitroglycerin mediated dilatation, 
NMD). The responses during reactive hyperemia are measured after a temporary 
(usually 4 to 5 minutes) occlusion of the brachial artery using a cuff placed on the 
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forearm [65,66]. FMD is expressed as (percentual) change in diameter after the 
stimulus. A higher FMD reflects a “better” endothelial function. [67]. One of the 
principal mediators of the FMD response is endothelium-derived NO [68]. The 
brachial FMD is closely correlated to coronary endothelial function [46], and 
impaired FMD predicts future cardiovascular events [69,70].  
 
Oxidative stress and advanced glycation end-products 
 
Numerous studies have identified hyperglycemia as an important risk factor in the 
development of diabetic complications (reviewed in [71]), and several mechanisms 
have been proposed [72,73]. These included, but were not limited to altered 
lipoprotein metabolism, oxidative stress, dicarbonyl stress, and glycation reactions. 
Glycation is the non-enzymatic reaction of glucose and other reducing sugars with 
amino groups of proteins. The amino groups of the side chains of arginine and 
lysine are the primary targets for this type of posttranslational modification. Over 
time, the initial glycation products undergo intramolecular rearrangements and 
oxidation reactions (glycoxidation) and ultimately transform into stable so-called 
advanced glycation end-products (AGEs) (Figure 1.1). AGE-modification of proteins 
can alter or limit their functional or structural properties, which ultimately can lead 
to tissue damage as seen in age-related pathologies and diabetes. AGE formation is 
promoted by high concentrations of sugars, including glucose, and α-oxoaldehydes 
(e.g. 3-deoxyglucosone, methylglyoxal and glyoxal) and enhanced by oxidative 
stress [74]. The mechanisms linking hyperglycemia to micro- and macrovascular 
complications overlap and interact with each other, e.g. AGE formation and 
carbonyl stress may lead to oxidative stress and oxidative stress may enhance AGE 
formation [75].  
 
Low-grade inflammation 
 
The insulin resistant state is accompanied by (systemic) low-grade inflammation. 
The proinflammatory cytokines include interleukin-6 (IL-6) and tumor necrosis 
factor-α (TNF-α). They induce attraction of inflammatory cells and the production of 
acute-phase proteins, including C-reactive protein (CRP), by the liver. IL-6 is a 
pleiotropic cytokine, required to control the extent of local and systemic 
inflammatory responses [76]. IL-6 is increased in hypertension [77], obesity [78], 
DM2 [79], and non-alcoholic fatty liver disease (NAFLD) [80]. IL-6 is positively 
associated with CVD risk in individuals without DM2 [81]. 
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Figure 1.1. Pathways for the formation of advanced glycation end-products (AGE) and AGE-
precursors (adapted from: Thorpe SR, Baynes JW. Amino Acids 2003;25:275-281.) 
 
C-reactive protein (CRP) is an acute phase protein, which is produced by the liver 
and is widely used as an indicator of low-grade inflammation. The synthesis of CRP 
is largely mediated by cytokines, in particular by IL-6. CVD risk factors that increase 
CRP concentrations include obesity [82], hypertension [77], dyslipidemia [83], and 
DM2 [83,84]. Some [85], but not all studies [80], have demonstrated an association 
of CRP with NAFLD. CRP concentrations are higher in individuals with CVD as 
compared to those without CVD. In addition, CRP is positively associated with risk 
of CVD, both in patients with DM2 [86,87] and in individuals without DM2 [88]. A 
more classical and clinical marker of (low-grade) inflammation is the blood 
leukocyte count, which is also associated with CVD events [89,90]. The exact role 
of leukocytes in the pathogenesis of CVD is not yet fully elucidated. Postprandial 
recruitment and activation of these cells have been suggested to contribute to 
endothelial dysfunction [91]. Myeloperoxidase (MPO) is a heme protein which is 
abundantly expressed in leukocytes, and released upon activation into phagocytic 
vacuoles and in the extra cellular space [92,93], and is regarded as maker of low-
grade systemic inflammation [94]. Several in vitro and in vivo studies have shown 
that MPO may interact with the vessel wall by various mechanisms including 
binding and transcytosis through endothelial cells, and inflicts damage by 
hypochlorous acid generation, nitric oxide oxidation and tyrosine nitration [95]. 
MPO has been associated with recurrent coronary events [96], and endothelial 
dysfunction [97]. 
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Non-alcoholic fatty liver disease and liver enzymes 
 
NAFLD includes a wide spectrum of liver pathology, ranging from fatty liver alone 
to the more severe non-alcoholic steatohepatitis. It usually has a benign clinical 
course, but it may progress to steatohepatitis, fibrosis, and cirrhosis and ultimately 
to liver failure. NAFLD resembles alcohol-induced liver disease, but develops in 
subjects who are not heavy alcohol consumers and have negative tests for viral and 
autoimmune liver diseases [98-102]. This condition was first described in detail by 
Ludwig and colleagues in 1980, who reported 20 moderately obese patients with 
liver biopsy changes resembling alcohol induced hepatitis, although none of these 
patients reported a history of alcohol abuse [103]. Only in recent years, NAFLD has 
gained appreciation as a pathogenic factor of insulin resistance and DM2. In 
addition, several studies have shown an association between NAFLD and features of 
the metabolic syndrome, including dyslipidemia and (visceral) obesity, stressing the 
association with insulin resistance as an important feature of NAFLD. Currently, 
NAFLD is considered by some authors to be the hepatic component of the 
metabolic syndrome [104,105]. In the majority of cases, NAFLD causes 
asymptomatic elevation of liver enzyme levels (including alanine aminotransferase 
[ALT], aspartate aminotransferase and γ-glutamyltransferase) [106]. Of these liver 
enzymes, ALT is most closely related to liver fat accumulation [107], and 
consequently ALT has been used as a marker of NAFLD.  
 
The exact mechanisms leading to hepatic triglyceride accumulation are not 
completely understood. Insulin resistance is an early important mechanism leading 
to an increased free fatty acid (FFA) influx into the liver [108,109], contributing to 
hepatic triglyceride accumulation. In addition, the hepatic FFA pool is increased by 
de novo lipogenesis [110]. The quantitative importance of the contribution of the 
de novo lipogenesis to the hepatic fat pool is disputed. Hyperinsulinemia in 
combination with a high FFA flux and hyperglycemia are known to up-regulate 
lipogenic transcription factors. In addition, pathways that decrease the hepatic FFA 
pool, i.e. both FFA oxidation and efflux of lipids from the liver are impaired. The 
increased availability of FFA, glucose and insulin contribute to the increase of 
malonyl-CoA by stimulating acetyl-CoA carboxylase that converts acetyl-CoA to 
malonyl-CoA. Malonyl-CoA is an inhibitor of carnitine palmitoyl transferase 1 (CPT-
1), required to transport FFA into the mitochondria. The inhibition of CPT-1 
prevents FFA oxidation and facilitates accumulation and re-esterification of long-
chain fatty-acyl CoA and subsequent formation of triglycerides [111].  
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Evidence is accumulating that patients with NAFLD have an increased risk to 
develop CVD, but the mechanisms linking NAFLD to CVD are not yet fully 
understood. 
 
HOW DO THE VARIOUS CARDIOMETABOLIC RISK DETERMINANTS 
RELATE TO EACH OTHER?  
 
The interrelationship of the above mentioned cardiometabolic determinants with 
respect to CVD risk is complex. In particular it is not yet possible to infer any 
causality for any of these new risk markers. Indeed, NAFLD may be a cause or a 
consequence of the metabolic syndrome and postprandial dysmetabolism may 
contribute to the development and progression of NAFLD, but also, once a fatty 
liver has evolved, postprandial dysmetabolism may aggravate, especially in patients 
with DM2. These cardiometabolic determinants are likely to interact and contribute 
to the enhanced CVD risk in patients with DM2 and/or individuals with the 
metabolic syndrome. A better understanding of these interrelationships and their 
relative contribution to CVD is of importance to design strategies, which will lower 
CVD risk in populations at risk. 
 
AIMS AND OUTLINE OF THE THESIS  
 
This thesis is divided into two parts.  
 
Part 1 (Chapters 2 to 5) presents the results of studies assessing the responses to 
two consecutive fat-rich or carbohydrate-rich meals on the (apo)lipoproteins and 
glucose and to study mechanisms that link postprandial glucose and triglyceride 
levels to CVD risk in patients with DM2 and individuals with normal glucose 
metabolism.  
 
Part 2 (Chapters 6 to 9) focuses on ALT as a marker for NAFLD in relation to CVD, 
the metabolic syndrome and DM2.  
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ABSTRACT 
 
Background: Both postprandial hyperglycemia and hypertriglyceridemia have been 
identified as risk markers for cardiovascular disease. However, the determinants of 
the magnitude of postprandial triglyceride and glucose responses are largely 
unknown. The objective was to assess potential determinants of postprandial 
glucose and triglyceride responses following two consecutive meals in women with 
normal glucose metabolism (NGM) and with type 2 diabetes (DM2). 
 
Methods: Post-menopausal women, 76 with NGM and 41 with DM2, received two 
consecutive fat-rich meals and carbohydrate-rich meals on separate occasions. 
Blood samples were taken before and at t=1, 2, 4, 6 and 8 hours following 
breakfast; lunch was given at t=4h.  
 
Results: In NGM women, fasting triglycerides, HbA1c, total cholesterol, and, 
inversely, HDL-cholesterol were independently associated with TG-iAUC, and age 
and fasting triglycerides were independently associated with glucose-iAUC (GL-
iAUC). In women with DM2, fasting triglycerides were independently associated 
with TG-iAUC while HbA1c and fasting glucose were stronger than fasting 
triglycerides associated with GL-iAUC. GL-iAUC and TG-iAUC were associated with 
each other in women with DM2, but not in NGM. 
 
Conclusions: In conclusion, GL-iAUC and TG-iAUC were correlated with each other 
in women with DM2 and fasting triglycerides were associated with GL-iAUC and TG-
iAUC. These findings suggest a common underlying mechanism for postprandial 
increments in glucose and triglycerides, especially occurring in women with DM2. 
In healthy women, elevated TG-iAUC may be part of a dyslipidemic lipid profile, 
whereas the relation between fasting triglycerides and GL-iAUC is suggestive for an 
association with insulin resistance. 
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INTRODUCTION 
 
Already in 1979, Zilversmit postulated that atherogenesis might be a postprandial 
phenomenon [1]. Since then, both postprandial hyperglycemia and 
hypertriglyceridemia have been identified as risk markers for cardiovascular 
disease (CVD) [2,3]. Glucose values two hours following an oral glucose tolerance 
test (OGTT) have been shown to be better indicators of CVD risk than fasting 
glucose concentration in the general population [4]. We recently demonstrated that 
postprandial glucose levels were stronger than the fasting levels, associated with 
carotid intima-media thickness in women with normal glucose metabolism (NGM) 
[5]. Others have shown that postprandial hypertriglyceridemia is more strongly 
related to carotid intima-media thickness than the fasting triglyceride levels [6,7].  
The determinants of these postprandial glucose and triglyceride responses are not 
well known but might, at least in part, overlap. However, the possible determinants 
of postprandial triglyceride and glucose concentrations have not been described in 
a single study population before. To date, most studies used a single, often 
artificially composed liquid fat and/or carbohydrate load to assess postprandial 
responses. Since a first meal can affect the glucose and triglyceride response to a 
second meal, we chose to apply two consecutive meals [8,9]. Postmenopausal 
women were invited for the present study because in these women, postprandial 
triglyceride responses have been shown to be elevated [10], and type 2 diabetes 
(DM2) was shown to confer a higher relative risk for CVD as compared to men [11].  
 
In light of the above considerations, we assessed associations of clinical and 
biochemical variables with postprandial triglyceride and glucose day profiles in 
postmenopausal women with NGM and DM2, in order to investigate whether 
postprandial hypertriglyceridemia and hyperglycemia are the result of a similar 
underlying mechanism.  
 
SUBJECTS AND METHODS 
 
Study population  
 
The study population has been described in detail previously [5]. In brief, women 
with DM2 were randomly selected from the registry of the Diabetes Care System in 
the city of Hoorn, the Netherlands. Women with NGM were randomly selected from 
the municipal registry of the city of Hoorn. All women were between 50 and 65 
years of age, were post-menopausal, non-smokers, had no untreated endocrine 
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disorder other than DM2, did not use HMG-CoA reductase inhibitors, short acting 
insulin analogues, peroxisome proliferator-activated receptor-α and/or γ agonists, 
oral corticosteroids, or hormone replacement therapy. Women without known DM2 
underwent an OGTT and were selected on NGM status (fasting glucose <6.1, 2-hour 
post-load glucose <7.8 mmol/L [13]). Women with DM2 were excluded if they had 
HbA1c >9.0%. Of the 1,063 women who were invited, a total of 431 of the women 
were total non-responders and 258 women were unwilling to participate. A total of 
257 women did not meet the inclusion criteria.  
 
Finally, 76 women with NGM and 41 women with DM2 completed the study 
protocol. All women gave written informed consent. The study was approved by the 
ethics committee of the VU University Medical Center, Amsterdam, the Netherlands. 
 
Measurements 
 
The study consisted of a screening visit and two separate visits for the test-meals 
with a minimum interval of one week and a maximum interval of one month 
between visits. On the screening visit, blood samples were drawn after a 12-h 
overnight fast to determine levels of HbA1c, plasma glucose, total cholesterol, 
triglycerides, alanine aminotransferase (ALT) and creatinine. Women who were 
selected from the municipal registry underwent an OGTT.  
 
Blood pressure was measured at the left upper arm three times with 5 minutes 
intervals using an oscillometric blood pressure measuring device (Collin Press-mate 
BP-8800, Colin, Komaki-City, Japan) after a 15-minute supine rest. Weight and 
height were measured twice in barefooted participants wearing light clothes only. 
BMI was calculated as weight (in kg) divided by the square of height (in m). Waist 
circumference was measured twice at the level midway between the lowest rib 
margin and the iliac crest, and hip circumference was measured at the widest level 
over the greater trochanters. Medical history, medication, (former) smoking and 
alcohol use were assessed by a questionnaire [14]. Finally, habitual physical activity 
was assessed by the Short Questionnaire to Assess Health-enhancing physical 
activity of which reproducibility and relative validity were described previously [15].  
On the second and the third visit, women arrived at the test facility in the morning 
after an overnight fast. They had abstained from exercise 24 hours before the 
study visit. Blood samples were taken before (twice) and at t=1, t=2, t=4, t=6 and 
t=8 hours after ingestion of the first test meal. The second test meal was given at 
t=4 hour, immediately after the blood sample was taken. 
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Test meal composition 
 
Postprandial meal responses were examined following the consumption of two 
standardized test meals (breakfast and lunch) on two separate occasions, either 
with a high fat content or a high carbohydrate content. The fat-rich and the 
carbohydrate-rich occasions were performed in random order. Each portion of the 
ingredients was weighed before the meal was prepared. The nutrient composition 
of the meals was calculated from the Dutch Food Composition Tables [16]. The fat-
rich meals (both breakfast and lunch) consisted of 2 croissants, 10 g of butter, 40 
g of fat-rich cheese and 300 ml of fat-rich milk (3349 kJ; 50 g fat; 56 g 
carbohydrates and 28 g proteins). The carbohydrate-rich meals (both breakfast and 
lunch) consisted of 2 slices of bread, 25 g of marmalade, 30 g of cooked chicken 
breast, 50 g of ginger bread and 300 ml of drinkable yogurt enriched with 45 g of 
soluble sugars (3261 kJ; 4 g fat, 162 g carbohydrates and 22 g of proteins). Both 
meals were eaten within 10 minutes. Apart from the test meals and water (ad 
libitum), participants refrained from food and drinks. In addition, physical activity 
was limited during the day. 
 
Laboratory analysis 
 
All laboratory analyses were performed at the VU University Medical Center 
(department of Clinical Chemistry) in Amsterdam, the Netherlands. Serum total 
cholesterol, HDL-cholesterol and triglycerides were measured by enzymatic 
colorimetric assays (Roche, Mannheim, Germany). LDL-cholesterol was calculated 
according to the Friedewald-formula [17]. ALT was determined by an enzymatic 
assay (Roche, Mannheim, Germany) according to the methods proposed by the 
International Federation of Clinical Chemistry and Laboratory Medicine [18]. Plasma 
glucose concentration was determined with a glucose oxidase method (Granutest, 
Merck, Darmstadt, Germany) and HbA1c was measured with cation-exchange 
chromatography (Menarini Diagnostics, Florance, Italy). The inter-assay coefficients 
of variation for the triglyceride and glucose measurements were <1.8% and <2.2%, 
respectively. Immunospecific insulin was measured in serum by an immunometric 
assay in which proinsulin does not cross-react (ACS Centaur, Bayer Diagnostics, 
Mijdrecht The Netherlands). The inter- and intra-assay coefficients of variation for 
insulin were 6% and 3%, respectively. 
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Statistical analyses 
 
Analyses were performed by SPSS for Windows 10 (SPSS Inc. Chicago, IL). Data are 
presented as mean values (standard deviation), percentage or, in case of skewed 
distribution, as median values (interquartile range) unless otherwise indicated. 
Differences in characteristics between NGM and DM2 were tested with t-test for 
continuous variables and with χ2-test for dichotomous variables. Postprandial 
responses were calculated as incremental area under the curve (iAUC) with the 
trapezoid method. Missing values for a given time-point (0.5% of all the glucose 
and triglyceride values) were imputed by interpolation. Insulin resistance was 
estimated by homeostasis model assessment (HOMA-IR), calculated as (mean 
fasting insulin(mU/mL)*mean fasting glucose(mmol/L))/22.5 [19]. Mean glucose 
and insulin concentrations were derived from fasting measurements on two 
separate study days. To study the associations of possible determinants of 
postprandial triglyceride and glucose responses, linear regression analysis was 
performed with adjustment for age. As dependent variables, postprandial 
triglycerides (iAUC) after the fat-rich meals and postprandial glucose concentrations 
(iAUC) after the carbohydrate-rich meals were used. The associations were 
expressed as standardized regression coefficients (95% CI) by dividing the 
dependent and independent variables by the SD derived from the entire study 
population. A regression coefficient of 0.5 means that if the independent variable 
increases by 1.0 SD, the dependent variable increases by 0.5 SD. Multivariate 
models included age and all variables that were associated with the outcome 
variables at level P < 0.10. For all other analysis, we considered a two-sided P-value 
<0.05 to indicate statistical significance. 
 
RESULTS 
 
Characteristics of the study population 
 
Clinical and biochemical characteristics of the participants are listed in Table 1. 
Figure 1 shows the 8h-time courses of triglyceride and glucose concentrations 
following two consecutive fat-rich and two consecutive carbohydrate-rich meals. 
Triglyceride-iAUC (TG-iAUC) after the fat-rich meals was similar in the two groups 
(P=0.33) (Table2). Following the carbohydrate-rich meals, TG-iAUC was most 
marked in women with DM2 compared to NGM women (P=0.01). As expected, 
glucose-iAUC (GL-iAUC) and insulin-iAUC after the fat-rich and the carbohydrate-rich 
meals was most marked in the women with DM2 (All P<0.01). 
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Table 2.1. Clinical and biochemical characteristics of the 117 participants a 
 NGM DM2 
N 76 41 
Age (years) 60.1 (4.0) 58.9 (3.7) 
Duration of DM2 (years) NA 5 (3-9) 
Anthropometry    
      BMI (kg/m2)  26.3 (3.6) 32.7 (6.0) b 
      Waist (m)   0.88 (0.10) 1.04 (0.14) b 
       Hip (m) 1.04 (0.08) 1.12 (0.12) b 
Glucose metabolism    
      HbA1c (%) 5.6 (0.3) 6.6 (0.6) b 
      Fasting insulin (pmol/L) c 33.2 (25.5-47.5) 82.7 (38.8-122.5) b 
      HOMA-IR c 1.29 (0.94-1.95) 4.05 (1.92-7.07) b 
Lipids (mmol/L)   
      Total cholesterol 6.0 (0.9) 5.6 (1.0) 
      HDL-cholesterol 1.80 (0.49) 1.51 (0.34) b 
      LDL-cholesterol 3.7 (0.9) 3.2 (1.0) b 
Blood pressure (mmHg)   
      Systolic 131 (15) 143 (16) b 
      Diastolic 72 (8) 79 (7) b 
Liver enzyme (U/L)   
      Alanine aminotransferase 20 (16-26) 27 (20-40) b 
Medication (%)   
     Antihypertensive medication 16 66 b 
     Blood glucose lowering medication NA 71 
     Use of insulin  NA 17 
Lifestyle    
      Former smoking (%) 49 39 
      Habitual physical activity (h/week) 35 (23-46) 35 (22-46) 
      Alcohol > 0 gram/day (%) 78 37 b 
NGM: Normal Glucose Metabolism, DM2: Diabetes Mellitus, HOMA-IR: Insulin resistance estimated 
by Homeostasis Model Assessment. Differences between groups tested with t-test for continuous 
variables and with χ2-test for dichotomous variables. a Data presented as mean values (SD) or 
percentages. In case of skewed distribution, data presented as median (interquartile range) and Ln-
transformed values were tested. b P < 0.05. c Subjects using insulin were excluded and fasting 
insulin was calculated as mean of two measurements. 
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Figure 3.1. Triglyceride, glucose and insulin concentrations (mean±SEM) after ingestion of 
two consecutive meals. For insulin figures, patients who use insulin (n=7) were excluded. 
B: breakfast, L: lunch. NGM: normal glucose metabolism (○), DM2: type 2 diabetes mellitus 
(●). 
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Table 2.2. Fasting and postprandial glucose and triglyceride levels 
after fat-rich meals and after carbohydrate-rich meals
 a
 
 NGM DM2 
Fat-rich meals   
     Fasting triglycerides 
(mmol/L) 
1.2 (0.6) 1.7 (0.7) b 
     TG-iAUC (mmol/L) 0.9 (0.5) 1.0 (0.5) 
     Fasting glucose (mmol/L) 5.3 (0.4) 7.2 (1.5) b 
     GL-iAUC (mmol/L) 0.1 (0.5) 0.7 (1.5) b 
Carbohydrate-rich meals   
     Fasting triglycerides 
(mmol/L) 
1.2 (0.6) 1.7 (0.6) b 
     TG-iAUC (mmol/L) 0.2 (0.3) 0.3 (0.3) b 
     Fasting glucose (mmol/L) 5.2 (0.4) 7.1 (1.3) b 
     GL-iAUC (mmol/L) 0.4 (0.8) 3.6 (2.9) b 
NGM: Normal Glucose Metabolism, DM2: Diabetes Mellitus, TG: triglycerides, 
iAUC: incremental area under the curve, GL: glucose. TG-iAUC and GL-iAUC 
were presented as mean iAUC during the day. a Data presented as mean 
values (SD). b T-test P < 0.05. 
 
 
Associations with postprandial triglycerides 
 
Results of linear regression analyses are presented in Table 3. In the NGM group, 
fasting triglycerides were associated with TG-iAUC; also, HbA1c, fasting insulin, 
HOMA-IR, total cholesterol were positively associated, whereas HDL-cholesterol and 
hip circumference were negatively associated with TG-iAUC. To study whether 
potential determinants of TG-iAUC were independent of fasting triglyceride levels, 
we made a multivariate model. For women with NGM, we included fasting 
triglycerides, hip circumference, HbA1c, fasting insulin, total cholesterol and HDL-
cholesterol and adjusted for age and BMI (R2=0.52), and all these variables, except 
fasting insulin (P=0.08) and hip circumference (P=0.07), remained statistically 
significantly associated with TG-iAUC. In the DM2 group, fasting triglyceride, HbA1c 
and age were the strongest predictors of TG-iAUC. In a multivariate model with 
fasting triglycerides, HbA1c and age (R2=0.29) fasting triglycerides was the only 
independent determinant of TG-iAUC. 
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Table 2.3. Linear regression analysis of clinical and biochemical parameters with postprandial triglyceride and glucose concentrations
NGM (n=76) DM2 (n=41)
Variables (SD) 
a
TG-iAUC GL-iAUC TG-iAUC GL-iAUC
Age (3.9 years) 0.04 (-0.18;0.25) 0.07 (-0.003;0.14)
b,c 0.40 (0.04;0.75) b -0.04 (-0.46;0.39)
DM2 duration (4.3 years) - - 0.02 (-0.32;0.35) 0.18 (-0.22;0.58)
BMI (5.4 kg m
-2
) 0.05 (-0.29;0.39) 0.04 (-0.07;0.16) 0.07 (-0.24;0.37) 0.27 (-0.09;0.62)
Waist (0.14 m) 
d
0.41 (-0.15;0.97) 0.20 (0.01;0.38)
b
0.34 (-0.62;1.29) 0.22 (-0.90;1.34)
Hip (0.10 m) 
d
-0.75 (-1.21;-0.29)
b -0.13 (-0.29;0.03) 0.43 (-0.32;1.18) 0.06 (-0.82;0.94)
Fasting glucose (1.2 mmol/L) 0.50 (-0.21;1.21) -0.08 (-0.32;0.16) 0.11 (-0.20;0.41) 0.30 (-0.05;0.65)
b
HbA1c (0.7%) 0.77 (0.31;1.22)
b,c 0.13 (-0.03;0.29) 0.33 (-0.01;0.67)
b
0.86 (0.54;1.18)
b,c
Fasting insulin (ln) (0.67) 
e 0.39 (0.05;0.74) b 0 (-0.12;0.12) 0.23 (-0.23;0.68) 0.47 (0.001;0.93)
b
HOMA-IR (ln) (0.79) 
e 0.32 (0.05;0.59) b 0 (-0.09;0.10) 0.18 (-0.16;0.51) 0.42 (0.09;0.74)
b
Total cholesterol (1.0 mmol/L) 0.32 (0.09;0.55)
b,c -0.01 (-0.09;0.07) 0.24 (-0.06;0.54) 0.33 (-0.03;0.68)
b
HDL-cholesterol (0.47 mmol/L) -0.31 (-0.51;-0.12)
b,c -0.10 (-0.17;-0.04) b 0.01 (-0.47;0.50) -0.16 (-0.74;0.42)
Fasting triglycerides (0.6 mmol/L) 0.60 (0.39;0.81)
b,c 0.13 (0.05;0.21)
b,c
0.40 (0.06;0.73)
b,c
0.48 (0.08;0.88) b
ALT (ln) (0.45) 0.09 (-0.16;0.33) 0.01 (-0.08;0.09) 0.03 (-0.30;0.36) 0.31 (-0.07;0.70)
Systolic BP (16 mmHg) 
f
0.14 (-0.13;0.41) 0.04 (-0.05;0.13) 0.17 (-0.18;0.52) 0.07 (-0.37;0.51)
Alcohol (65 g/week) 0.06 (-0.15;0.27) 0.02 (-0.05;0.09) 0.11 (-0.40;0.62) -0.47 (-1.06;0.12)
Habitual physical activity (18 h/week) 0 (-0.23;0.23) -0.05 (-0.12;0.03) -0.33 (-0.72;0.07) -0.42 (-0.90;0.06)
b
NGM: Normal Glucose Metabolism, DM2: Diabetes Mellitus, TG: triglycerides, iAUC: incremental area under the curve, HOMA -IR: Insulin resistance estimated by Homeostasis 
Model Assessment, ALT: alanine aminotransferase.
a Standardized regression coefficients (95% CI) adjusted for age in SD per 1 SD increase in independent variable. SD for TG -iAUC 0.5 mmol/L and for GL -iAUC 2.3 mmol/L. 
b
P < 0.10, variable included in the multivariate model; insulin and not HOMA- -IR were included when both were significant. c variable significant at level P < 0.05 in 
multivariate model. 
d
Additionally adjusted for BMI. 
e
Subjects using insulin (n=7) were excluded. 
f
Additionally adjusted for use of antihypertensive medication. 
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Associations with postprandial glucose  
 
Results of the linear regression analyses for fasting and postprandial glucose after 
the carbohydrate-rich meals are presented in Table 3. In the NGM group, age, waist 
circumference and fasting triglycerides were positively, and HDL-cholesterol was 
inversely associated with GL-iAUC. In a multivariate model containing age, waist 
circumference, BMI, HDL-cholesterol and fasting triglycerides (R2=0.24), fasting 
triglycerides were still associated with GL-iAUC and age became significantly 
associated with GL-iAUC (beta=0.07 [0.01;0.14]). In women with DM2, HbA1c, 
fasting insulin, HOMA-IR and fasting triglycerides were positively associated with 
GL-iAUC. For this reason, fasting insulin was part of the multivariate model, and we 
excluded women with DM2 who used insulin (n=7). In this model, only HbA1c 
remained associated with GL-iAUC when adjusted for age, fasting glucose, fasting 
insulin, total cholesterol, triglycerides and habitual physical activity in a 
multivariate model (R2=0.68). Because HbA1c is not considered as a determinant of 
GL-iAUC, we also made a multivariate model including the above mentioned 
variables except HbA1c. In this model (R2=0.51), fasting glucose was the strongest 
determinant of GL-iAUC (beta=0.49 [0.19;0.82]).  
 
Association between postprandial triglyceride and glucose responses 
 
We additionally assessed the age-adjusted association of GL-iAUC with TG-iAUC. In 
NGM women, no statistically significant association was found between these 
metabolic responses (beta=0.39 [-0.31;1.08]). In contrast, for women with DM2, GL-
iAUC and TG-iAUC were associated (beta=0.26 [0.002;0.53]). The latter association 
was in part dependent of fasting triglycerides; the regression coefficient reduced to 
0.18 [-0.10;0.45] when fasting triglycerides were added to the model with age and 
GL-iAUC. 
 
DISCUSSION 
 
The present study is to our knowledge the first to assess both postprandial 
triglyceride and glucose responses at two separate occasions in one study 
population. We demonstrated that fasting triglycerides were associated with both 
TG-iAUC and GL-iAUC, but other potential determinants of TG-iAUC and GL-iAUC 
differed. In spite of similar TG-iAUC responses in NGM and DM2, determinants of 
TG-iAUC and also of GL-iAUC clearly differed between women with NGM and DM2. 
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We expected a more markedly prolonged triglyceride response especially after the 
second meal in patients with DM2 [20]. The relative lack of exaggerated triglyceride 
response in women with DM2 might be the result of the meal-composition. The 
substantial amount of carbohydrates in the fat-rich mixed meal might have resulted 
in a high insulin response. Indeed, attenuation of the triglyceride response was 
previously shown when glucose was added to a liquid fat-load [21]. Also, the 
patients with DM2 included in the present study were well-controlled, possibly 
contributing to an ameliorated response of the liver to the meal-induced insulin 
response. On the other hand, since the women with DM2 were more insulin 
resistant than women with NGM (HOMA-IR), an elevated TG-iAUC was expected [22]. 
Finally, we cannot exclude the possibility that a prolonged triglyceride response in 
patients with DM2 might have become evident with a longer observation period 
[23].  
 
A common mechanism for elevated postprandial triglyceride and glucose 
responses? 
 
Insulin resistance or central obesity, both components of the metabolic syndrome, 
might contribute to increased postprandial triglyceride and glucose levels. 
Resistance to the suppressive effect of insulin on hepatic VLDL-production results 
in exaggerated postprandial triglyceride responses [24,25]. We found that fasting 
insulin and HOMA-IR, as a reflection of insulin resistance and in particular hepatic 
insulin resistance, were associated with TG-iAUC in women with NGM, but the 
association disappeared when fasting triglycerides were added to the model. 
Furthermore, no association of HOMA-IR and fasting insulin with TG-iAUC in women 
with DM2 was found. However, also fasting triglycerides are a recognized 
component of the metabolic syndrome [26], and the association between fasting 
triglycerides and TG-iAUC might, at least in part, be the result of underlying hepatic 
insulin resistance.  
 
Impaired glucose tolerance has been attributed to a combination of  peripheral 
insulin resistance and beta-cell dysfunction, whereas impaired fasting glucose is 
mainly associated with hepatic insulin resistance and impaired insulin secretion 
[27]. This corroborates with our finding that fasting glucose was associated with 
GL-iAUC in women with DM2, but not in NGM. The combination of hepatic insulin 
resistance and beta-cell dysfunction, reflected by elevated fasting and postprandial 
glucose levels, is common in DM2, but not in NGM. 
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Central obesity as a component of the metabolic syndrome may be the common 
mechanism for elevated postprandial triglyceride and glucose concentration. The 
increased flux of free fatty acids in central obesity and elevated levels of pro-
inflammatory adipocytokines result in so-called ectopic fat depositions in liver, 
muscle and beta-cells contributing to the development of hepatic and peripheral 
insulin resistance, and beta-cell dysfunction [28]. Studies in men reported an 
association between visceral obesity and TG-iAUC [29,30]. In line with these 
observations, a study among obese women showed that abdominal obesity, but not 
obesity as such, was associated with TG-iAUC. In the present study, the association 
between waist circumference and TG-iAUC was, although not statistically 
significant, stronger than the association between BMI and TG-iAUC. Furthermore, 
we found that hip circumference was inversely associated with TG-iAUC in women 
with NGM. An inverse relationship between larger hip circumference and fasting 
triglycerides was previously found in both men and women [31,32], and may be 
explained by an enhanced buffering capacity for triglyceride storage which 
prevents from fat deposition in other organs [33]. The findings for GL-iAUC are 
comparable to those for TG-iAUC; central obesity seemed to be more strongly 
associated with elevated postprandial glucose than BMI in NGM women.  
 
The present data also suggest that an elevated postprandial triglyceride response 
might be part of a dyslipidemic lipid profile in women with NGM. Independent of 
fasting triglycerides, total cholesterol was positively and fasting HDL-cholesterol 
concentration was inversely associated with TG-iAUC. It is known that high levels of 
triglycerides and low HDL-cholesterol concentrations are associated [34] and 
postprandial lipemia might be another feature of this so-called ‘diabetic’ 
dyslipidemia. An important observation is that TG-iAUC was associated with GL-
iAUC in DM2, but not in NGM. This suggests that the underlying mechanisms, e.g. 
hepatic insulin resistance and/or beta-cell dysfunction, is present in DM2, but not 
(yet) in NGM. Other potential mechanisms for postprandial triglyceride and glucose 
responses. An interesting finding was that HbA1c was strongly associated with TG-
iAUC in women with NGM. It is known that improvement of glycemic control also 
improves postprandial triglyceride concentrations in patients with DM2 [35]. This 
effect is attributed to the lipoprotein lipase (LPL) mediated clearance of TG-rich 
lipoproteins, which is hampered when insulin action and/or secretion is inadequate 
[36]. Since we did not measure LPL activity in this study, we cannot verify this 
assumption. The proportion of variance explained by the multivariate model for TG-
iAUC is lower for patients with DM2 (R2 = 0.29) compared to women with NGM (R2 
= 0.52). In DM2, insulin resistance, only partly reflected by fasting triglycerides 
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possibly plays an important role in increasing postprandial triglycerides, including 
the earlier discussed decreased LPL activity. The proportion of variance explained 
(R2) by the multivariate model for GL-iAUC was 0.51 for DM2 and 0.24 for the NGM 
group. Obviously, the range in GL-iAUC is much smaller in women with NGM. 
Furthermore, we did not consider the effect of gut hormones (incretins), rate of 
gastric emptying and peripheral insulin resistance on GL-iAUC, which play 
important roles in glucose regulation. 
 
Study limitations 
 
A number of potential limitations of this study should be considered. First, the 
population consisted of Caucasian post-menopausal women aged 50 to 65, and 
caution should be exercised to generalise our findings to other populations. 
Second, the cross-sectional design limits us to assess causal relationships. Third, 
as a result of the smaller sample size of the DM2 population as compared to the 
NGM study population, less associations in the DM2 study population might have 
reached statistical significance. 
 
Conclusion 
 
In conclusion, GL-iAUC and TG-iAUC were interrelated in women with DM2 and 
fasting triglycerides were associated with both GL-iAUC and TG-iAUC. These 
findings suggest, at least partly, a common underlying mechanism for postprandial 
increments in glucose and triglycerides, especially occuring in women with DM2. In 
healthy women, elevated TG-iAUC may belong to a dyslipidemic lipid profile 
whereas fasting triglycerides were related to GL-iAUC, suggestive for an association 
with insulin resistance. 
 
ACKNOWLEDGEMENTS  
 
The authors thank Jannet Entius, Tanja Nansink, Lida Ooteman and Marianne 
Veeken for their excellent technical assistance, Jolanda Bosman for her support in 
organizing the study at the Diabetes Research Center, and all participants for their 
contributions. This research was financially supported by a grant from the Dutch 
Diabetes Research Foundation (grant no.2001.00.052) and by funding from 
Novartis International AG, Switzerland. 
 
POSTPRANDIAL GLUCOSE AND TRIGLYCERIDES 
   41 
REFERENCES 
 
 1. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-
85. 
 2. Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes 
mellitus. Diabetes Metab Res Rev 2000;16:125-32. 
 3. Heine RJ, Dekker JM. Beyond postprandial hyperglycaemia: metabolic factors 
associated with cardiovascular disease. Diabetologia 2002;45:461-75. 
 4. de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all-cause and 
cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 
1999;42:926-31. 
 5. Alssema M, Schindhelm RK, Dekker JM, et al. Postprandial glucose, and not 
triglyceride concentrations, are associated with carotid intima media thickness in 
women with normal glucose metabolism: The Hoorn prandial study. Atherosclerosis 
2007 (in press). 
 6. Teno S, Uto Y, Nagashima H, et al. Association of postprandial hypertriglyceridemia 
and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 
2000;23:1401-6. 
 7. Sharrett AR, Chambless LE, Heiss G, et al. Association of postprandial triglyceride and 
retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in 
middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study. 
Arterioscler Thromb Vasc Biol 1995;15:2122-9. 
 8. Silva KD, Wright JW, Williams CM, Lovegrove JA. Meal ingestion provokes entry of 
lipoproteins containing fat from the previous meal: possible metabolic implications. 
Eur J Nutr 2005;44:377-83. 
 9. Brighenti F, Benini L, Del Rio D, et al. Colonic fermentation of indigestible 
carbohydrates contributes to the second-meal effect. Am J Clin Nutr 2006;83:817-22. 
 10. van Beek AP, Ruijter-Heijstek FC, Erkelens DW, de Bruin TW. Menopause is associated 
with reduced protection from postprandial lipemia. Arterioscler Thromb Vasc Biol 
1999;19:2737-41. 
 11. Becker A, Bos G, de Vegt F, et al. Cardiovascular events in type 2 diabetes: 
comparison with nondiabetic individuals without and with prior cardiovascular 
disease. 10-year follow-up of the Hoorn Study. Eur Heart J 2003;24:1406-13. 
 12. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus 
and its complications. Part 1: diagnosis and classification of diabetes mellitus 
provisional report of a WHO consultation. Diabet Med 1998;15:539-53. 
 13. Mooy JM, Grootenhuis PA, de Vries H, et al. Prevalence and determinants of glucose 
intolerance in a Dutch caucasian population. The Hoorn Study. Diabetes Care 
1995;18:1270-3. 
CHAPTER  2 
42 
 14. Wendel-Vos GC, Schuit AJ, Saris WH, Kromhout D. Reproducibility and relative validity 
of the short questionnaire to assess health-enhancing physical activity. J Clin 
Epidemiol 2003;56:1163-9. 
 15. Voorlichtingsbureau voor de Voeding.  NEVO Table Netherlands (Dutch Nutrient 
Database).  2001.  
 16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-
density lipoprotein cholesterol in plasma, without use of the preparative 
ultracentrifuge. Clin Chem 1972;18:499-502. 
 17. Bergmeyer HU, Horder M, Rej R. International Federation of Clinical Chemistry (IFCC) 
Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC 
methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC 
method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC 
2.6.1.2). J Clin Chem Clin Biochem 1986;24:481-95. 
 18. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin 
resistance and beta-cell function from fasting plasma glucose and insulin 
concentrations in man. Diabetologia 1985;28:412-9. 
 19. Silva KD, Wright JW, Williams CM, Lovegrove JA. Meal ingestion provokes entry of 
lipoproteins containing fat from the previous meal: possible metabolic implications. 
Eur J Nutr 2005;44:377-83. 
 20. Cohen JC, Berger GM. Effects of glucose ingestion on postprandial lipemia and 
triglyceride clearance in humans. J Lipid Res 1990;31:597-602. 
 21. Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in 
humans. Implications for the insulin-resistant state. Diabetes Care 1996;19:390-3. 
 22. Tushuizen ME, Nieuwland R, Scheffer PG, et al. Two consecutive high-fat meals affect 
endothelial-dependent vasodilation, oxidative stress and cellular microparticles in 
healthy men. J Thromb Haemost 2006;4:1003-10. 
 23. Garg A. Insulin resistance in the pathogenesis of dyslipidemia. Diabetes Care 
1996;19:387-9. 
 24. Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in 
humans. Implications for the insulin-resistant state. Diabetes Care 1996;19:390-3. 
 25. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. 
Diabetes 1988;37:1595-607. 
 26. Meyer C, Pimenta W, Woerle HJ, et al. Different mechanisms for impaired fasting 
glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 
2006;29:1909-14. 
 27. Raz I, Eldor R, Cernea S, Shafrir E. Diabetes: insulin resistance and derangements in 
lipid metabolism. Cure through intervention in fat transport and storage. Diabetes 
Metab Res Rev 2005;21:3-14. 
 28. Wideman L, Kaminsky LA, Whaley MH. Postprandial lipemia in obese men with 
abdominal fat patterning. J Sports Med Phys Fitness 1996;36:204-10. 
POSTPRANDIAL GLUCOSE AND TRIGLYCERIDES 
   43 
 29. Couillard C, Bergeron N, Prud'homme D, et al. Postprandial triglyceride response in 
visceral obesity in men. Diabetes 1998;47:953-60. 
 30. Snijder MB, Zimmet PZ, Visser M, et al. Independent and opposite associations of 
waist and hip circumferences with diabetes, hypertension and dyslipidemia: the 
AusDiab Study. Int J Obes Relat Metab Disord 2004;28:402-9. 
 31. Snijder MB, Zimmet PZ, Visser M, et al. Independent association of hip circumference 
with metabolic profile in different ethnic groups. Obes Res 2004;12:1370-4. 
 32. Frayn KN. Adipose tissue as a buffer for daily lipid flux. Diabetologia 2002;45:1201-
10. 
 33. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in 
insulin resistance and diabetes. Arch Med Res 2005;36:232-40. 
 35. Jeppesen J, Zhou MY, Chen YD, Reaven GM. Effect of metformin on postprandial 
lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 
1994;17:1093-9. 
 36. Ginsberg HN. Efficacy and mechanisms of action of statins in the treatment of 
diabetic dyslipidemia. J Clin Endocrinol Metab 2006;91:383-92. 
 
 
 
CHAPTER 2 
44 
 
 45 
Chapter 3 
 
 
 
POSTPRANDIAL GLUCOSE AND NOT TRIGLYCERIDE CONCENTRATIONS 
ARE ASSOCIATED WITH CAROTID INTIMA MEDIA THICKNESS IN WOMEN 
WITH NORMAL GLUCOSE METABOLISM: THE HOORN PRANDIAL STUDY 
 
 
 
Marjan Alssema1  
Roger K. Schindhelm2  
Jacqueline M. Dekker1 
Michaela Diamant2  
Piet J. Kostense1,3 
Tom Teerlink4 
Peter G. Scheffer4  
Giel Nijpels1,5 
Robert. J. Heine1,2 
 
From the 1EMGO Institute and the Departments of 2Endocrinology/Diabetes Center, 
3Clinical Epidemiology and Biostatistics, 4Clinical Chemistry, and 5General Practice, 
VU University Medical Center, Amsterdam, The Netherlands. 
 
 
 
Atherosclerosis (in press) 
Copyright © 2007 Elsevier Ireland Ltd. 
Reprinted with permission from Elsevier. 
CHAPTER 3 
46 
ABSTRACT 
 
The present study aimed to compare the associations of postprandial glucose 
(ppGL) and postprandial triglycerides (ppTG) with carotid intima media thickness 
(cIMT) in women with normal glucose metabolism (NGM) and type 2 diabetes 
(DM2). Post-menopausal women (76 with NGM, 78 with DM2), received two 
consecutive fat-rich and two consecutive carbohydrate-rich meals on separate 
occasions. Blood samples were taken before and 1, 2, 4, 6 and 8 hours following 
breakfast; lunch was given at t=4. Ultrasound imaging of the carotid artery was 
performed to measure cIMT. In women with NGM, an increase of 1.0 mmol/l 
glucose following the fat-rich meals was associated with a 50 µm cIMT increase 
(P=0.04), and following the carbohydrate meals, an increase of 1.8 mmol/l glucose 
was associated with a 50 µm larger cIMT (P=0.08). These associations were not 
explained by classical cardiovascular risk factors. However, no association between 
ppGL and cIMT was found in women with DM2 and ppTG were not associated with 
cIMT. The association between ppGL and cIMT in normoglycemic women suggests 
that ppGL in the normal range is a marker or a risk factor for atherosclerosis. 
Postprandial glucose levels might be a better indicator of risk than post-OGTT 
glucose levels or triglyceride levels. 
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INTRODUCTION 
Men with type 2 diabetes mellitus (DM2) have a two- to three-fold and women a 
three- to four-fold increased risk of cardiovascular disease (CVD) [1,2]. The 
increased risk for CVD in patients with DM2 is only partly explained by the classical 
CVD risk factors hypertension, high LDL-cholesterol, low HDL-cholesterol and 
smoking [3].     
Disturbances in the postprandial metabolism are hypothesized to contribute to the 
excess risk of CVD, because of the elevated concentrations of glucose, triglyceride-
enriched lipoproteins and inflammatory markers in the postprandial period [4]. 
Glucose levels after an oral glucose tolerance test (OGTT) have been shown to be 
better indicators of CVD risk than fasting glucose levels in the general population 
and in subjects with a family history of DM2 [5-7]. Also, postprandial triglyceride 
levels were more strongly related to cIMT than fasting triglyceride levels in both 
healthy subjects [8-10] and in patients with DM2 [11,12]. However, the relative 
contributions of postprandial glucose (ppGL) levels and postprandial triglyceride 
(ppTG) levels to atherosclerosis are not clarified yet. 
Most postprandial studies applied a single fat-rich liquid-formula or an OGTT, but 
the association of the more physiological meal-related glucose and triglyceride 
responses with CVD might be more relevant. Furthermore, during daytime, glucose 
excursions following a first meal are known to affect the responses after a second 
meal [13]. A cumulative effect of the triglyceride excursions following breakfast 
and lunch is likely to occur, especially in subjects with DM2 [14].  
The aim of the present study was to investigate the relation of ppGL and ppTG 
following two consecutive fat-rich meals or two consecutive carbohydrate-rich 
meals on two separate days, to cIMT, and to investigate whether these associations 
differ between women with normal glucose metabolism (NGM) and women with 
DM2.  
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METHODS 
 
Study population  
 
Women with DM2 (n=522), from the registry of the Diabetes Care System in the city 
of Hoorn, the Netherlands, and women who were randomly selected from the 
municipal registry of Hoorn (n=541) aged 50-65 years at the beginning of the 
study, were invited to participate in the study. Exclusion criteria were non-post-
menopausal status (menses in the last 12 months), smoking, untreated endocrine 
disorder other than DM2, use of short acting insulin analogues, use of PPAR-α and -
γ agonists, use of oral corticosteroids, use of hormone replacement therapy, 
fasting cholesterol >8.0 mmol/l, fasting triglycerides >4.0 mmol/l, systolic blood 
pressure>190 mmHg, liver or renal impairment (liver derived enzymes >2.5 time 
the upper limit of the laboratory reference range, creatinine >120 µmol/l). Women 
who were selected from the municipal registry underwent a 75-g OGTT to verify 
their glucose tolerance status (fasting glucose ≤6.0 mmol/l and 2-hour post-load 
glucose <7.8 mmol/l [15]). Women with DM2 were excluded if they had HbA1c 
>9.0%. Women with NGM were excluded if they used HMG-CoA reductase inhibitors 
(statins), and women with DM2 who used statins were considered as a separate 
study group. Of the 1,063 women who were invited, 431 women were complete 
non-responders and 258 women were not willing to participate. A total of 220 
women did not meet the inclusion criteria. Reasons for exclusion were: smoking 
n=65, elevated fasting and/or post-load glucose levels (NGM only) n=33, pre-
menopausal n=28, drop-out n=22, failure to draw blood samples from a canula 
n=19, use of hormone replacement therapy n=13, use of short acting insulin 
analogues n=12, illness during study participation n=6, elevated triglycerides n=4, 
use of PPAR-γ agonists n=4, use of statins (NGM only) n=3, blood pressure n=3, 
miscellaneous reasons n=4, cholesterol n=1, creatinine n=1, liver enzymes n=1 and 
missing cIMT n=1. Finally, 76 women with NGM and 78 women with DM2 
completed the study protocol. All women gave written informed consent. The study 
was approved by the ethics committee of the VU University Medical Center.  
 
Screening visit 
 
The study consisted of three separate visits, i.e. a screening visit and two visits for 
the test-meals, with a maximum of one month apart. On the screening visit, fasting 
blood samples were drawn after a 12-h overnight fast.  
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Blood pressure was measured at the left arm three times with 5 minutes intervals 
with an oscillometric blood pressure measuring device (Collin Press-mate BP-8800, 
Colin, Komaki-City, Japan) after a 15-minute supine rest. Weight and height were 
measured twice in barefooted participants wearing light clothes only. BMI was 
calculated as weight (in kg) divided by the square of height (in m). Waist 
circumference was measured twice at the level midway between the lowest rib 
margin and the iliac crest, and hip circumference was measured at the widest level 
over the greater trochanters. Medical history, medication, smoking and alcohol 
consumption were assessed by a questionnaire [16]. Finally, physical activity was 
assessed by the Short Questionnaire to Assess Health-enhancing physical activity 
[17].  
 
Ultrasound imaging 
 
A single observer (MA) performed ultrasound imaging with an ultrasound scanner 
(350 Series, Pie Medical, Maastricht, The Netherlands), equipped with a 7.5-MHz 
linear probe. Measurements were performed in the right common carotid artery at 
10 mm proximal to the carotid bulb. Images were registered and analyzed by a 
personal computer equipped with vessel wall movement detection software and an 
acquisition system (Wall Track System, Pie Medical, Maastricht, the Netherlands).  
After a 15-minute supine rest, the artery was visualized in B-mode. After defining 
the segment, 10 mm proximal to the carotid bulb, the screen was switched to the 
M-mode and data acquisition in real-time presentation on the computer screen was 
enabled. Data were obtained by 3 consecutive measurements of 4 seconds each, 
triggered by the R-top of a simultaneously recorded ECG [18]. Carotid IMT was 
measured from the posterior wall, as the distance from the first to the second 
echogenic line [19]. Reproducibility of scanning was assessed in 7 women with 
DM2 and in 5 women with NGM, who were examined twice, two weeks apart. The 
intra-observer coefficient of variation (=SD of the mean difference / (√2 * pooled 
mean) * 100%) for cIMT was 5.2%. 
 
Test meals 
 
All participants received two consecutive fat-rich meals on one occasion and two 
consecutive carbohydrate-rich meals on another occasion, in random order. Women 
arrived at the test facility in the morning after an overnight fast. Blood samples 
were taken before and at t=1, t=2, t=4, t=6 and t=8 hour after ingestion of the first 
test meal (breakfast). Lunch was given at t=4, immediately after a blood sample 
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was taken. The nutrient composition of the meals was calculated from the Dutch 
Nutrient Database [20]. The fat-rich meals consisted of croissants, butter, cheese 
and fat-rich milk (3349 kJ; 50 g fat; 56 g carbohydrates and 28 g proteins). The 
carbohydrate-rich meals consisted of bread, marmalade, cooked chicken breast, 
ginger bread and drinkable yogurt enriched with soluble carbohydrates (3261 kJ; 4 
g fat, 162 g carbohydrates and 22 g proteins). Meals were eaten within 10 minutes. 
Apart from the test meals and water (ad libitum), participants refrained from food 
and drinks. In addition, throughout the visit, physical activity was limited to a short 
walk between two adjacent rooms.  
 
Laboratory analysis 
 
All laboratory analyses were performed at the VU University Medical Center in 
Amsterdam, the Netherlands. Serum total cholesterol, HDL-cholesterol and 
triglycerides were measured by enzymatic calorimetric assays (Roche, Mannheim, 
Germany). The inter-assay coefficients of variation for the triglyceride levels were 
2.2% at a mean level of 1.0 mmol/l and 1.8% at a mean level of 1.9 mmol/l. Fasting 
LDL-cholesterol was calculated according to the Friedewald-formula [21]. Plasma 
glucose levels were determined with a glucose oxidase method (Granutest, Merck, 
Darmstadt, Germany) and HbA1c was measured with reversed-phase cation 
exchange chromatography (Menarini Diagnostics, Florence, Italy). The inter-assay 
coefficients of variation for the glucose levels were 1.2% at a mean level of 4.9 
mmol/l and 1.3% at a mean level of 19.0 mmol/l. Specific insulin was measured in 
serum by an immunometric assay in which proinsulin did not cross-react (Advia 
Centaur, Bayer Diagnostics, Mijdrecht, The Netherlands). The intra- and inter-assay 
coefficients of variation for insulin were <4% and <7%, respectively.  
Statistical analyses 
 
Analyses were performed in SPSS 12.0.1 for Windows (SPSS Inc. Chicago, IL). 
Differences in baseline characteristics between the three groups (NGM, DM2 and 
DM2-ST) were tested with ANOVA with post-hoc analyses (LSD) for continuous 
variables that were ln-transformed in case of skewed distribution. Dichotomous 
variables were tested with χ2-test. Postprandial responses were calculated with the 
trapezoid method as total area under the curve (AUC) divided by 8 (hours). Insulin 
resistance was estimated by homeostasis model assessment (HOMA-IR), calculated 
as (mean fasting insulin (µU/ml) * mean fasting glucose (mmol/l))/22.5 [22]. Means 
for glucose and insulin were derived from fasting measurements on two separate 
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study days. To study the possible associations between risk factors and cIMT and 
between postprandial responses and cIMT, we performed linear regression analysis 
with adjustment for age. The associations were expressed as regression 
coefficients per 1 SD (of the total study population) increase in independent 
variable. We tested for possible interactions of independent variables with DM2 and 
use of statins by calculating the p values of the interaction terms. Subsequently, 
regression coefficients for ppGL and ppTG were adjusted for fasting levels to 
investigate whether fasting levels explained the possible association between 
postprandial response and cIMT. To investigate the relative contribution of ppTG 
and ppGL to cIMT, we also made a mutually adjusted model for ppTG and ppGL. 
Finally, we tested BMI, total cholesterol, fasting insulin, HOMA-IR, systolic blood 
pressure, smoking, LDL-cholesterol and HDL-cholesterol as potentially confounding 
factors. We considered a two-sided P-value <0.05 to indicate statistical significance. 
For interaction terms, we considered P<0.15 statistically significant. 
 
 
RESULTS 
 
Clinical and biochemical characteristics assessed at the screening visit and fasting 
and postprandial glucose and triglycerides were presented separately for women 
with NGM, DM2 and women with DM2 using statin medication (DM2-ST, Table 1). 
Fasting and postprandial triglycerides and glucose, were similar in the DM2 group 
and in the DM2-ST group, but were higher compared to the NGM group (all p<0.01, 
Table 3.1). Carotid IMT was increased and CVD was more prevalent in women with 
DM2 who were not using statins, but these differences did not reach statistical 
significance.  
In Table 3.2, results of linear regression analysis of known CVD risk factors with 
regard to cIMT are shown. Because no interaction with DM2 status or use of statins 
was found for most of the risk factors, we combined the subgroups for these 
analyses. Age was associated with cIMT: the estimated beta was 20.2, indicating 
that a 4 year difference in age is associated with a 20 µm larger cIMT (P=0.02). Also 
systolic blood pressure was associated with cIMT, a difference of 16 mmHg in 
systolic blood pressure was associated with a 19 µm difference in cIMT (P=0.04). 
However, the latter association became non-significant after adjustment for DM2 
status and use of statins.  
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Table 3.1. Population characteristics (N=154) 
 NGM DM2  DM2-ST 
N 76 41 37 
Age (years) 60.1 (4.0) 58.9 (3.7) 61.1 (4.0) a 
Duration of DM2 (years) - 5 (3-9) 4 (2-9) 
BMI (kg/m2) 26.3 (3.6) 32.7 (6.0) b 30.6 (4.6) b 
Waist (cm) 88 (10) 104 (14) b 102 (13) b 
Hip (cm) 104 (8) 112 (12) b 108 (10) b  
2-h post-load glucose (mmol/l) 5.4 (1.0) - - 
HbA1c 5.6 (0.3) 6.6 (0.6) b 6.8 (0.7) b 
Fasting insulin (pmol/l) c,d 33.2 (25.5-47.5) 82.7 (38.8-122.5) b 82.3 (53.3-107.3) b 
HOMA-IR c,d  1.29 (0.94-1.95) 4.05 (1.92-7.07) b 4.33 (2.53-6.61) b 
Total cholesterol (mmol/l) c 5.7 (0.8) 5.5 (1.0) 4.4 (0.8) a,b 
HDL-cholesterol (mmol/l) c 1.62 (0.42) 1.36 (0.29) b 1.33 (0.29) b 
LDL-cholesterol (mmol/l) c 3.5 (0.8) 3.4 (0.9) 2.3 (0.7) a,b 
Systolic blood pressure (mmHg) 131 (15) 143 (16) b 134 (16) a 
Former smoking (%) 49 39 43 
Physical activity (hours/week) 37 (19) 36 (17) 31 (21) b 
Alcohol intake >0gram/day (%) 78 37 b 46 b 
Antihypertensive medication (%) 16 66 b 62 b 
Diabetes treatment (%)    
  Diet alone - 24 14 
  Metformin only - 39 35 
  Sulfonylureas only - 7 14 
  Metformin and sulfonylureas - 10 19 
  Metformin and acarbose - 2 0 
  Use of insulin  - 17 19 
Meal measurements    
  Fasting triglycerides (mmol/l) c 1.2 (0.5) 1.7 (0.6) b 1.8 (0.6) b 
  Fasting glucose (mmol/l) c 5.2 (0.4) 7.1 (1.4) b 7.5 (1.2) b 
Fat-rich meals:    
    PpTG (mmol/l)  2.1 (0.9) 2.7 (1.0) b 2.7 (0.9) b 
    PpGL (mmol/l) 5.4 (0.5) 7.9 (1.8) b 7.8 (1.6) b 
Carbohydrate-rich meals:    
    PpTG (mmol/l) 1.4 (0.7) 2.0 (0.6) b 2.0 (0.7) b 
    PpGL (mmol/l) 5.7 (0.8) 10.7 (3.5) b 11.5 (3.6) b 
Prevalent cardiovascular disease (%)e 22 34 26 
Carotid Intima Media Thickness (µm) 764 (110) 790 (107) 769 (121) 
Data as means (SD) or percentages. In case of skewed distribution, medians (interquartile range) are 
presented and Ln-transformed values were tested. NGM= normal glucose metabolism, DM2= type 2 
diabetes mellitus, DM2-ST= type 2 diabetes mellitus using statins, HOMA-IR=homeostasis model 
assessment for insulin resistance, ppTG=postprandial triglycerides, ppGL=postprandial glucose. a 
P<0.05 compared to DM2 group, b P<0.05 compared to NGM group, c mean of 2 measurements, d 
women using insulin excluded, e prevalent cardiovascular disease defined as ankle-brachial-index 
<0.90, ECG abnormalities (1.1-1.3, 4.1-4.3, 5.1-5.3 or 7-1), history of arterial surgery, cerebral 
vascular event, angina, amputation, claudication or possible myocardial infarction. 
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Table 3.2. Linear regression analysis (beta (95% CI)) of risk factors and carotid  
Intima Media Thickness (n=154) 
Variable  SD Model 1 Model 2  
Age  4.0 years 20.2 (2.6;37.8) a 22.7 (4.8;40.6) a 
DM2  (yes versus no) 17.2 (-17.9;52.3) 33.1 (-9.3;75.5) 
DM2 duration b 4.7 years 12.7 (-11.1;36.5) 11.0 (-12.5;34.5) 
BMI  5.4 kg/m2 11.4 (-6.2;29.0) 7.7 (-13.0;28.3) 
Waist c 14.0 cm 13.0 (-31.6;57.6) 16.6 (-30.6;63.8) 
Hip c 10.3 cm -8.3 (-45.4;28.8) -8.7 (-47.6;30.3) 
2-hour post-load glucose d 1.0 mmol/l 2.1 (-22.8; 27.0) - 
HbA1c  0.76 % 12.4 (-5.2;29.9) 16.1 (-10.2;42.3) 
Fasting insulin b,e 59 pmol/l 1.7 (-19.2;22.6) -4.1 (-28.8;20.6) 
HOMA-IR b,e  3.4 5.0 (-15.3;25.2) -0.1 (-26.8;26.7) 
Total cholesterol  1.01 mmol/l 6.7 (-10.9;24.3) 7.4 (-13.6;28.3) 
HDL-cholesterol  0.39 mmol/l -8.0 (-25.8;9.8) -5.6 (-24.6;13.5) 
LDL-cholesterol  0.93 mmol/l 10.1 (-7.5;27.6)  12.4 (-9.1;33.9) 
Systolic blood pressure f  16 mmHg 18.9 (0.6;37.1) a 17.1 (-1.8;35.9) 
Former smoking g  (yes versus no) 23.5 (-25.6;72.5) - 
Alcohol intake b  63 gram/week 11.5 (-6.4;29.4) 17.7 (-1.1;36.6) 
Physical activity  19 hours/week -12.3 (-31.7;7.0) -12.0 (-31.5;7.4) 
Beta in µm intima media thickness per 1 SD increase in independent variable. DM2= type 2 diabetes 
mellitus, HOMA-IR=homeostasis model assessment for insulin resistance. Model 1: Adjusted for age. 
Model 2: Adjusted for age, DM2 and use of statins. a P<0.05, b ln-transformed for analyses, c waist and 
hip are additionally adjusted for each other and for BMI, d after an OGTT in women with NGM only, e 
women using insulin excluded, f additionally adjusted for use of antihypertensive medication, g 
interaction with DM2 (P=0.08) and use of statins (P=0.03), betas for women with NGM only. Other betas 
were: -50.6 (-117.4;16.1) and 59.2 (-22.4;140.7) for women with DM2 with DM2-ST, respectively. 
 
 
 
Results of linear regression analysis of fasting and postprandial glucose and 
triglycerides are shown in Table 3. Because we observed different associations of 
ppGL with cIMT for women with DM2 and women with NGM after both the fat-rich 
(P-value for interaction P=0.12) and the carbohydrate-rich meals (P-value for 
interaction P=0.15), results are presented separately for women with NGM and 
DM2. We also found an interaction between fasting glucose and use of statin 
medication (P=0.07). Therefore, we performed the regression analysis of fasting 
glucose with cIMT for women in the DM2-ST group separately.  
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Table 3.3. Associations (beta (95% CI)) of fasting and postprandial glucose and 
triglycerides with carotid Intima Media Thickness 
  
NGM (n=76) 
Variable (SD) Model 1 Model 1 +  
fasting levels 
Model 1 +  
mutually adjusted a 
Fasting    
  Triglycerides (0.6 mol/l) 2.3 (-26.0;30.7) - -0.8 (-29.9;28.2) 
  Glucose (1.4 mmol/l) 50.4 (-45.8;146.6) - 51.0 (-48.1;150.0) 
    
Fat meals    
  PpTG (1.0 mmol/l) 3.9 (-23.1;30.9) 8.6 (-48.5;65.9) -3.7 (-31.0;23.6) 
  PpGL (1.8 mmol/l) 92.6 (6.1;179.1) 91.8 (-8.0;191.7) 95.7 (5.5;185.9) 
    
Carbohydrate meals     
  PpTG (0.7 mmol/l) 10.0 (-16.7;36.6) 43.5 (-18.5;105.5) 1.3 (-27.3;29.9) 
  PpGL (3.7 mmol/l) 98.8 (-13.7;211.3) 89.9 (-35.9;215.7) 96.7 (-26.0;219.3) 
 
 
 
 
 
 DM2 (n=78) 
Variable (SD) Model 1 Model 1 +  
fasting levels 
Model 1 +  
mutually adjusted a 
Fasting    
  Triglycerides (0.6 mol/l) -5.6 (-34.1;22.9) - -12.5 (-43.0;17.9) 
  Glucose (1.4 mmol/l) 38.6 (6.2;71.0) b - 51.6 (16.8;86.5) b 
    
Fat meals    
  PpTG (1.0 mmol/l) -13.4 (-40.3;13.6) -26.8 (-73.3;19.7) -14.0 (-41.1;13.1) 
  PpGL (1.8 mmol/l) 8.6 (-18.5;35.6) c -4.6 (-40.1;30.9) 9.5 (-17.6;36.5) 
    
Carbohydrate meals     
  PpTG (0.7 mmol/l) -10.1 (-39.8;19.6) -20.6 (-81.2;39.9) -12.7 (-42.7;17.2) 
  PpGL (3.7 mmol/l) 14.4 (-13.1;42.0) c 5.7 (-29.2;40.7) 16.2 (-11.7;44.2) 
    
Beta in µm intima media thickness per 1 SD increase in independent variable. NGM= normal glucose 
metabolism, DM2= type 2 diabetes mellitus, ppTG=postprandial triglycerides, ppGL=postprandial 
glucose. Model 1: adjusted for age and (DM2 group) use of statins. a Mutually adjusted as follows: 
Fasting triglycerides and fasting glucose; ppTG and ppGL following fat-rich meals; ppTG and ppGL 
following carbohydrate-rich meals, b Interaction with use of statins (P=0.07) beta for women with 
DM2, not using statins only. Beta for DM2-ST-group –13.6 (-62.8;35.5), c Interaction with DM2 
P<0.15. 
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Fasting levels of glucose were statistically significantly associated with cIMT in 
women with DM2. In women with NGM, this association was of similar magnitude, 
although not statistically significant (Table 3). After mutual adjustment of fasting 
glucose and fasting triglycerides, the association between fasting glucose and cIMT 
in women with DM2 became stronger. After adjustment for CVD risk factors, (BMI, 
total cholesterol, fasting insulin, HOMA-IR, systolic blood pressure, smoking, LDL-
cholesterol or HDL-cholesterol) the association between fasting glucose and cIMT 
remained statistically significant (data not shown). 
PpTG after both the test meals was not associated with cIMT in women with NGM 
and not in women with DM2. However, PpGL after both the fat-rich meals (p=0.04) 
and the carbohydrate-rich meals (borderline significant P=0.08) was associated with 
cIMT in women with NGM. A 1.0 mmol/l higher glucose level during the day of the 
fat-rich meals was associated with a 50 µm larger cIMT. In addition, after the 
carbohydrate meals, a 1.8 mmol/l higher glucose level was associated with a 50 µm 
larger cIMT. These associations only slightly changed after adjustment for fasting 
glucose or ppTG. Also adjustment for BMI, total cholesterol, fasting insulin, HOMA-
IR, systolic blood pressure, smoking, LDL-cholesterol or HDL-cholesterol as 
potentially confounding factors did not alter the associations between ppGL and 
cIMT (data not shown). Age-adjusted IMT in quartiles of ppGL for women with NGM 
is shown in Figure 3.1. 
To further explore the association between ppGL and cIMT, we performed 
regression analyses for each of the glucose measurements separately (1,2 and 4 
hour) and for ppGL after breakfast only (AUC 0-4 hour) with regard to cIMT. 
Although borderline significant, glucose levels at t=1 and t=2 hour after the fat-rich 
meal were associated with cIMT (1.0 mmol/l glucose associated with a 19 µm larger 
cIMT at t=1 and 32 µm at t=2, both P=0.05). PpGL, after one meal (AUC 0-4 hour) 
was associated with cIMT similar to ppGL calculated after two consecutive meals. A 
1.0 mmol/l higher glucose level after the fat-rich breakfast was associated with a 
44 µm larger cIMT (P=0.03). 
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Figure 3.1. Age-adjusted cIMT (±SEM) in quartiles of mean postprandial glucose levels 
(mmol/l, 0-8 hour) following fat-rich meals (upper) and following carbohydrate-rich meals 
(lower) for women with NGM. P for trend derived from linear regression analyses with 
postprandial glucose levels as continuous variable: P<0.05 and P=0.08 for fat-rich and 
carbohydrate-rich meals, respectively. 
 
DISCUSSION 
 
In the present cross-sectional study, we compared the relative contribution of ppGL 
and ppTG to cIMT as an early marker of atherosclerosis. We found that ppGL, 
irrespective of the meal composition, was associated with cIMT in women with NGM 
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but not in women with DM2. The association between ppGL and cIMT remained 
unaltered after adjustment for ppTG or other CVD risk factors.  
 
Mild hyperglycemia has previously been discussed as an underestimated 
cardiovascular risk factor [23]. However, in the present study, we also included 
women with NGM, confirmed by OGTT. Remarkably, only in this normal range of 
fasting and postprandial glucose levels, ppGL was associated with cIMT. In the 
women with DM2, an association was found with fasting glycemia but not with 
ppGL. Possibly, a high biological variation in ppGL has obscured the association 
with cIMT in these patients with DM2. Another possibility is that treatment with 
glucose lowering medication and dietary intervention in the women with DM2 
might have influenced the association between ppGL levels and cIMT [24].  
 
Based on previously published papers, we would have expected an association 
between ppTG and cIMT, especially in patients with DM2 [11,12], but also in 
healthy subjects [8-10]. Moreover, post-menopausal women have been shown to 
have higher postprandial lipemia [25], which could potentially contribute to the 
high risk of CVD in these women [26,27]. However, no associations between ppTG 
and cIMT were found in the present study. As to ppTG, no differences were found 
in a study with persons with and without CVD [28]. In contrast, in another study, 
patients with coronary heart disease were found to have higher fasting triglycerides 
and higher ppTG than subjects without coronary heart disease [29]. In the 
Atherosclerosis Risk in Communities Study, ppTG levels were found to be 
associated with early atherosclerosis, but only in non-obese subjects [8] and the 
investigators suggested that this association might be explained by high levels of 
atherogenic triglyceride-rich lipoprotein remnants in the postprandial state. These 
lipoprotein remnants were indeed related to cIMT, independent of ppTG [30]. Since 
we did not measure lipoprotein remnant particles in the present study, we cannot 
address this question. It should furthermore be considered that gender-specific 
studies on the relation between ppTG and cardiovascular risk are scarce. The above 
mentioned Atherosclerosis Risk in Communities Study reported an association 
between ppTG and cIMT in both men and women, but an association with exercise-
induced myocardial ischemia was only present in men and not in women [8,31]. 
Because of the increased risk for CVD converted by DM2 in postmenopausal 
women, studies in older women are urgently needed. 
 
Our fat-rich meal should be considered as a mixed meal because it contained 
carbohydrates, through which beta-cell stimulation will be induced. Our data show 
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that despite differences in test-meal composition and carbohydrate content (56 g 
or 162 g) an association between average ppGL levels and cIMT can be found. We 
also found that measuring glucose after one meal was enough to assess the 
association between ppGL and cIMT. However, glucose measured two hours after 
an OGTT, did not give a similar strong association with cIMT in women with NGM. 
This could not be due to limited precision of the single glucose measurement after 
the OGTT compared to the multiple postprandial glucose measurements, because 
we found a single 2-hour glucose measurement after a meal, although borderline 
significant, associated with a relevant increase in cIMT. This leads us to the 
conclusion that ppGL following a meal gives additional clinical relevant information 
compared to 2-hour post-load glucose following a glucose solution. First of all, we 
should consider that the OGTT contained 75 gram glucose whereas the 
carbohydrate-rich meal contained 162 gram carbohydrates which takes longer to 
digest due to higher carbohydrate load and the more complex molecular structure 
of carbohydrates in the meals. Secondly, it has been suggested that the relation 
between hyperglycemia and cardiovascular disease is mediated by oxidative stress. 
Ceriello et al. showed a cumulative effect of postprandial hyperglycemia and 
postprandial hypertriglyceridemia on oxidative stress generation [32]. Although a 
cumulative effect was possible after the mixed meal, we cannot confirm this 
because we did not find an independent association between ppTG and cIMT.  
Carotid IMT is a well-accepted marker for atherosclerosis and cardiovascular risk 
[33]. Age and systolic blood pressure were associated with cIMT in our study. The 
estimated age-related increase of 50 µm per ten years is similar to that observed in 
a European study population [34] and is comparable to the age-effect in a study 
among women of the same age [35]. Probably due to limited power, other CVD risk 
factors, systolic blood pressure excepted, were not statistically significantly 
associated with cIMT. Although the direction of the associations with cIMT were as 
expected, it should be noticed that not only atherosclerosis but also other 
mechanisms (thrombosis) play a role in development of CVD.  
 
The cross-sectional study design is a potential limitation to our study. We assumed 
that cIMT reflects the cumulative effect of previous atherogenic processes. 
However, cIMT is a result of dynamic processes over time: progression as well as 
regression due to treatment or lifestyle interventions occurs [24]. Especially in the 
present population of women with DM2, who were treated intensively, the 
treatment-related modification of the cIMT might have led to an underestimation of 
the true association between metabolic responses and atherosclerosis.  
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The relative paucity of data in women and the disproportionately high risk of CVD 
in the present study population prompted us to perform the study. However, we 
should be careful in extrapolating the present results to other populations. In 
addition, the present study population cannot be viewed as a population-based 
cohort of post-menopausal women because from the 24% who agreed to 
participate, 40% did not meet the inclusion-criteria or dropped out of the study.    
 
The association of ppGL with cIMT in women with NGM was stronger than that of 
ppTG. The association between ppGL and cIMT in women with NGM suggests that 
ppGL, in the normal range, is a marker or a risk factor of CVD. Postprandial glucose 
measured after a fat-rich or a carbohydrate-rich meal, might give more information 
about development of atherosclerosis than 2-hour glucose, measured after an 
OGTT. 
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ABSTRACT  
 
Objective:  We studied acute changes in markers of glycoxidative and lipoxidative 
stress, including oxidized low-density-lipoprotein, Nε-(carboxyethyl)-lysine (CEL), 
Nε-(carboxymethyl)-lysine (CML) and 3-deoxyglucosone (3DG), following  two 
consecutive meals.  
 
Research Design and Methods: Post-menopausal women (27 with normal glucose 
metabolism [NGM]; 26 with type 2 diabetes [DM2]), received two consecutive fat-
rich meals and two consecutive carbohydrate-rich meals on two occasions. Glucose 
and triglyceride concentrations were measured at baseline and 1,2,4,6 and 8h 
following breakfast; lunch was given at 4h. Oxidized-LDL-to-LDL-cholesterol ratio 
(oxLDL/LDL-C), CEL, CML and 3DG were measured at baseline and at 8h.  
 
Results: Fasting oxLDL/LDL-C, 3DG and CML were higher in women with DM2 
compared to women with NGM and were comparable to the postprandial values at 
8 hours in NGM. Postprandial rises in oxLDL/LDL-C and 3DG were similar in both 
groups. However, oxLDL/LDL-C increased more after the fat-rich meals, whereas 
CML and 3DG increased more after the carbohydrate-rich meals. After the fat-rich 
meals, the increase in oxLDL/LDL-C was correlated with postprandial triglycerides, 
whereas the increase in 3DG was correlated with postprandial glucose. 
 
Conclusions:  The acute changes in markers of glycoxidative and lipoxidative 
stress in both DM2 and NGM suggest that post-absorptive oxidative stress may 
partly underlie the association of postprandial derangements and cardiovascular 
risk. 
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INTRODUCTION 
 
Patients with type 2 diabetes mellitus (DM2) have an increased risk of 
cardiovascular disease (CVD)[1], which can only partly be explained by the classical 
CVD risk factors such as hypertension, high LDL-cholesterol, low HDL-cholesterol 
and smoking [2]. In post-menopausal women, as compared to men, the relative risk 
of CVD conferred by DM2 is even higher [3]. Zilversmit postulated in 1979 that 
disturbances in postprandial metabolism may contribute to the excess risk of CVD 
[4], due to postprandial elevations of glucose and triglyceride-enriched lipoproteins 
[5,6]. 
 
Oxidative stress is regarded as a common pathway by which many of the classical 
CVD risk factors and postprandial dysmetabolism may initiate and promote 
atherosclerosis [7]. Indeed, elevated levels of oxidized LDL (oxLDL) are associated 
with an increased risk for CVD [8]. Prolonged exposure to a high-fat diet has been 
shown to result in an increase in plasma levels of oxLDL [9]. Another mechanism 
that might link postprandial dysmetabolism and the risk of CVD in patients with 
DM2 includes the formation of advanced glycation endproducts (AGEs), which are 
related to micro- and macrovascular complications [10]. Two of the most studied 
AGEs, Nε-(carboxyethyl)lysine (CEL) and Nε-(carboxymethyl)lysine (CML), can be 
formed on proteins by both glycoxidation and lipid-peroxidation pathways. α-
Dicarbonyl compounds such as 3-deoxyglucosone (3DG), glyoxal and 
methylglyoxal, are reactive intermediates in the formation of AGEs [11]. 3DG is a 
relatively stable intermediate, whereas glyoxal and methylglyoxal convert readily 
into CML and CEL, respectively. Because the latter are stable compounds, their 
quantification may yield more relevant information than quantification of their 
reactive dicarbonyl precursors.  
 
Data on acute meal-induced changes in oxLDL, 3DG and CML and CEL are limited. 
To date, one study in healthy young men demonstrated an increase in the oxLDL-
to-LDL-cholesterol-ratio after two consecutive fat-rich mixed meals [12], and one 
study in patients with coronary artery disease (CAD) found that postprandial oxLDL 
was associated with the severity and extent of CAD [13]. 
 
In the present study, 26 women with DM2 and 27 women with normal glucose 
metabolism (NGM) received two consecutive (breakfast and lunch) fat-rich or 
carbohydrate-rich meals, in order to study meal-related changes in oxidative stress 
(oxLDL), AGE-compounds (CML and CEL), and a reactive AGE-precursor (3DG). In 
CHAPTER 4 
 
66 
addition to the effects of meal composition and the presence of diabetes, we also 
studied associations between postprandial changes of these markers and changes 
in glucose and triglycerides. 
 
METHODS 
 
Subjects 
 
The present study was a sub-study of a cross-sectional study to assess the effect 
and relative contributions of two consecutive fat-rich and carbohydrate-rich meals 
on markers of CVD risk in women with NGM (fasting glucose<6.1 mmol/l and 2-h 
post-load glucose<7.8 mmol/l) (n=76) and DM2 (n=79). Women with DM2 (n=522), 
recruited from the registry of the Diabetes Care System in the city of Hoorn, the 
Netherlands, and women who were randomly selected from the municipal registry 
of Hoorn (n=541), aged 50-65 years at the beginning of the study, were invited to 
participate in the study. Of these 1,063 women, 431 women were complete non-
responders, 258 women were not willing to participate and 220 women did not 
meet the inclusion criteria. Inclusion criteria were: post-menopausal status, non-
smoking, no untreated endocrine disorder other than DM2, no use of short acting 
insulin analogues, no use of PPAR-α and -γ agonists, no use of oral corticosteroids, 
no use of hormone replacement therapy, no statin use (for NGM-subjects only), 
HbA1c<9.0%, fasting cholesterol<8.0 mmol/l, fasting triglycerides<4.0 mmol/l, 
systolic blood pressure<190 mmHg, no liver impairment or renal impairment. For 
the present study, a sub-sample of 26 women with DM2 (no use of statins or 
insulin analogues) and 27 women with NGM matched for age, were studied. All 
participants gave written informed consent, and the study protocol was approved 
by the ethics committee of the VU University Medical Center in Amsterdam. 
 
Study design 
 
The study consisted of a screening visit and two visits for the test-meals. On the 
screening visit, fasting blood samples were drawn after a 12h overnight fast. Blood 
pressure was measured thrice with an oscillometric blood pressure measuring 
device (Collin Press-mate BP-8800, Colin, Komaki-City, Japan) after a 15-minute 
supine rest. Weight and height were measured in participants wearing light clothes 
only. Smoking and alcohol consumption were assessed by a questionnaire [14]. 
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Test meals  
 
Postprandial meal responses were examined following two standardized 
consecutive test meals (breakfast and lunch). On one day, both test meals were 
high in fat content and on the other occasion, both meals were high in 
carbohydrate content. Both occasions were performed in random order. The fat-rich 
meals (both breakfast and lunch) consisted of 2 croissants, 10 g of butter, 40 g of 
high-fat cheese and 300 ml of high-fat milk (3349kJ; 50 g fat; 56 g carbohydrates). 
The carbohydrate-rich meals (both breakfast and lunch) consisted of 2 slices of 
bread, 25 g of marmalade, 30 g of cooked chicken breast, 50g of ginger bread and 
300ml of drinking yogurt fortified with 45 g of soluble carbohydrates (3261kJ; 4 g 
fat, 162 g carbohydrates). Both meals were eaten within 10 minutes. Apart from the 
test meals and water (ad libitum), participants were not allowed to eat. 
 
Laboratory analysis 
 
Serum total cholesterol, HDL-cholesterol and triglycerides were measured by 
enzymatic colorimetric assays (Roche, Mannheim, Germany). Fasting and 
postprandial LDL-cholesterol was calculated according to the Friedewald-formula if 
triglycerides <4.5 mmol/l [15]. Plasma glucose levels were determined with a 
glucose oxidase method (Granutest, Merck, Darmstadt, Germany) and HbA1c was 
measured with cation-exchange chromatography (Menarini Diagnostics, Florence, 
Italy).  
 
OxLDL was measured in EDTA-plasma in duplicate with a competitive ELISA 
(Mercodia, Uppsala, Sweden), with inter-assay and intra-assay coefficients of 
variation of 7.8% and 4.8%, respectively. We expressed oxLDL as a ratio per LDL-
cholesterol (oxLDL/LDL-C) as proposed by Holvoet et al [16]. 
  
3DG was measured with a newly developed LC-MS/MS method after pre-column 
derivatization according to a published procedure [17]. In brief, 0.5 ml of whole 
blood was mixed with 1.0 ml of 1.2 mol/l perchloric acid and immediately stored at 
-80 ˚C until assayed. After thawing, the samples were centrifuged (5 min at 20,000 
g) and 80 µl of the supernatant was mixed with 100 µl of the internal standard 
solution (1 µmol/l 2,3-pentanedione dissolved in ethanol). After addition of 20 µl of 
the derivatization reagent (10 mmol/l  2,4-dinitrophenylhydrazine dissolved in 1.2 
mol/l perchloric acid), the samples were incubated for 16 h at room temperature. 
Chromatographic separation was performed on a Xterra MS C18-column (4.6x50 
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mm; 3.5 µm particle size) from Waters (Milford, MA, USA) using a linear gradient 
from 40% to 95% acetonitrile in water over 9 min at a flow rate of 1 ml/min. Mass 
transitions of 521.1→431.0 and 521.1→182.1 for 3DG and 459.1→182.1 for the 
internal standard were monitored in negative-ion mode. Intra-assay and inter-assay 
coefficients of variation for 3DG were 8% and 12%, respectively. Two subjects with 
NGM had missing 3DG because of missing blood samples. In a pilot study applying 
the same study-protocol, we assessed the time-course of 3DG in 9 DM2 and 8 NGM 
subjects and measured 3DG with an HPLC-method with fluorescence detection as 
described previously [18].  The highest 3DG concentration was observed at 8 hours 
after the first meal [19].  
 
Unbound CML and CEL were measured in EDTA-plasma by HPLC with stable-
isotope-dilution tandem mass spectrometric detection (LC-MS/MS) using a 
procedure developed for the analysis of protein-bound CML and CEL [20], with a 
modified sample preparation procedure. Briefly, after centrifugation of the plasma 
samples (5 min at 20,000 g), 50 µl of the supernatant was mixed with 150 µl of a 
combined internal standard solution (containing deuterated CML and CEL) and 
proteins were removed by centrifugation (20 min at 15,000 g) in a 10 kDa cut-off 
ultrafiltration device (Vivaspin 500 PES from Vivascience AG, Hannover, Germany). 
A 90 µl aliquot of the ultrafiltrate was mixed with 10 µl of a 50 mmol/l 
nonafluoropentanoic acid solution and 25 µl of this mixture was subjected to LC-
MS/MS analysis as described before [20]. Intra-assay and inter-assay coefficients of 
variation for CML were 3% and 4%, respectively and for CEL 5% and 9%, respectively.  
To assess the cumulative effect of both consecutive meals we measured oxLDL, 
3DG, CML, and CEL at baseline and at 8h. 
 
Statistical analyses 
 
Analyses were performed with SPSS for Windows 11.01 (SPSS Inc., Chicago, IL, USA). 
Data are presented as mean values (standard deviation), and in case of a skewed 
distribution, as median values (interquartile range). Data were ln-transformed 
before testing in case of a skewed distribution. Differences between women with 
NGM and DM2 were tested with Student’s t-test for continuous variables and c2-test 
for dichotomous variables. Differences between meals were tested with paired 
samples t-tests. Postprandial changes in glucose and triglycerides were calculated 
as incremental area under the curve (iAUC) by the trapezoid method. Correlations 
between postprandial responses were calculated by Spearman’s correlation-
coefficients. We considered a two-sided P<0.05 to indicate statistical significance. 
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RESULTS 
 
Characteristics of the study population 
 
The clinical and biochemical characteristics of the participants at the screening visit 
are presented in Table 4.1. 
 
Table 4.1. Clinical and biochemical characteristics of the study-population at the screening 
visit 
Variables NGM DM2 P-value 
N 27 26  
Age (years) 60.3  (4.0) 60.4 (3.2) 0.93 
BMI (kg/m2) 26.0 (3.1) 31.8 (5.8) <0.001 
Fasting glucose (mmol/l) 5.5 (0.3) 7.6 (1.3) <0.001 
HbA1c (%) 5.6 (0.3) 6.5 (0.6) <0.001 
Total cholesterol (mmol/l) 6.0 (1.0) 5.6 (0.9) 0.69 
HDL-cholesterol (mmol/l) 1.93 (0.57) 1.47 (0.30) 0.01 
LDL-cholesterol (mmol/l) 3.6 (0.9) 3.3 (0.9) 0.22 
Triglycerides (mmol/l)* 0.9 (0.8-1.6) 2.0 (1.4-2.4) <0.001 
Systolic blood pressure (mmHg) 125 (12) 143 (16) <0.001 
Diastolic blood pressure (mmHg) 69 (8) 79 (7) <0.001 
Smoking (former) 56% 39% 0.16 
Alcohol-intake (g/week) 78 ± 12 24 ± 7 <0.01 
Antihypertensive medication (%) 0 58 <0.001 
Diabetes treatment (%)    
- diet alone - 35 - 
- metformin  - 54 - 
- sulfonylureas  - 19 - 
- acarbose - 4 - 
Data are mean (standard deviation) or median (interquartile range) in case of skewed data  
NGM= normal glucose metabolism, DM2= type 2 diabetes mellitus  
*ln-transformed before analysis  
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Figure 4.1. Time course of triglycerides and glucose concentrations (mean±SD) following 
two consecutive fat-rich or carbohydrate-rich meals in women with normal glucose 
metabolism (open circles) and type 2 diabetes mellitus (black circles). 
 
Figure 4.1 shows the 8 h-time courses of triglycerides and glucose after two 
consecutive fat-rich and after two consecutive carbohydrate-rich meals. At both 
meal visits, fasting triglyceride and glucose levels were higher in women with DM2 
compared to the women with NGM (both P<0.001). Triglycerides-iAUC was higher 
following the fat-rich meals than after the carbohydrate-rich meals in both women 
with DM2 and NGM (both P<0.001), but was similar in both groups. Following the 
carbohydrate-rich meals, glucose-iAUC was higher in women with DM2 compared to 
NGM (P<0.001), whereas this difference was borderline significant after the fat-rich 
meals (P=0.06).  
 
LDL-C significantly decreased from baseline to 8h in both groups and after both 
meal types (from 3.6±0.8 mmol/l to 3.2±0.7 mmol/l and 3.7±0.8 mmol/l to 
3.3±0.7 mmol/l, fat-rich meals and carbohydrate-rich meals, respectively in NGM 
and from 3.3±0.7 mmol/l to 2.9±0.7 mmol/l and 3.3±0.7 mmol/l to 3.0±0.7 
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mmol/l, fat-rich meals and carbohydrate-rich meals, respectively in DM2 (all 
P<0.001). 
 
Glycoxidative and lipoxidative stress markers 
 
The oxLDL/LDL-C, 3DG, CML and CEL values in women with NGM and DM2 at 
baseline and at 8h are listed in Table 2. Baseline oxLDL/LDL-C, 3DG and CML were 
significantly higher in DM2 compared to NGM. The increase of oxLDL/LDL-C during 
the fat-rich meals was higher than the increase during the carbohydrate-rich meals 
(17±10% versus 10±7% in NGM and 15±13% versus 7±9% in DM2, both P<0.05). Of 
interest, the fasting values of ox-LDL/LDL-C, 3DG and CML in women with DM2 
were similar to the postprandial values at 8h in women with NGM (all P>0.1). 
 
Table 4.2. Fasting and postprandial (8 hours) levels of oxLDL/LDL-C, 3DG, CML and CEL in 
women with NGM compared to women with DM2* 
  NGM DM2 
  Fasting Postprandial Fasting Postprandial 
OxLDL/LDL-C (U/mmol) Fat 21.6 (3.8) 25.1 (4.8)‡ 25.4 (4.6)‡  29.6 (8.7)‡ 
 Carb 21.6 (2.8) 23.7 (3.8)‡ 25.7 (4.3)‡ 27.3 (4.9)‡ 
3DG (nmol/l) Fat 164 (41) 183 (45)‡ 208 (60)§ 236 (58)‡ 
 Carb 164 (37) 208 (40)§ 210 (49)§ 281 (50)§ 
CML (nmol/l) Fat 39.6 (10.1) 45.1 (10.6)‡ 52.2 (18.1)‡ 47.9 (14.1)† 
 Carb 43.3 (10.7) 54.7 (9.4)§ 48.2 (16.2)‡ 55.9 (16.0)§ 
CEL (nmol/l) Fat 62.7 (31.2) 67.4 (15.1) 67.0 (27.4) 66.0 (16.3) 
 Carb 56.4 (13.5) 72.1 (12.8) § 65.8 (23.3) 72.9 (17.9) 
*Abbrevations: NGM:normal glucose metabolism, DM2:type 2 diabetes mellitus,  
Fat:fat-rich meal, Carb:carbohydrate-rich meal, OxLDL/LDL-C:ratio of oxidized LDL to total LDL-cholesterol, 
3DG:3-dexoxyglucosone, CML:Nepsilon-(carboxymethyl)-lysine, CEL:Nepsilon-(carboxyethyl)-lysine 
†p<0.05 DM2 baseline versus NGM baseline or 8h versus baseline 
‡p<0.01 DM2 baseline versus NGM baseline or 8h versus baseline 
§p<0.001 DM2 baseline versus NGM baseline or 8h versus baseline 
 
Baseline oxLDL/LDL-C was correlated with fasting triglycerides in women with DM2 
(r=0.39, P<0.05), but not in women with NGM. After the fat-rich meals, changes in 
oxLDL/LDL-C correlated with changes in triglycerides, either expressed as 
triglycerides-iAUC (r=0.32, P<0.05; Figure 4.2a) or as increase over baseline at 8h 
(r=0.50, P<0.001). 
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The mean increase of 3DG after the carbohydrate-rich meals was higher than after 
the fat-rich meals (29±21% versus 13±24%, P<0.05 in NGM, and 36±17% versus 
15±20%, P<0.001 in DM2). Fasting plasma glucose concentration was correlated 
with baseline 3DG in women with DM2 (r=0.50, P<0.01), but not in women with 
NGM. Postprandial changes in 3DG correlated to glucose-iAUC after the fat-rich 
meals (r=0.37, P<0.01; Figure 4.2b), but not with glucose-iAUC after the 
carbohydrate-rich meals. The changes of CML and CEL were neither correlated to 
triglycerides-iAUC nor to glucose-iAUC, irrespective of meal composition. 
 
 
 
Figure 4.2. Relations between postprandial changes of the oxLDL-to-LDL-cholesterol ratio 
and 8h incremental area under the curve for plasma triglycerides (A) and between changes 
of 3-deoxyglucosone and 8h incremental area under the curve for glucose (B) after two 
consecutive fat-rich meals in women with normal glucose metabolism (open circles) and 
type 2 diabetes mellitus (black circles). Strengths of the associations are indicated by 
Spearman’s correlation coefficients. 
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DISCUSSION 
 
In the present cross-sectional study in postmenopausal women with NGM and DM2, 
we studied the postprandial changes of oxLDL/LCL-C, 3DG, CML and CEL, following  
two consecutive fat-rich or carbohydrate-rich meals. The main findings are that the 
fasting values of oxLDL/LDL-C, 3DG and CML are higher in women with DM2 
compared to women with NGM. In women with DM2, the fasting values of 
oxLDL/LDL-C, 3DG and CML were similar to the postprandial values at 8h in women 
with NGM. Overall, the postprandial rises of oxLDL/LDL-C and 3DG were of similar 
magnitude in DM2 and NGM. OxLDL/LDL-C showed a greater increase after the fat-
rich meals, whereas CML and 3DG increased more after the carbohydrate-rich 
meals. The increase in oxLDL/LDL-C was correlated with the rise in postprandial 
triglycerides, whereas the increase in 3DG was correlated with the postprandial rise 
of glucose.  
 
There is increasing evidence that postprandial glucose and triglycerides may play 
an important role in macro- and microvascular complications [21]. However, their 
relative contributions and the mechanisms leading to the increased CVD risk are 
not yet fully understood [5]. Prospective studies have shown that postprandial or 
post-load glucose levels are more strongly associated with increased CVD than 
fasting glucose [22,23]. Oxidative stress is hypothesized to be an important 
pathway linking postprandial glucose and triglyceride responses to CVD [24,25]. 
Indeed, in a recent study it was found that postprandial oxLDL was a determinant 
of the extent of coronary atherosclerosis in patients with CAD [13]. A limitation of 
most previous studies is that responses after a single meal were studied, which 
might not reflect the “real life” burden of the postprandial state, possibly leading to 
an underestimation of the associations between postprandial responses and CVD 
risk. A recent study from our group that applied two consecutive meals (breakfast 
and lunch) in healthy young men, demonstrated that even slightly increased levels 
of triglycerides and glucose were associated with endothelial dysfunction and 
increased markers of oxidative stress, including oxLDL [12]. We concluded that 
these findings might be relevant for insulin resistant subjects and DM2 individuals 
who have a more pronounced (exaggerated and prolonged) postprandial elevation 
of glucose and triglycerides, possibly leading to more oxidative stress. Our present 
findings support this conjecture, as we found that baseline oxLDL was higher in 
DM2 than in NGM, with a greater increase of oxLDL after the fat-rich meals 
compared to the carbohydrate-rich meals. Interestingly, although fasting 
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oxLDL/LDL-C was higher in the DM2 group, we found no difference in the 
postprandial increase in oxLDL/LDL-C between NGM and DM2. 
 
There are multiple sources and mechanisms in the formation of AGEs in vivo, 
involving both oxidative and non-oxidative reactions of reducing carbohydrates and 
other metabolic intermediates with amino acid residues [26]. The AGE precursor 
3DG, which is increased in patients with diabetes [27], is formed by non-oxidative 
modifications of Amadori adducts and from fructose-3-phosphate [28]. In line with 
these observations, we found that 3DG increased more after the carbohydrate-rich 
meals than after the fat-rich meals. In addition, postprandial changes in 3DG were 
strongly correlated to changes in glucose, but surprisingly, only after the fat-rich 
meals, suggesting additional involvement of oxidative mechanisms in its formation. 
In patients with type 1 diabetes Beisswenger et al observed an increase in 3DG 
within two hours [29], whereas in our pilot study in patients with DM2 we did not 
observe a rise in 3DG after the first meal [19]. 
 
Some studies have shown that total serum CML is higher in DM2 than in healthy 
individuals [30,31], although in other studies no difference was observed [20]. We 
chose not to measure total CML and CEL, but rather the unbound forms of these 
compounds, that are continuously released during degradation of intracellular 
proteins with a rapid turn-over. Because oxidative stress not only enhances 
formation of protein-bound CML and CEL, but also triggers proteasomal 
degradation of damaged proteins [32,33], the unbound fraction of CML and CEL 
may better reflect formation of AGEs by oxidative stress. We observed that CML was 
affected by both meal types. However, possibly due to a relatively large biological 
variation, as reflected by differences in the baseline CML and CEL values at the two 
meal visits, these changes were less consistent than for oxLDL and 3DG. Future 
studies should assess whether changes in the protein-bound forms of CML and CEL 
are more informative. 
 
The major precursor of CML is glyoxal and oxidative stress seems to enhance the 
formation of glyoxal from glucose [34], which is consistent with our finding of a 
greater increase in CML after the carbohydrate-rich meals compared to the fat-rich 
meals.  
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Potential limitations 
 
First, both groups were not matched for BMI, lipids, blood pressure and alcohol 
intake, all of which may have independent effects on the parameters measured. 
However, we chose not to match for these variables, to avoid selection of relatively 
healthy DM2 patients. Second, our study was performed in elderly postmenopausal 
women and the changes observed may be different in younger women as well as in 
men. 
 
Conclusion 
 
In summary, we found significant elevations of postprandial oxLDL/LDL-C, 3DG and 
CML in postmenopausal women with DM2 and NGM. Since postprandial increases in 
α-dicarbonyls and associated AGEs are related to cellular damage, therapies aimed 
at reducing postprandial glycemia and triglyceridemia, may contribute to the 
reduction in micro- and macrovascular complications. 
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ABSTRACT 
 
Background:  Patients with type 2 diabetes mellitus (DM2) have an increased risk of 
cardiovascular disease (CVD). Myeloperoxidase (MPO), expressed in leukocytes, and 
released upon activation, is associated with CVD and endothelial dysfunction. 
Postprandial leukocyte recruitment and activation with subsequent MPO release 
may contribute to atherosclerosis and CVD. We hypothesized that MPO may 
increase in the postprandial state, due to postprandial leukocyte recruitment 
and/or activation, especially in subjects with DM2. 
 
Methods:  One hundred post-menopausal women, aged 50-65 years (66 with 
normal glucose metabolism [NGM], and 34 with DM2), received two consecutive fat-
rich meals and two consecutive carbohydrate-rich meals on separate occasions. 
Blood samples were taken before (t=0), and at 2,4 and 8 hours following breakfast; 
lunch was given at t=4. Plasma MPO-concentration was measured by sandwich 
ELISA. 
 
Results:  The number of leukocytes in fasting blood samples was higher in DM2 
compared with NGM (6.1±1.4 and 5.4±1.2x109/l, respectively; P<0.05). Baseline 
MPO concentration did not differ between NGM and DM2 (51.4±12.9 and 
54.5±18.4 µg/L, respectively; P=0.39). Baseline MPO was positively associated with 
leukocytes (r=0.20; P<0.05) and inversely associated with high-density lipoprotein 
cholesterol (r=-0.22; P<0.05). Leukocytes increased from 5.0±1.5 to 6.1±1.5x109/L 
and from 5.8±1.4 to 6.6±1.4x109/l in NGM and DM2, respectively (both P<0.01) 
following the fat-rich meals. In contrast to our hypothesized increase in MPO, we 
found a significant decrease in MPO in NGM (both meal types) and DM2 (fat-rich 
meals only). 
 
Conclusions: Our findings provide no support to our initial hypothesis that meal-
induced release of MPO might be a mechanism that contributes to CVD risk.
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INTRODUCTION 
 
Patients with type 2 diabetes mellitus (DM2) have an increased risk of 
cardiovascular disease (CVD) [1-3[. Evidence has been accumulating that chronic 
low-grade inflammation may be an important factor in the pathogenesis of 
atherosclerosis and CVD [4,5]. The number of white blood cells, especially 
polymorphonuclear neutrophils, is associated with future CVD events [6,7]. 
However, the role of leukocytes in the pathogenesis of CVD has not yet been fully 
elucidated. It has been demonstrated that the number of leukocytes was increased 
between one and six hours after a fat challenge [8]. Postprandial recruitment and 
activation of these cells have been suggested to contribute to endothelial 
dysfunction [9], which is an early event in the atherosclerotic process. Since 
postprandial responses after a fat-rich mixed-meal may be more pronounced and 
prolonged in subjects with DM2 than in healthy controls [10], this may result in a 
higher postprandial leukocyte recruitment in these patients. This may be even more 
the case in postmenopausal women, who have higher postprandial triglyceride 
responses compared to premenopausal women [11]. 
 
Myeloperoxidase (MPO) is a heme protein which is abundantly expressed in 
leukocytes, and released upon activation into phagocytic vacuoles and in the extra 
cellular space [12,13]. Several in vitro and in vivo studies have shown that MPO 
interacts with the vessel-wall by various mechanisms, including binding and 
transcytosis through endothelial cells, and leads to hypochlorous acid generation, 
nitric oxide oxidation and tyrosine nitration [14]. MPO has been associated with 
coronary artery disease [15], recurrent coronary events [16], heart failure [17] and 
endothelial dysfunction [18]. 
 
Postprandial leukocyte recruitment and activation with subsequent MPO activation 
may thus contribute to atherosclerosis and CVD, especially in patients with DM2 
because of the prolonged and exaggerated dysmetabolic state. Based on these 
observations, we hypothesized that, in particular in subjects with DM2, MPO would 
increase in the postprandial state due to postprandial leukocyte recruitment and/or 
activation. Therefore we assessed postprandial plasma MPO after two consecutive 
fat-rich or carbohydrate-rich meals in women with DM2 and in women with normal 
glucose metabolism (NGM). 
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MATERIAL AND METHODS 
 
Subjects and study design 
 
The women included in the present study were part of a cross-sectional study to 
assess the effect and relative contributions of two consecutive fat-rich and 
carbohydrate-rich meals on markers of CVD risk in postmenopausal women with 
NGM (n=76) and DM2 (n=79). Women with DM2 (n=522), recruited from the registry 
of the Diabetes Care System in the city of Hoorn, the Netherlands, and women who 
were randomly selected from the municipal registry of Hoorn (n=541), aged 50-65 
years at the beginning of the study, were invited to participate in the study. Of 
these 1,063 women, 431 women were complete non-responders, 258 women were 
not willing to participate and 219 women did not meet the inclusion criteria, 
yielding 155 eligible participants. Inclusion criteria were: post-menopausal status 
(no menses in the last 12 months), non-smoking, no untreated endocrine disorder 
other than DM2, no use of short acting insulin analogues, no use of PPAR-α and -γ 
agonists, no use of oral corticosteroids, no use of hormone replacement therapy, 
no use of HMG-CoA reductase inhibitors (statins) (for NGM only), HbA1c<9.0%, 
fasting cholesterol <8.0 mmol/l, fasting triglycerides <4.0 mmol/l, systolic blood 
pressure <190 mmHg, no liver impairment or renal impairment. Women who were 
selected from the municipal registry underwent a 75-g oral glucose tolerance test 
to verify their glucose tolerance status (fasting glucose <6.1 mmol/l and 2-hour 
post-load glucose <7.8 mmol/l). In addition to the above-mentioned inclusion 
criteria of the main study protocol, for the present analyses we chose not to include 
DM2 women using statins (n=38), as statins have been shown to down regulate 
MPO gene expression [19,20]. Thus, for the present study 41 women with DM2, 
and 76 women with NGM were included. The protocol consisted of three separate 
visits, i.e. a screening visit and two visits for the test-meals. Postprandial meal 
responses were examined following the consumption of two consecutive 
standardized test meals (breakfast and lunch; fat-rich meals [3349 kJ; 50 g fat; 56 
g carbohydrates and 28 g proteins] and carbohydrate meals [3261 kJ; 4 g fat, 162 g 
carbohydrates and 22 g of proteins]) on two separate occasions and in random 
order. Blood samples were taken before and at t=2, 4 and 8 hours following 
breakfast for measurement of glucose, triglycerides and MPO. Lunch was given 4 
hours after breakfast  (t=4). Apart from the test meals and water (ad libitum), 
participants were not allowed to eat. In addition, physical activity was limited 
during the day. All participants gave informed consent, and the study protocol was 
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approved by the ethics committee of the VU University Medical Center in 
Amsterdam. 
 
Measurements  
 
At the screening visit, blood pressure was measured at the left arm three times 
with 5 minute intervals with an oscillometric blood pressure measuring device 
(Collin Press-mate BP-8800, Colin, Komaki-City, Japan) after a 15-minute supine 
rest. Waist circumference was measured twice at the level midway between the 
lowest rib margin and the iliac crest. Medical history was assessed by a 
questionnaire [21]. 
 
Laboratory analyses  
 
MPO was determined in duplicate by a sandwich ELISA (Mercodia, Uppsala, Sweden) 
in EDTA-plasma using a CODA® automated EIA analyzer (Biorad, San Francisco, CA, 
USA). The concentration of MPO was measured in baseline samples, and in samples 
that were taken at 2, 4 and 8 hours after breakfast. The intra-assay and inter-assay 
coefficients of variation were 3.3% and 5.0%, respectively. Serum total cholesterol, 
high-density lipoprotein (HDL) cholesterol and triglycerides were measured by 
enzymatic colorimetric assays (Roche, Mannheim, Germany). Low-density 
lipoprotein (LDL) cholesterol was calculated according to the Friedewald-formula 
[22]. Plasma glucose levels were determined with a glucose oxidase method 
(Granutest, Merck, Darmstadt, Germany) and glycated hemoglobin (HbA1c) was 
measured with cation exchange chromatography (Menarini Diagnostics, Florence, 
Italy). Leukocytes were measured at baseline in all subjects and at 8 hours after 
breakfast in a sub-sample (n=43; 29 NGM and 14 DM2) to determine the 
postprandial leukocyte response. 
 
Statistical analyses 
Analyses were performed in SPSS for Windows 11.0.1 (SPSS Inc. Chicago, IL). Data 
are presented as mean values (standard deviation) or in case of skewed 
distribution, as median values (interquartile range). Differences in baseline 
characteristics between the NGM and DM2 groups were tested with a Students’ t-
test for continuous variables. Postprandial triglyceride, glucose and MPO responses 
were calculated as incremental and total area under the curve (iAUC and tAUC, 
respectively) with the trapezoid method and expressed as mean incremental or 
total concentration by dividing the incremental or total response by 8 hours. 
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Differences in postprandial MPO responses (mean total and mean incremental area 
under the curve) between the fat-rich and the carbohydrate-rich meals were tested 
by a paired samples t-test. A one-samples t-test with zero as test-value was used to 
test whether the mean incremental area was different from zero (i.e. no change in 
mean incremental MPO). Differences in postprandial time-point (2, 4 and 8h) were 
tested with a paired-samples t-test compared to baseline. Correlations between 
MPO and clinical and biochemical characteristics were expressed as Spearman’s 
correlation coefficients. A two-sided P-value<0.05 was considered as statistically 
significant.  
 
RESULTS 
 
Characteristics of study population 
 
Subjects with one or more missing values were excluded (n=17) and all statistical 
analyses were performed on the remaining 100 subjects (66 with NGM and 34 with 
DM2). Subjects who were excluded from the statistical analyses did not significantly 
differ with respect to fasting total leukocyte count, triglycerides and glucose (all 
P>0.05, for NGM and DM2 separately). The characteristics of the 100 subjects are 
presented in Table 5.1. On average, women with DM2 were more obese, had higher 
fasting plasma glucose, HbA1c, triglycerides, and blood pressure compared to 
women with NGM. No differences were observed in total and LDL-cholesterol, 
whereas HDL-cholesterol was lower in DM2.  
 
Postprandial glucose and triglycerides 
 
Figure 1 shows the 8 hour time courses of triglycerides and glucose after two 
consecutive fat-rich and after two consecutive carbohydrate-rich meals. The 
increase (iAUC) in postprandial triglycerides was similar in women with DM2 and 
women with NGM after the fat-rich meals (0.9±0.5 versus 0.9±0.5 mmol/l; P=0.97). 
The rise of plasma glucose (iAUC) levels after the fat-rich meals was higher in 
women with DM2 compared to the NGM women (0.7±1.5 versus 0.1±0.4 mmol/l, 
respectively; P<0.05). Following the carbohydrate-rich meals, postprandial glucose 
(iAUC) values were higher in women with DM2, compared to women with NGM 
(3.1±2.7 versus 0.4±0.6 mmol/l, respectively; P<0.001). 
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Table 5.1. Clinical and biochemical characteristics of the study-population (n = 100) 
Variablea NGM DM2 P-value 
n 66 34  
Age, years 60.5 (4.0) 58.7 (3.7) 0.03 
Waist, cm 87.1 (9.8) 102.4 (14.4) <0.001 
Fasting glucose, mmol/lb 5.2 (0.3) 7.0 (1.3) <0.001 
HbA1c, % 5.5 (0.3) 6.5 (0.6) <0.001 
Total cholesterol, mmol/lb 5.7 (0.8) 5.6 (1.0) 0.41 
HDL-cholesterol, mmol/lb 1.65 (0.41) 1.40 (0.30) <0.01 
LDL-cholesterol, mmol/lb 3.5 (0.8) 3.4 (0.8) 0.40 
Triglycerides, mmol/lb, c 1.1 (0.9-1.4) 1.5 (1.2-2.0) <0.001 
Systolic blood pressure, mmHg 129 (14) 143 (17) <0.001 
Diastolic blood pressure, mmHg 70 (8) 79 (7) <0.001 
NGM= normal glucose metabolism, DM2= type 2 diabetes mellitus 
a Data are mean (standard deviation)  
b mean of the two meal-visits 
c ln-transformed before analysis 
 
 
 
Figure 5.1. Time course of triglycerides [left panel] and glucose [right panel] (mean ± SEM) 
following two consecutive carbohydrate-rich meals (solid line) and two fat-rich meals 
(dotted line), given at 0 and 4 hours in individuals with normal glucose metabolism (NGM: 
open dots) and patients with type diabetes mellitus (DM2: solid dots) 
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Baseline and postprandial leukocytes and MPO  
 
Baseline number of leukocytes was higher in DM2 compared to NGM (6.1±1.4 
versus 5.4±1.2 x 109 /l, respectively; P < 0.05). Changes in postprandial leukocyte 
counts were measured in a sub-sample of 43 participants (29 NGM and 14 DM2). In 
this sub-sample, the number of leukocytes did not significantly increase after the 
carbohydrate-rich meals (from 5.0±1.2 to 5.3±1.3 x 109 /l in NGM and from 
5.8±1.3 to 6.0±1.4 x 109 /l in DM2; P = 0.07 and P = 0.23, respectively). Following 
the fat-rich meals, leukocytes increased from 5.0±1.5 to 6.1±1.5 x 109 /l and from 
5.8±1.4 to 6.6±1.4 x 109 /l in NGM and DM2, respectively (both P < 0.01). The 
postprandial changes in MPO are presented in Figure 2 and in Table 2. Baseline 
MPO (mean value of the two meal visits) was not statistically significantly different 
between NGM and DM2 (51.4±12.9 and 54.5±18.4 µg /l respectively; P = 0.39). 
Baseline MPO was positively associated with total leukocyte counts (r=0.20; P = 
0.04), whereas an inverse association of fasting MPO with fasting HDL-cholesterol 
(r=-0.22; P = 0.02) was observed. No significant associations of baseline MPO were 
found with age, triglycerides, fasting glucose, and total-cholesterol and systolic and 
diastolic blood pressure. MPO-iAUC and MPO-tAUC after both meal types did not 
significantly differ between DM2 and NGM, nor did MPO at any of the time-points 
differ between DM and NGM (all P > 0.1). MPO-iAUC was significantly different from 
zero in NGM (-2.5±5.5 and -2.9±5.3 µg/l, fat-rich meals and carbohydrate-rich 
meals respectively; both P<0.01), but not in DM2 (-1.7±5.5 and -1.6±5.2 µg/l; fat-
rich meals and carbohydrate-rich meals respectively; P = 0.08 and P = 0.09 
respectively). Furthermore, compared to baseline MPO was significantly lower at 8 
hours after breakfast in NGM (both meal types) and DM2 (fat-rich meals only) (all P 
< 0.05) (Table 2).  
  
Table 5.2. Fasting and postprandial levels of MPO (mean, SD) in women 
with NGM and women with DM2a 
 Time CARB FAT 
  NGM DM2 NGM DM2 
MPO [µg/l] baseline 51.8 (14.0) 55.6 (18.9) 51.0 (13.0) 53.8 (18.4) 
 2 50.6 (13.1) 52.3 (18.3) b 51.9 (13.8) 52.3 (17.4) 
 4 48.8 (13.4)b  54.1 (17.2) 49.5 (12.1) 53.2 (17.8) 
 8 48.0 (13.0)b 53.5 (18.5) 47.2 (12.6)b 50.5 (17.7)b 
aAbbrevations: NGM: normal glucose metabolism, DM2: type 2 diabetes mellitus,  
Fat: fat-rich meal, Carb: carbohydrate-rich meal, MPO: myeloperoxidase 
b P < 0.05 versus baseline 
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Figure 5.2. Time course of MPO (mean ± SEM) following two consecutive carbohydrate-rich 
meals (solid line) [left panel] and two fat-rich meals (dotted line) [right panel], given at 0 
and 4 hours in individuals with normal glucose metabolism (NGM: open dots) and patients 
with type diabetes mellitus (DM2: solid dots) 
 
DISCUSSION  
This is, to the best of our knowledge, the first study to examine postprandial MPO 
responses. We found no significant differences in baseline MPO between DM2 and 
NGM. Baseline MPO was negatively related to HDL-cholesterol and positively 
correlated to leukocyte counts. Total leukocytes increased after the fat-rich meals 
in both NGM and DM2, whereas MPO decreased postprandially in NGM (both meals) 
and in DM2 (fat-rich meals).  
 
Previous studies have shown that leukocytes increase following a fat-rich meal [9]. 
In addition, one study suggested that activation markers on monocytes and 
neutrophils are increased and related to postprandial changes in triglycerides [8]. 
Furthermore, activation markers on monocytes and neutrophils were higher in DM2 
as compared to healthy controls [23]. These observations suggest that postprandial 
leukocyte recruitment and activation may be a mechanism in the relation between 
postprandial derangements and increased CVD risk. In addition, a number of 
studies suggest that patients with higher MPO levels have an increased CVD risk 
[15-18]. In the present study, the number of leukocytes in the fasting blood 
samples was higher in DM2 as compared to NGM, but in spite of this, MPO was not 
significantly higher in DM2 as compared to NGM. This lack of difference may be 
explained by an impaired leukocyte function in DM2. Indeed, a previous study 
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showed lower MPO in lymphocytes and neutrophils in patients with DM2 compared 
to healthy controls [24]. In contrast to our initial hypothesis, we found lower MPO 
values in the postprandial state after both meal types. Therefore, changes may not 
only be meal-induced, but also due to diurnal changes in leukocytes and MPO. 
Future studies assessing diurnal MPO course in the fasting state should address 
this issue. In addition, because of unavailable plasma samples at 6 hours 
postprandial, the present data may have underestimated the true changes in 
postprandial MPO.  
 
Of interest, we found a negative correlation between MPO and HDL-cholesterol. 
Indeed, MPO binds to apolipoprotein AI of HDL particles and may subsequently be 
inactivated or excreted [25]. Furthermore, MPO may be involved in generating 
dysfunctional HDL and thus promote atherogenesis by this pathway [26]. In line 
with this conjecture, a recent study has shown that MPO is associated with 
progression of carotid artery stenosis in patients with low HDL-cholesterol levels 
[27]. MPO has also been shown to promote oxidation of LDL particles [28,29], 
which may provide another mechanism linking MPO to CVD risk. 
 
We measured MPO in EDTA-plasma instead of heparin-plasma or serum. MPO mass 
determined in serum is in general higher than in heparin plasma due to in vitro 
release of MPO from activated leukocytes [30]. For heparin plasma it is necessary to 
collect the samples on ice before sample processing (i.e. centrifugation) to avoid 
MPO release [30]. When EDTA-blood was taken, we observed no changes in MPO 
concentrations over a period of 2 hours at room temperature before sample 
processing, whereas MPO rose gradually in heparin-plasma as well as in blood 
withdrawn in tubes without an added anticoagulant (data not shown). Hence, EDTA-
plasma was chosen for MPO measurements because we assume that this may 
reflect the in vivo MPO secretion of leukocytes most precisely. Although Zhang and 
coworkers reported a high correlation between MPO mass and MPO activity (r = 
0.95) [15], we cannot exclude that postprandial changes in MPO activity are more 
pronounced than alterations in MPO concentrations.  
 
In conclusion, we found no increase in MPO concentration despite the postprandial 
increase in leukocytes after the fat-rich meals, suggesting that postprandial 
leukocyte recruitment is likely to occur, but without a concomitant MPO release in 
plasma. Our findings provide no support to the initial hypothesis that meal-induced 
release of MPO might be a mechanism that contributes to CVD risk in 
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postmenopausal women with NGM or DM2 and therefore other mechanisms may 
link postprandial leukocytes to CVD risk.  
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ABSTRACT 
For a long time, hepatic steatosis was believed to be a benign condition. Only 
recently, liver steatosis, also termed non-alcoholic fatty liver disease (NAFLD), has 
gained much interest. In most cases of NAFLD, a condition regardedas the hepatic 
component of the metabolic syndrome, the enzyme alanine aminotransferase (ALT) 
is elevated and consequently has been used as a marker for NAFLD. More recently, 
several cross-sectional and prospective studies have demonstrated associations of 
this liver enzyme with features of the metabolic syndrome and type 2 diabetes 
mellitus. This review discusses the biochemical and metabolic properties of ALT, its 
applicability as a marker of NAFLD and describes its possible role in the 
pathogenesis of the metabolic syndrome and type 2 diabetes mellitus and 
subsequent cardiovascular disease. In addition treatment strategies to ameliorate 
NAFLD and the associated risks are discussed. 
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INTRODUCTION 
 
For a long time, hepatic steatosis was believed to be a benign condition. Only 
recently, liver steatosis, also termed non-alcoholic fatty liver disease (NAFLD), has 
gained much interest. NAFLD, which is characterized by a wide spectrum of liver 
pathology ranging from mere liver steatosis to the more severe non-alcoholic 
steatohepatitis, resembles alcohol-induced liver disease, but develops in subjects 
who are not heavy alcohol consumers and have negative tests for viral and auto-
immune liver diseases [1–3]. This condition was first described in detail by Ludwig 
and colleagues in 1980, who reported 20 moderately obese patients with liver 
biopsy changes resembling alcohol-induced hepatitis, although none of these 
patients reported a history of alcohol abuse [4]. Only in recent years, NAFLD has 
gained appreciation as a pathogenic factor of insulin resistance and type 2 diabetes 
mellitus. Furthermore, several studies showed an association between NAFLD and 
features of the metabolic syndrome, including dyslipidemia and (visceral) obesity, 
stressing the association with insulin resistance as an important feature of NAFLD. 
Currently, NAFLD is considered by some authors to be the hepatic component of 
the metabolic syndrome [5,6]. 
 
In the majority of cases, NAFLD causes asymptomatic elevation of the level of liver 
enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ-
glutamyltransferase (GGT)) [7]. Of these liver enzymes, ALT is most closely related 
to liver fat accumulation [8], and consequently ALT has been used as marker of 
NAFLD. GGT may also be elevated in patients with NAFLD, but only limited data on 
its occurrence and degree of elevation are available. Furthermore, the correlation of 
liver fat measured by proton-MR spectroscopy with GGT is markedly lower than 
with ALT [8], possibly because GGT is also produced in other tissues [9,10]. Finally, 
to the best of our knowledge no direct validation of GGT with fat content in liver 
biopsy specimen has been reported. Several cross-sectional studies have found 
associations of ALT with several features of the metabolic syndrome. At present, 
ALT is often used in epidemiological studies as a surrogate marker for NAFLD. In 
addition, recent prospective epidemiological studies have demonstrated that ALT is 
associated with future risk of type 2 diabetes mellitus and the metabolic syndrome 
[11–17].  
 
This review discusses the biochemical and metabolic properties of ALT, its 
applicability as a marker of NAFLD and describes its possible role in the 
pathogenesis of the metabolic syndrome and type 2 diabetes mellitus and 
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subsequent cardiovascular disease (CVD), as well as discusses the treatment 
strategies to ameliorate NAFLD and the associated risks. 
 
BIOCHEMISTRY AND LABORATORY ANALYSIS 
 
ALT catalyses the reversible transamination between L-alanine and α-ketoglutarate 
to form pyruvate and L-glutamate and as such has an important role in 
gluconeogenesis and amino-acid metabolism (Figure 6.1). The reaction is 
reversible, but the equilibrium of the ALT reaction favors the formation of L-
alanine. The vitamin B6 vitamers pyridoxal-5’-phosphate (PLP) and its amino 
analogue pyridoxamine-5’-phosphate, function as coenzymes in the amino transfer 
reaction. ALT enzyme activity is primarily found in the liver, but its activity, 
although much lower, is also found in many other organs including muscle, heart, 
kidney, brain and adipose tissue [18-20]. 
 
 
 
Figure 6.1. Alanine aminotransferase (ALT) catalyses the interconversion of the amino-group from L-
alanine to α-ketoglutarate and forms pyruvate and L-glutamate. Pyridoxal-5’-phosphate (PLP) 
functions as a coenzyme in the amino-transfer reaction. 
 
 
In 1957, Wroblewski and Cabaud described a colorimetric ALT assay based on 
measurement of glutamate by paper chromatography [21]. In later assays, the 
transamination reaction was coupled to a second reaction involving the reduction 
of pyruvate to lactate by lactate dehydrogenase [22]. In this reaction nicotinamide 
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adenine dinucleotide (NADH) is oxidized to NAD+ and the decrease in NADH is 
assessed by measuring the absorption at 340 or 334 nm. In the past, comparison 
between ALT activities reported by different laboratories was hampered by the fact 
that assay temperatures ranging from 25 to 37 ˚C were used, leading to large 
inter-laboratory differences in reported ALT activities and reference values. The 
International Federation of Clinical Chemistry and Laboratory Medicine established 
in 2002 a reference system for the measurement of enzyme activity of clinically 
important enzymes, including ALT, to be measured at 37 ˚C [23]. Levels of 10 to 
45 U/l are considered as normal although reference values may still vary among 
laboratories [24]. ALT activity is stable for 24 hours in whole blood, with a marked 
decrease thereafter. In serum, ALT enzyme activity is stable for three days at room 
temperature and for three weeks in the refrigerator, but a marked decrease is 
observed after repeated freezing and thawing [25-28]. It is therefore strongly 
advisable not to determine ALT activity in frozen samples, as a falsely decreased 
ALT activity may be found. Day-to-day variations of 10-30% have been observed 
[29]. Moreover, significant diurnal variations have been reported in both healthy 
subjects and in patients with chronic liver disease, necessitating standardized 
blood sampling times when comparing enzyme values in clinical practice and 
research [30].  
 
Early biochemical studies have suggested the existence of two isoforms of ALT in 
humans. Based on the amino acid sequence of liver ALT [31], Sohocki and 
colleagues have cloned the human ALT1 located on human chromosome 8q24.3 
[32]. Recently, Yang and colleagues cloned the second isoform ALT2 that was 
mapped to the human chromosome 16q12.1 and demonstrated that this isoform 
was mainly expressed in muscle and adipose tissue [33]. The expression of ALT2 in 
adipose tissue may indicate that this isoform may contribute to the homeostasis of 
fatty acid metabolism and storage. In fatty livers of obese mice, Jadhao and 
colleagues demonstrated that murine ALT2 gene expression was induced 2-fold 
whereas expression of murine ALT1 remained the same, and the total hepatic ALT 
enzyme activity was elevated by 30% [34]. These observations indicate that ALT2 
may be responsible for the increased ALT activity in hepatic steatosis. In the 
pathogenesis of NAFLD, the role of different isoforms in humans has not been 
studied yet. With the standard ALT assay used in clinical practice, enzyme activity 
of both ALT isoforms is measured. 
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ALT AND FATTY LIVER 
 
Fatty liver content can be assessed with different methods. Direct measurement of 
hepatic fat by means of liver biopsies, which is regarded as the “gold standard” 
[35], although questionable because of the unknown distribution of fatty 
infiltration in the liver, has only limited applicability in epidemiological and clinical 
studies, because of the elaborate and invasive nature and associated risks of this 
technique. Furthermore, no consensus exists on the standardization of diagnostic 
criteria bases on liver histology, although only recently a scoring system for NAFLD 
has been proposed [36]. Imaging techniques, such as ultrasound, computed 
tomography and proton magnetic resonance spectroscopy (1H-MRS), are non-
invasive and can be used rather than biopsies [37,38]. Ultrasound of the liver is 
another non-invasive technique which can be used to indicate the presence or 
absence of fatty infiltration of the liver, however, at present, this technique at its 
best can provide only semi-quantitative data with regard to NAFLD. However, non-
invasive techniques cannot differentiate between fatty liver alone or steatohepatitis. 
1H-MRS has been validated against direct determination of triglyceride content in 
human liver biopsies [39], and may be used for clinical purposes, but has limited 
applicability in larger populations, because of logistics and high costs. In more 
recent epidemiological studies, ALT has been used as a surrogate marker for liver 
fat accumulation. This was first described by Nanji and colleagues in 1986, who 
reported an association of liver enzymes (i.e. the ALT to AST ratio) with fatty liver in 
obese patients [40]. Studies assessing the specificity and sensitivity of ALT as 
marker of NAFLD are limited [41,42]. Prati and colleagues have suggested new cut-
off values for ALT in order to facilitate the identification of subjects with NAFLD 
[43]. However, since cut-off values depend on the assay used, this proposal has 
been questioned by others [24,44]. One study has assessed the correlation of ALT 
with 1H-MRS and found a modest, but significant correlation (r=0.5) [8]. We found a 
similar correlation between liver fat accumulation measured by 1H-MRS and ALT 
(r=0.58; P<0.001) in 36 healthy men and men with the metabolic syndrome with 
and without hyperglycemia (type 2 diabetes mellitus) (M.E. Tushuizen et al., 
unpublished data).  
 
In order to avoid confounding by other factors that might cause ALT elevation, a 
detailed history on alcohol intake is mandatory to exclude those patients with ALT 
elevation caused by alcohol-abuse, and to address alcohol-intake as a possible 
confounder or effect-modifier. Viral and auto-immune liver disease and hepatotoxic 
medication should be considered as well. With these limitations in mind, ALT is an 
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acceptable marker for hepatic steatosis in epidemiological studies; its use for 
diagnostic and monitoring purposes in clinical care needs to be further delineated.  
 
ALT AND INCIDENT METABOLIC SYNDROME AND TYPE 2 DIABETES 
MELLITUS 
 
The putative role of the liver in the pathogenesis of type 2 diabetes mellitus has 
gained much interest and several cross-sectional and prospective studies have 
shown associations of ALT with type 2 diabetes mellitus and the metabolic 
syndrome. Several cross-sectional studies have demonstrated that ALT is related to 
features of the metabolic syndrome and type 2 diabetes mellitus [7,45-48]. Clark 
and colleagues for example found in their analysis of The National Health and 
Nutrition Examination Survey (NHANES) that up to 31% of the elevated 
aminotransferase activity could be explained by high alcohol consumption, 
hepatitis B or C infection and/or high transferrin saturation. In the remaining 69%, 
the elevated ALT activity was significantly associated with higher body mass index, 
waist circumference, triglycerides, fasting insulin and lower HDL-cholesterol. 
Additionally, in women, this elevation was associated with type 2 diabetes mellitus 
and hypertension [7]. In one study it was demonstrated that ALT can be normal in 
uncomplicated obesity [49], but this does not guarantee absence of NAFLD, as 
normal ALT levels have been observed in patients with NAFLD, diagnosed by liver 
biopsy, which is regarded as the gold standard in the diagnosis of NAFLD [50]. 
Several studies addressed the prospective relation of ALT with the metabolic 
syndrome and type 2 diabetes mellitus (Table 6.1). Nakanishi and co-workers found 
that of the liver enzymes studied, ALT was associated with future risk of metabolic 
syndrome in middle-aged Japanese men, but used body mass index instead of 
waist circumference to define the metabolic syndrome [16]. Hanley and co-workers 
studied the relation of four different liver enzymes (including ALT) with the 
development of the metabolic syndrome in a multiethnic cohort and demonstrated 
that ALT was associated with an increased risk of incident metabolic syndrome 
[17]. In patients with type 2 diabetes mellitus, elevated serum ALT enzyme activity 
is more frequently observed than in the general population [54,55]. Some [11-15], 
but not all studies [16,51-53] have demonstrated independent and significant 
associations of ALT with incident type 2 diabetes mellitus. In 1988, Ohlson and 
colleagues demonstrated that baseline ALT was a predictor of incident type 2 
diabetes mellitus after 13.5 years of follow-up in a cohort of 766 Swedish men, 
with a significant four-fold risk for those men in the upper quintile compared to 
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those in the lower quintile. In the final multivariate model, ALT was a predictor of 
incident type 2 diabetes mellitus in 451 Pima Indians after an average of 6.9 years, 
after adjustment for fasting blood glucose levels, body mass index, bilirubin, 
systolic blood pressure, uric acid and a family history of diabetes [11]. Vozarova 
and colleagues found that higher ALT (upper compared to lower decile) was a 
significant and independent predictor of incident type 2 diabetes mellitus with a 
two-fold increase risk, after adjustment for age, sex, body fat, insulin sensitivity 
and acute insulin response [12]. Other studies, mainly performed in men, 
confirmed these earlier reports [13,14], while recent population-based studies 
could not demonstrate independent associations of ALT with risk of type 2 diabetes 
mellitus [52,53]. The observed association between ALT and incident type 2 
diabetes mellitus in these reports may thus be explained by the fact that these 
studies were performed in high-risk populations and may not be representative for 
the general population. An alternative explanation is that the applied models over-
adjust for potential mediating variables, such as insulin and 2h glucose, that might 
be directly related to liver fat and/or for risk factors clustered in the metabolic 
syndrome. More population-based studies and a better understanding of the 
pathophysiology are needed to confirm and understand the predictive value of ALT 
in relation to the metabolic syndrome and type 2 diabetes mellitus. 
 
ALT AND CARDIOVASCULAR DISEASE 
 
Several studies have demonstrated associations between NAFLD or ALT and 
markers of atherosclerosis or inflammation. Previously, we reported an association 
of ALT with endothelial dysfunction, measured as flow-mediated vasodilatation 
[56], and Kerner and colleagues found a relation of ALT with C-reactive protein 
[57]. Only a limited number of studies have addressed the prospective relation of 
ALT with cardiovascular disease and mortality. Arndt and colleagues studied the 
association of ALT with all-cause mortality in 8,043 male construction workers and 
found no significant association [58]. A recent study by Nakamura and co-workers 
found a positive association of ALT with all-cause mortality in Japanese men and 
women, but only for those with a body mass index below the median (22.7 kg/m2) 
[59]. In the Hoorn Study, a population-based cohort of Caucasian men and women 
aged 50 to 75 years, we studied the association of ALT at baseline with all-cause 
mortality, incident cardiovascular and coronary heart disease events and found a 
significant association of ALT with coronary heart disease after adjustment for the 
other components of the metabolic syndrome and traditional risk factors [60].  
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Table 5.1. Prospective studies assessing the relation of ALT and incident metabolic syndrome and type 2 diabetes mellitus
First Author Cohort Subjects Age Sex (%male) Follow -up, y Relative Risk Comparison Groups
Metabolic Syndrome
Nakanishi[16] Japanese men 2957 35-59 100% 7.0 1.42 (0.95 -2.11) Upper versus lower quintile
Hanley[17] IRAS 633 40-69 44% 5.2 2.12 (1.10 -4.09) Upper versus lower quartile
Type 2 diabetes mellitus
Ohlson[11] Swedish men 54 100% 13.5 3.9 (1.4 -11.1) Upper versus lower quintile
Vozar ova[12] Pima Indians 451 18-50 61% 6.9 1.9 (1.1 -3.3) Upper versus lower decile
Sattar[13] WOSCOPS 5974 45-64 100% 5.6 2.04 (1.16 -3.58) Upper versus lower quartile
Hanley[14] IRAS 906 40-69 44% 5.2 2.00 (1.22 -3.38) Upper versus lower three quartiles
Wann amethee[15] British Regional Heart 
Study
3500 40-59 100% 5.0 1.91 (1.01 -3.60) Upper versus lower quartile
Nakanishi[16] Japanese men 3620 35-59 100% 7.0 2.07 (1.07 -3.98) Upper versus lower quintile
Nannipieri[51] Mexico City Diabetes 
Study
1233 35-64 39% 7.0 No significant association Upper quartile vs. lower quartiles
Schindhelm[52] Hoorn Study 1289 50-75 46% 6.4 1.18 (0.66 –2.11) Upper  tertile versus lower tertile
Andre[53] DESIR Study 2071
2130
30-65 100%
0%
3.0 1.5 (0.6 -30) 
0.7 (0.2 -2.1)
Upper ver sus lower quartile
6
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PATHOGENIC MECHANISMS  
 
To date, an elevated ALT is considered a consequence of hepatocyte damage due 
to  NAFLD. However, the measured plasma elevations of ALT may also be a 
consequence of  high systemic ALT2 isoform levels that is largely derived from 
adipose tissue in obesity and insulin resistance, as has been observed in mice [34]. 
Insulin resistance, increased pro-inflammatory cytokine production, oxidative stress 
and mitochondrial dysfunction leading to hepatocyte damage/destruction, all have 
been posed as important pathophysiological mechanisms [61]. Indeed a recent 
study reported on the association of ALT and GGT with markers of inflammation 
and oxidative stress [62].  
 
Adiponectin, released by adipose tissue has been implied in the pathogenesis of 
NAFLD. Obese subjects and patients with type 2 diabetes mellitus have lower levels 
of adiponectin compared to healthy controls. Yokoyama and colleagues found an 
inverse association of ALT, AST and GGT with adiponectin levels in Japanese male 
workers. These associations were independent of age, body mass index, insulin 
resistance, serum triglycerides and total cholesterol [63]. Aygun and co-workers 
found that adiponectin levels were lower in patients with biopsy proven NAFLD and 
elevated liver enzymes, compared to patients with NAFLD and normal liver enzymes 
and to those without NAFLD [64]. The exact mechanisms, by which adiponectin is 
related to NAFLD are not fully elucidated and need further clarification.  
 
Insulin resistance and visceral obesity have a major impact on regulatory processes 
of the (postprandial) lipoprotein and glucose metabolism. The normal suppression 
of lipolysis by insulin is impaired in the insulin resistant state and this leads to an 
elevated release of free fatty acids from the adipose tissue and subsequent 
accumulation in hepatocytes, further enhancing hepatic steatosis and contributing 
to increased risk of atherothrombotic disease in subjects with NAFLD and insulin 
resistance. Dietary fat composition also seems to influence the degree of hepatic 
steatosis [65], although the majority of triglycerides arise from free fatty acids, 
derived from adipose tissue lipolysis [66]. It has been demonstrated that a fatty 
liver is insulin resistant, resulting in an elevated glucose and very low-density 
lipoprotein production [12]. Furthermore, cytokines released from the (visceral) 
adipose tissue, including interleukin-6 and tumor necrosis factor-alpha, both 
associated with decreased hepatic insulin sensitivity [67], may further enhance fatty 
infiltration and decrease hepatocyte integrity.  
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Another explanation might be up-regulation of ALT enzyme activity. Among the 
amino acids, alanine is the most effective precursor for gluconeogenesis [68]. 
Gluconeogenesis is increased in subjects with type 2 diabetes mellitus [69], due to 
increased substrate delivery (e.g. alanine), and an increased conversion of alanine 
to glucose [70]. This increased conversion might contribute to the increased ALT 
activity, as previously observed in alloxan-diabetic rats [71].   
ALT might thus be up-regulated as a compensatory response to the impaired 
hepatic insulin signaling or, alternatively, may leak more easily out of the 
hepatocytes as a consequence of fatty infiltrations and subsequent damage. 
 
THERAPEUTIC INTERVENTIONS 
 
Therapeutic approaches, including diets and exercise, leading to weight loss and 
improvement of the cardiovascular disease risk profile, have also been shown to 
lower liver fat content.. These interventions concomitantly improve insulin 
sensitivity and/or reduce oxidative stress. Ueno and colleagues compared the 
effect of restricted diet and exercise in a group of 15 obese subjects during 3 
months to that of no lifestyle changes in a control group of 10 obese subjects. 
They found a decrease in biochemical markers of NAFLD including ALT, total 
cholesterol and fasting blood glucose. This was confirmed by liver biopsies 
demonstrating significant lower fat in the treatment group compared to the control 
group [72]. Similar results were found in a recent study by Suzuki and co-workers, 
who studied the effect of diet and exercise induced weight reduction on the change 
of serum ALT and found that subjects with more than 5% weight reduction and 
persistence of this weight reduction showed improvement of serum ALT [73]. 
Hickman and colleagues assessed the effect of weight loss in patients with chronic 
liver disease. In addition to improvements in quality of life and insulin sensitivity, 
they also demonstrated that ALT reduction was correlated with the amount of 
weight loss (r=0.35; P=0.04) after 15 months. ALT remained significantly lower in 
those patients who maintained their reduced weight [74]. Although these life-style 
interventions seem promising in the short term, long term effects have not yet 
been established and might not be sufficient in patients with multiple 
cardiovascular disease risk factors, such as subjects with the metabolic syndrome 
and/or type 2 diabetes mellitus. 
 
Several pharmacological agents, including metformin and peroxisome proliferator-
activated receptor-γ (PPAR-γ) agonists have been used in the treatment of NAFLD. 
Only a limited number of studies addressed the effect of metformin and/or PPAR-γ 
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agonists on ALT. An open-labeled trial of 20 mg/kg metformin for one year, 
demonstrated only a transient improvement of liver enzymes [75]. Tiikkainen and 
co-workers compared the effect of 2 g of metformin to 8 mg of the PPAR-γ agonists 
rosiglitazone on liver fat content and hepatic insulin sensitivity in a 16 week 
double-blind randomized trial in 20 subjects. They found that rosiglitazone 
decreased liver fat by 51%, whereas no significant decrease was observed in the 
metformin treated subjects [76]. In contrast, Bugianesi and co-workers found that 2 
g of metformin lead to more ALT normalization (i.e. below the reference range) 
than either vitamin E or diet induced weight reduction in 55 subjects in an 12 
months open-labeled randomized trail. Metformin induced a decrease of 50% in 
liver fat and a decrease of inflammation and necrosis, using paired liver biopsies 
[77]. Unfortunately, in this study no paired biopsies were performed in the subjects 
who were randomized to vitamin E or the weight reduction intervention, thus the 
level of liver histology improvement in the treatment group could not be compared 
with the effect in the control group. Sanyal and co-workers compared the effect of 
vitamin E versus vitamin E and the PPAR-γ agonists pioglitazone (30 mg/day) in a 
randomized clinical trial with 10 patients with non-alcoholic steatohepatitis in each 
treatment arm. They found that vitamin E reduced the amount of hepatic steatosis, 
whereas the combination of vitamin E with pioglitazone also improved liver 
histology [78]. In a recently published study, Ding and co-workers demonstrated 
that 60 days administration of a glucagon-like peptide-1 (GLP-1) receptor agonists, 
an incretin-mimetic known to promote insulin production and secretion, reduced 
hepatic steatosis in ob/ob mice [79]. Studies in humans assessing the effect of GLP-
1 receptor agonists on hepatic steatosis are needed to confirm these results and 
assess the applicability of these agents for the treatment of hepatic steatosis. Long-
term effects and reduction of morbidity and mortality of the above mentioned 
treatment modalities need further evaluation to achieve optimal treatment 
strategies. 
 
CONCLUSIONS 
 
In epidemiological studies, ALT seems an appropriate marker of fatty liver disease, 
if known factors that cause ALT elevation have been addressed properly (e.g 
alcohol consumption and hepatitis B and C infections). ALT enzyme activity and 
NAFLD are associated with cardiovascular risk factors and treatment of NAFLD 
should be aimed at reducing hepatic fat content and reduce the concomitant CVD 
risk. Moreover, ALT might provide guidance in clinical practice for the choice 
between the different treatment options and to monitor the effect of therapy. 
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ABSTRACT 
 
Background Plasma levels of liver transaminases, including alanine 
aminotransferase (ALT), are elevated in most cases of nonalcoholic fatty liver 
disease (NAFLD). Elevated ALT levels are associated with insulin resistance, and 
subjects with NAFLD have features of the metabolic syndrome that confer high-risk 
cardiovascular disease. Alanine aminotransferase predicts the development of type 
2 diabetes (DM2) in subjects with the metabolic syndrome. However, the role of 
elevated ALT levels in subjects with overt DM2 has yet not been explored. 
 
Materials and methods In a cross-sectional study, 64 normotriglyceridemic 
subjects with DM2 were studied with regard to the relation between liver 
transaminases with whole-body insulin sensitivity, measured with the euglycemic 
hyperinsulinemic clamp and with brachial artery flow-mediated dilation (FMD) as a 
marker of endothelial dysfunction. 
 
Results On average, patients were normotriglyceridemic (plasma triglycerides 
1.3±0.4 mmol/l) and had good glycemic control (HbA1c 6.2±0.8%). The mean ALT 
level was 15.0±7.5 U/l, and the mean aspartate aminotransferase concentration 
equaled 10.6±2.6 U/l. Alanine aminotransferase levels were negatively associated 
with whole-body insulin sensitivity as well as with FMD (both P = 0.03, in 
multivariate analyses; regression coefficients beta [95%CI]: -0.76 [-1.4 to –0.08] and 
–0.31 [-0.58 to –0.03] respectively). 
 
Conclusions In metabolically well-controlled patients with DM2, ALT levels are 
related to decreased insulin-sensitivity and an impaired conduit vessel vascular 
function. 
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INTRODUCTION 
 
Non-alcoholic fatty liver disease (NAFLD) includes a wide spectrum of liver 
pathology, ranging from fatty liver alone to the more severe non-alcoholic 
steatohepatitis [1]. NAFLD develops in people who are not heavy alcohol 
consumers, and usually has a benign clinical course [2,3]. Recent studies have 
shown associations between NAFLD and obesity, dyslipidemia and insulin 
resistance, all of which are features of the so-called metabolic syndrome [3,4]. 
People with the metabolic syndrome are at increased risk of type 2 diabetes (DM2) 
and cardiovascular and all-cause mortality [5]. In the majority of cases, NAFLD 
causes asymptomatic elevation of liver enzyme levels [6], including alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), which are sensitive 
indicators of hepatocellular injury [7]. The former is primarily found in the liver, the 
latter is also found in other tissues and is a less specific marker of liver integrity 
[7,8]. Recent studies have demonstrated that elevated levels of liver enzymes, and 
in particular ALT, are associated with obesity [9], insulin resistance and DM2 [10]. 
Recent prospective studies found that levels of ALT predicted incident DM2, 
independently of the classical risk factors [11] or changes in obesity [10]. 
Endothelial dysfunctions are an early event in the development of atherosclerosis 
[12,13]. One of these functions, i.e. the nitric oxide or endothelium-dependent 
regulation of vascular tone can be assessed by measuring vasodilatation of the 
brachial artery in response to ischemia-induced increases in blood flow (flow-
mediated dilation; FMD) [14]. The brachial FMD is closely correlated to coronary 
endothelial function [15], and endothelial dysfunction predicts future 
cardiovascular events [16].  
 
To date, there are no studies in subjects with DM2, assessing the association 
between liver enzyme plasma levels and the severity of insulin resistance, and 
vascular endothelial dysfunction. The aim of the present study was to assess the 
association between alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels with whole-body insulin sensitivity and brachial-artery 
FMD in normotriglyceridemic subjects with DM2. 
 
CHAPTER 7 
116 
MATERIALS AND METHODS 
 
Subjects 
 
Patients with DM2 were recruited from shared care projects in Amsterdam and 
Hoorn, and via local newspaper advertisements. The following inclusion criteria 
were used: age between 40 and 70 years, DM2 as diagnosed by a physician 
according to the WHO-criteria [17], HbA1c <8.5% and fasting triglyceride 
concentrations as defined as a mean value from three measurements of <2.2 
mmol/l, current smoking was allowed. Pregnancy, the premenopausal state 
(defined as the presence of menstrual bleeds), the use of lipid lowering drugs or 
insulin, alcohol abuse (see below), and liver impairment (serum ALT>70 U/l, serum 
AST>50 U/l) or renal impairment (serum creatinine>130 µmol/l or creatinine 
clearance<50 ml/min) were exclusion criteria. Written informed consent was 
obtained from all subjects and the Ethics Committee of VU University Medical 
Center approved the study-protocol. In total, 293 subjects were invited for 
screening, of whom 93 fulfilled the inclusion criteria.  
 
Study Design 
 
The study was performed between 1997 and 1999 and the values for the above 
mentioned inclusion and exclusion criteria are those that were in accordance with 
the prevailing guidelines and generally accepted at that time. Patients were seen on 
6 occasions during a period of 14 weeks. The study consisted of one screening visit 
(at week –1) to assess eligibility, 3 follow-up visits (at week 0, 6 and 12), during 
which dietary intake was assessed and anthropometry and blood collections were 
performed (see below). Finally, patients underwent a hyperinsulinemic euglycemic 
clamp and a vascular ultrasound examination during 2 separate visits (between 
week 12 and 14). 
 
Alcohol intake  
 
Subjects were asked to record their dietary intake from one day in a week 
(morning, afternoon and evening), during a total of 5 occasions, with an interval of 
2 weeks between the recorded days. From these recordings, the mean alcohol 
intake was calculated as an average of the five recorded days. Subjects with a mean 
alcohol intake of more than 40 gram per day were excluded from further analyses.  
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Hyperinsulinemic-euglycemic clamps 
 
Insulin sensitivity was measured using a hyperinsulinemic euglycemic clamp 
technique as previously described [18]. In short, following an overnight fast, 
subjects were placed in the semi-supine position and two polytetrafluoroethylene 
cannulas (Venflon, Viggo Helsiborg, Sweden) were inserted into the antecubital or 
antebrachial veins of each arm, one for intermittent blood glucose sampling and 
the other for the infusion of the glucose and insulin solutions.  A volume of 0.5 mL 
insulin (100 U mL-1; Velusolin, Novo Nordisk, Bagsvaerd, Denmark) was diluted to 
50 mL with 45 mL  0.9% sodium chlorine solution and 4.5 mL human albumin (20%; 
CLB, Amsterdam, The Netherlands). Arterialized blood glucose levels were 
measured every 5 minutes with an automated glucose oxidase method (Yellow 
Springs Instruments, Yellow Springs, OH, USA) after the start of the insulin infusion. 
The initial insulin infusion rate (120 mU/m2/min) was decreased to 40 mU/m2/min 
once the glucose level was 5.0 mmol/l, and thereafter the glucose 20% infusion 
rate was adjusted to maintain this blood glucose level for 2 hours. The M-value, 
expressed as glucose uptake in mg/m2/min, was calculated from the average 
glucose infusion rate during the last 60 minutes and expressed per unit of plasma 
insulin concentration (M/I-value).   
 
Vascular Ultrasound 
 
A non-invasive ultrasound method for measuring FMD of the brachial artery as 
described previously was used [19]. In short, vessel diameter of the right brachial 
artery was measured with an ultrasound system (Ultramark IV, ATL, Bothell, WA, 
USA) in combination with a vessel movement detector system (Wall Track System, 
Neurodata, Bilthoven, The Netherlands). Measurements were carried out by a single 
experienced ultrasound operator (RJAMvD) in a quiet room, in fasted subjects after 
a 15-minute rest in the supine position. An ischemia-induced increase in blood flow 
by releasing a blood pressure tourniquet that had been inflated for 4 minutes at 
the fore-arm to 100 mmHg above systolic blood pressure, which results in an 
increase in shear stress, was used as the stimulus for FMD. Nitroglycerin (0.4 mg 
sublingually) was used to obtain nitroglycerin mediated dilation (NMD). FMD was 
calculated as the percent change in diameter post-occlusion of the brachial artery 
at 60 seconds relative to the measurement at baseline before blood pressure 
tourniquet inflation {[(response x baseline)/baseline]e100}. NMD was calculated as 
the percent change in diameter before and 5 minutes after administration of the 
nitroglycerin. 
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Anthropometric measures and laboratory analysis  
 
A detailed history, in particular regarding alcohol intake and smoking status, was 
obtained from each participant. Furthermore height, weight, and waist and hip 
circumference were measured with the subjects wearing only light clothes. Waist 
circumference was measured at the level midway between the lowest rib margin 
and the iliac crest, and hip circumference was measured at the widest level over the 
greater trochanters. Body mass index (BMI; weight divided by height squared; kg m-
2) was calculated. Serum cholesterol and HDL-cholesterol were measured with the 
CHOD-PAP-method (Roche, Mannheim, Germany). Serum triglycerides were 
measured with the GPO-PAP-method (Roche, Mannheim, Germany). LDL-cholesterol 
was calculated according to the Friedewald-formula [20]. ALT and AST levels were 
determined by enzymatic assays (Roche, Mannheim, Germany). Plasma glucose was 
determined with a glucose oxidase method (Granutest, Merck, Darmstadt, 
Germany). Glycated hemoglobin (HbA1c) was measured with ion exchange high 
performance liquid chromatography (Modular Diabetes Monitoring System, BioRad 
Lab, Veenendaal, The Netherlands). Insulin was measured with a double antibody 
radio-immunoassay (SP21, Linco Research, St. Louis, USA). Pro-insulin was 
measured with an immunometric assay (Dako Diagnostics Ltd., Cambridgeshire, 
UK). C-reactive protein (CRP) was measured by an immunoturbidimetric assay (Tina-
quant CRP, Boehringer Mannheim, Mannheim Germany)(reference range: 0-8 mg/l).  
 
Statistical analysis 
 
Analyses were performed by SPSS for Windows 11.0.1 (SPSS Inc. Chicago, IL). Data 
are mean (standard deviation) or percentage. Reported values for serum lipids, 
glucose, and HbA1c are the mean value of three assessments, which were 
performed on the morning of inclusion, on the morning of week 6 and on the 
morning of week 12 after an overnight fast; all other laboratory assessments were 
determined once. Pearson’s correlation coefficients were calculated to evaluate 
relationships between variables. Multiple linear regression analyses were performed 
to investigate the associations between ALT as determinant and insulin sensitivity 
(M/I-value) and FMD as outcome variables. In the respective regression models for 
M/I-value and FMD, adjustments were made for age and sex (Model 1 and Model 4, 
respectively). Subsequently, these models were adjusted for AST levels, yielding 
Model 2 and Model 5, respectively. Model 3, which had insulin sensitivity as 
dependent variable, was Model 2, with additional correction for BMI, since former 
studies have shown that obesity was a confounder of the association between ALT 
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and insulin resistance [9,10]. In Model 6, which had FMD as outcome variable, 
Model 5 was adjusted for insulin sensitivity since previous investigations found 
insulin sensitivity to be an important determinant of FMD [21]. A two-sided P-value 
<0.05 was considered to indicate statistical significance.  
 
RESULTS 
 
Patient characteristics 
 
Subjects with missing data on insulin sensitivity and/or patients with missing data 
on FMD were excluded (n=26). Three subjects were excluded because of an alcohol 
intake of more than 40 grams per day or missing data on alcohol intake.   
 
Table 7.1. Clinical characteristics  
  
N 64 
Men / women 35 / 29 
Age (years) 61.8 ± 7.2 (44 – 70) 
Duration of DM2 (years) 4.7 ± 5.6 (0.3 – 33.6)  
Body mass index (kg/m2)  28.5 ± 5.3 
Waist (cm) male / female    101 ± 12.9 / 97.7 ± 13.7  
Hypertension (%)* 42.2 
Systolic blood pressure (mmHg) 144 ± 17 
Diastolic blood pressure (mmHg) 83 ± 8 
Use of alcohol (%) 65.6 
Alcohol intake (g/d) 10.0 ± 11.2 
Cigarette smoking (%) 15.5 
C-reactive protein (mg/l) 2.6 ±  2.6 (0.12-11.9) 
Values are mean ±  SD, percentage or (range)    
 *Defined as RR > 160/90 mmHg and/or use of anti-hypertensive medication. 
 
Finally, 64 subjects were included in the present analyses and their clinical and 
biochemical characteristics are listed in Tables 7.1 and 7.2. On average, patients 
were normotriglyceridemic and had good glycemic control. Forty-two subjects were 
treated by sulfonylurea drugs, 18 by metformin and 2 used α-glucosidase 
inhibitors (or combinations thereof). 
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Table 7.2. Metabolic and vascular characteristics  
Glucose and insulin metabolism  
Fasting glucose concentration (mmol/l) 8.0 ± 1.7 
Fasting insulin concentration (pmol/l)* 75.8 ± 43.0 
Fasting pro-insulin concentration (pmol/l) 17.8 ± 10.6 
M/I-value (mg/m2/min/pmol/l) 0.33 ± 0.17 
HbA1c (%) 6.2 ± 0.8 
  
Lipid metabolism  
Triglycerides (mmol/l) 1.3 ± 0.4 
Total cholesterol (mmol/l)  5.6 ± 0.9 
HDL-cholesterol (mmol/l) 1.29 ± 0.3 
LDL-cholesterol (mmol/l)  3.7 ± 0.9 
  
Vascular function of the brachial artery  
Flow-mediated dilation (%)  6.3 ± 6.0 
Nitroglycerin-mediated dilation (%)† 12.4 ± 8.1 
  
Liver enzyme levels‡  
Alanine aminotransferase  (U/l) 15.0 ± 7.5 (4 - 48) 
Aspartate aminotransferase (U/l) 10.6 ± 2.6 (5 - 17) 
Values are mean±SD or (range) 
*n=62  
†n=63  
‡ Reference ranges: ALT<35 U/l; AST<25 U/l 
 
 
 
Liver enzyme correlations 
 
Neither ALT nor AST were correlated with the reported amount of alcohol intake 
(r=-0.05; P=0.7 and r=-0.11; P=0.4, respectively) or smoking status (r=0.18; P=0.12 
and r=0.07; P=0.5, respectively) and additional corrections for alcohol intake or 
smoking status did not change the presented correlations. Table 7.3 lists the 
correlations between ALT and AST and anthropometric, metabolic and vascular 
parameters. ALT, but not AST, was weakly but significantly correlated with waist, 
hip, fasting insulin, fasting pro-insulin, M/I-value and NMD. The association 
between ALT and FMD tended to be significant (P=0.08). AST was weakly but 
significantly correlated with fasting blood glucose levels only. 
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Table 7.3. Correlations among hepatic enzymes and selected anthropometric,  
metabolic and vascular parameters 
 ALT  AST 
      
 r P  r P 
Anthropometry       
BMI 0.13 0.31  -0.06 0.63 
Waist 0.27 0.03  -0.003 0.98 
Hip 0.26 0.03  0.08 0.51 
      
Insulin and glucose metabolism      
Fasting glucose 0.03 0.83  -0.27 0.03 
Fasting insulin* 0.43 <0.001  0.20 0.12 
Fasting pro-insulin 0.39 0.006  0.09 0.49 
M/I-value -0.29_ 0.02  -0.08 0.53 
      
Vascular function      
FMD -0.22 0.08  -0.06 0.63 
NMD -0.27 0.04  -0.16 0.22 
r, correlations by Pearson; FMD, flow mediated dilation; NMD, nitroglcyerin mediated  dilation. 
*n=62   
 
 
Associations of liver enzymes with insulin resistance and endothelial function  
 
Multiple linear regression models were used to study the association of ALT with 
M/I-values and FMD. In multiple linear regression analyses, a significant association 
of insulin sensitivity with ALT after adjustment for AST (Model 2, Table 7.4) and 
adjustment for BMI (Model 3, Table 7.4) was found. The age- and gender adjusted 
association of FMD and ALT tended to be significant (P=0.06; Model 4, Table 7.4), 
was significant after adjustment for AST levels (P=0.045; Model 5, Table 7.4), and 
remained significant after adjustment for insulin sensitivity (P=0.03; Model 6, Table 
7.4). 
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Table 7.3. Correlations among hepatic enzymes and selected anthropometric,  
metabolic and vascular parameters 
 ALT  AST 
      
 r P  r P 
Anthropometry       
BMI 0.13 0.31  -0.06 0.63 
Waist 0.27 0.03  -0.003 0.98 
Hip 0.26 0.03  0.08 0.51 
      
Insulin and glucose metabolism      
Fasting glucose 0.03 0.83  -0.27 0.03 
Fasting insulin* 0.43 <0.001  0.20 0.12 
Fasting pro-insulin 0.39 0.006  0.09 0.49 
M/I-value -0.29_ 0.02  -0.08 0.53 
      
Vascular function      
FMD -0.22 0.08  -0.06 0.63 
NMD -0.27 0.04  -0.16 0.22 
r, correlations by Pearson; FMD, flow mediated dilation; NMD, nitroglcyerin mediated  dilation. 
*n=62   
  
Table 7.4. Regression models of the associations of ALT with insulin-sensitivity  
(M/I-value) and vascular dysfunction (FMD) 
Model* b 95% CI P 
    
M/I-value (*100)    
Model 1  -0.73 -1.3 to -0.18 0.010 
Model 2   -0.99 -1.7 to -0.30 0.006 
Model 3 -0.76 -1.4 to -0.08 0.029 
    
FMD    
Model 4 -0.20 -0.40 to  +0.08 0.060 
Model 5 -0.26 -0.52 to -0.006 0.045 
Model 6 -0.31 -0.58 to -0.03 0.030 
b, unstandardized regression coefficient; CI, confidence interval; FMD, flow-mediated dilation   
*Model 1: adjusted for age and gender; Model 2: as Model 1 with additional adjustment for AST; Model 3: as 
Model 2 with additional adjustment for BMI; Model 4: adjusted for age and gender; Model 5: as Model 4 with 
additional adjustment for AST; Model  6: as Model 5 with additional adjustment for insulin sensitivity (M/I-
value) 
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DISCUSSION 
 
We observed that circulating ALT was inversely associated with whole-body insulin 
sensitivity, measured with the hyperinsulinemic euglycemic clamp, in 
normotriglyceridemic subjects with DM2. Moreover, we demonstrated a negative 
association between plasma ALT levels and vascular endothelial function, which 
was measured as FMD. 
 
High ALT levels are associated with fatty liver disease and might therefore be 
considered  as a feature of the metabolic syndrome. Furthermore, elevated ALT, but 
not AST levels, were related to hepatic insulin resistance in normoglycemic subjects 
at high risk of DM2, and in these subjects, elevated ALT predicted the development 
of DM2 [10]. In some studies, the prospective relationship between ALT and DM2 
reflected the cross-sectional association with obesity and insulin resistance [9,10], 
whereas others found the predictive effect of ALT to be independent of obesity and 
body fat distribution [22]. In the present study, the association between ALT and 
whole-body insulin sensitivity was independent of BMI.  
 
The pathogenesis of NAFLD is not yet fully understood but oxidative stress and 
lipid peroxidation resulting from excessive lipid accumulation (lipotoxicity) are 
regarded as important pathophysiological factors [23-25]. Central obesity and the 
inappropriate suppression of lipolysis arising from insulin resistance, result in an 
increased flux of non-esterified or free fatty acids (FFA) and an increased output of 
triglyceride-rich VLDL particles from the liver. Due to the increased triglyceride/FFA 
load, in the presence of impaired glucose utilization, non-adipose tissues, including 
liver, muscle and the pancreatic β cells, accumulate triglycerides [26]. In these 
tissues, intracellular triglyceride overload increases the pool of long-chain acyl Co-
A, thus providing abundant substrate for nonoxidative metabolic pathways and the 
formation of toxic metabolites and also causing mitochondrial dysfunction and 
subsequent production of reactive oxygen species. These lipid-induced changes 
ultimately lead to organ dysfunction and cell apoptosis.  
 
At present there are no studies addressing the value of ALT as a risk marker once 
DM2 has developed. In addition, since hypertriglyceridemia is one of the hall-marks 
of the metabolic syndrome [27], demonstration of high plasma ALT levels in 
normotriglyceridemic DM2 subjects may be of additional value in predicting high 
risk of microvascular and/or macrovascular complications. Abnormal liver function 
tests are more common in DM than in non-DM populations as well as in subjects 
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with DM2 than in those with DM1 [28]. In DM1, elevated liver enzymes were 
associated with diabetic complications such as retinopathy and neuropathy, 
independently of alcohol consumption, BMI and glycemic control [29]. To our 
knowledge, at present no such data have been reported for DM2 subjects. Here, we 
show an association between ALT levels and impaired endothelial function in 
normotriglyceridemic subjects with DM2. Previously, the presence of generalized 
endothelial dysfunction in insulin-resistant subjects and patients with DM2 was 
proposed to explain the excess cardiovascular morbidity and mortality in these 
populations [21]. The mechanisms underlying this endothelial dysfunction include 
insulin resistance at the level of the vascular wall, in part due to elevated circulating 
FFA levels, causing a reduction in insulin-mediated nitric oxide production, as well 
as insulin- resistance associated induction of inflammatory pathways and oxidative 
stress [30,31]. Collectively, these mechanisms decrease the bioavailability of NO 
leading to loss of the anti-atherogenic properties of the vascular endothelium 
including impairment of NO-mediated vasodilatation. Indeed, the significant 
association between ALT and FMD did not change after adjustment for insulin 
resistance, indicating that the association of ALT with FMD is not only mediated by 
insulin resistance but that other factors, including oxidative stress and 
inflammation, may also play a role. This latter suggestion is in accordance with a 
recent study that demonstrated that ALT is associated with CRP-levels, indicating 
that a low-grade inflammatory process is involved in the pathogenesis of NAFLD 
[32].  
 
Our study has some limitations. First, the study population consisted of patients 
with relatively well-controlled DM2 with regard to glycaemia and triglyceridemia 
and therefore, the observed associations may be an underestimation of the 
relationships in diabetic subjects with poor metabolic control. Second, we used 
elevation of liver enzyme levels as an indicator of NAFLD instead of biopsies, which 
are regarded as the gold standard. Third, although we addressed alcohol as major 
potential confounder in this study, we could not account for other factors that may 
cause liver enzyme elevations, including iron-status [33], infections and/or 
hepatotoxic medication [34]. However, we acknowledge that the cut-off value of 40 
grams of alcohol per day is slightly higher that the most recently suggested cut-off 
value of 20 grams per day for women and 40 grams per day for men [35]. Fourth, 
the study had a cross-sectional design and the observed associations cannot be 
interpreted as a reflection of causal relationships. Finally, although we assessed 
whole-body insulin resistance and not hepatic insulin resistance, the positive 
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association of ALT with fasting insulin values might indicate that clearance of 
insulin in the liver is less effective [36,37]. 
 
In summary, in relatively well-controlled patients with DM2, plasma ALT levels are 
related to a decline in insulin-sensitivity and an impairment of conduit vessel 
endothelial function. The findings might suggest that elevated ALT is a marker of 
liver fat also in normotriglyceridemic DM2. Additional prospective studies are 
needed to confirm these results in other study populations and further clarify the 
underlying mechanisms. 
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ABSTRACT 
Alanine aminotransferase (ALT) is a marker of nonalcoholic fatty liver disease 
(NAFLD) and  predicts incident type 2 diabetes mellitus (DM2). Recently, ALT was 
shown to be also associated with endothelial dysfunction and carotid 
atherosclerosis. We studied the predictive value of ALT for all cause mortality, 
incident cardiovascular disease (CVD) and coronary heart disease (CHD) events in a 
population-based cohort of Caucasian men and women aged 50 to 75 years, at 
baseline. The ten-year risk of all-cause mortality, fatal and non-fatal CVD and CHD 
events in relation to ALT was assessed in 1439 subjects participating in the Hoorn 
study, using Cox survival analysis. Subjects with prevalent CVD/CHD and missing 
data were excluded. As compared with the first tertile, the age- and sex-adjusted 
hazard ratios (95 percent confidence intervals) for all-cause mortality, CVD events 
and CHD events were 1.30 (0.92-1.83), 1.40 (1.09-1.81) and 2.04 (1.35-3.10), 
respectively, for subjects in the upper tertile of ALT. After adjustment for 
components of the metabolic syndrome and traditional risk factors, the association 
of ALT and CHD events remained significant for subjects in the third relative to 
those in the first tertile, with a hazard ratio of 1.88 (1.21-2.92) and 1.75 (1.12-
2.73), respectively. In conclusion, the predictive value of ALT for coronary events, 
seems independent of traditional risk factors and the features of the metabolic 
syndrome in a population based cohort. Further studies should confirm these 
findings and elucidate the pathophysiological mechanisms. 
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INTRODUCTION 
 
Recently, the role of non-alcoholic fatty liver disease (NAFLD) in the pathogenesis of 
type 2 diabetes mellitus (DM2) has gained much interest. Several studies have 
demonstrated that NAFLD is associated with the components of the metabolic 
syndrome (MetS) and DM2 [1,2], and fatty liver is considered to be the hepatic 
component of the MetS [3,4]. Circulating concentrations of the liver transaminases, 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have been 
used as markers of NAFLD. Of these two liver enzymes, ALT appears to be the best 
marker of liver fat accumulation and is positively correlated with liver fat measured 
by magnetic resonance (MR) proton spectroscopy [5]. In cross-sectional and 
prospective studies ALT is associated with DM2 [6,7]. Collectively, these data 
suggest that hepatic steatosis might play a role in the pathogenesis of DM2, most 
probably by contributing to the development of hepatic insulin resistance resulting, 
among others, in increased hepatic gluconeogenesis and overproduction of 
triglyceride-rich lipoproteins. Subjects with features of the MetS are not only at 
increased risk of DM2, but also at risk of developing cardiovascular (CVD) and 
coronary heart disease (CHD) [8].  
 
In view of these observations, and the recently described associations between 
both NALFD or its marker ALT and vascular structural and functional properties 
[9,10], we studied the predictive value of ALT for all-cause mortality, CVD and CHD 
events in a population-based study of diabetes and related complications in 
Caucasian men and women aged 50 to 75 years. 
  
METHODS 
 
Study population  
 
Subjects were participants in the Hoorn Study, a prospective population-based 
cohort study of glucose metabolism and diabetes complications. The study 
population and research design have been described in detail previously [11]. In 
short, in 1989, a random sample of all men and women aged 50 to 75 was taken 
from the municipal registry of the medium-sized town of Hoorn in The Netherlands. 
Of the 3552 individuals, who where invited to take part in the study, 2540 agreed 
to participate (71.5%). Baseline data, including a 75-g oral glucose tolerance test 
(OGTT), were collected from October 1989 through February 1992. After excluding 
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56 non-Caucasians the cohort consisted of 2484 men and women. For the present 
study we excluded 612 subjects with missing information on morbidity during 
follow-up, because they did not provide written permission to accesses their 
medical records or they had moved out of Hoorn. Subjects with prevalent CVD/CHD 
and missing data on variables at baseline were excluded for the analysis, resulting 
in 1439 subjects. The Ethical Review Committee of VU University Medical Centre 
approved the Hoorn Study and written informed consent was obtained from all 
participants. 
 
Baseline Examination 
 
Serum ALT enzyme activity was measured according to the method of the 
International Federation of Clinical Chemistry from 1985, and expressed as U/L 
[12]. Since the reference range and cut-off values for ALT are controversial [13,14], 
we divided ALT into tertiles, instead of using a cut-off value to define abnormality. 
The OGTT was performed between 08.00 and 10.00h and subjects were asked not 
to drink alcohol from 17.00h and to fast (except for drinking water) from 22.00h 
the evening before the measurements. Blood samples were collected before and 2h 
after ingestion of the glucose load. Plasma glucose was measured with the glucose 
dehydrogenase method (Merck, Darmstadt, Germany). The glucose tolerance 
categories were defined according to the 1999 criteria of the World Health 
Organization. Immuno-specific insulin was measured in serum with a double-
antibody RIA (antibody SP21, Linco Research, St. Louis, USA). Insulin resistance was 
estimated by the homeostasis model assessment for insulin resistance  (HOMA-IR), 
calculated as fasting insulin (in IU/l ) x fasting glucose (mmol/l)/22.5 [15]. Glycated 
haemoglobin (HbA1c) was measured with ion exchange high performance liquid 
chromatography (Modular Diabetes Monitoring System, BioRad Lab, Veenendaal, 
The Netherlands; reference range 4.3-6.1%). Fasting triglycerides, total and HDL-
cholesterol were determined in serum by enzymatic techniques (Boehringer 
Mannheim, Germany). LDL-cholesterol was calculated according to the Friedewald-
formula, except in subjects with triglycerides>4.5 mmol/l. Seated systolic and 
diastolic blood pressure was measured at the right arm after a 5-minute rest with a 
random-zero mercury sphygmomanometer (Hawksley-Gelman, Lancing, UK). The 
average of two measurements was used for the analyses. Weight and height were 
measured in subjects wearing light clothes only, and the body mass index (BMI) 
was calculated as weight divided by height squared (kg/m2). Waist circumference 
was measured at the midpoint between the lowest rib and the iliac crest, hip 
circumference was measured at the widest level over the greater trochanters, and 
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the mean value of two measurements was used in the analysis. Information on 
alcohol intake was assessed by a validated semi-quantitative food frequency 
questionnaire [16]. Subjects were asked about their drinking habits and the weekly 
number of glasses of alcoholic drinks consumed. This information was converted to 
alcohol intake (g/day) using a computerized version of the Dutch Food 
Composition Table. Physical activity was assessed by questionnaire as described 
before [11]. Information on history of cardiovascular disease was assessed by the 
Rose questionnaire. Smoking status was assessed by questionnaire and categorized 
as never, former and current smoker.  
 
Follow-up 
 
The registration of follow-up data of the Hoorn Study participants is regularly 
updated using the municipal register of the city of Hoorn providing information 
about the vital status of the participants. Information of causes of death and non-
fatal events were obtained from medical records of general practitioners and from 
the local hospital. Causes of death were coded according to the ICD-9. CVD was 
defined as documented angina pectoris (chest pain followed by coronary artery 
bypass surgery or angioplasty, or in the presence of >50 % stenosis or ECG 
changes, i.e. ST-segment elevation ≥ 1 mm or ST-segment depression ≥0.5 mm, or 
positive exercise test), myocardial infarction (in the presence of at least 2 of the 
following: typical pain, elevated enzymes and/or ECG changes), congestive heart 
failure (in the presence of at least 2 of the following: shortness of breath, 
cardiomegaly, dilated neck veins or 1 of the former in the presence of edema or 
tachycardia), stroke or transient ischaemic attack (sudden onset of symptoms, 
neurological symptoms or change of consciousness), peripheral disease (both 
symptomatic and a-symptomatic: by procedure or typical pain accompanied by 
stenosis or ankle arm blood pressure ratio <0.9 or positive vascular stress test).  In 
fatal cases, CVD was defined with ICD codes 390-459 (Diseases of the circulatory 
system) or 798 (sudden death, cause unknown), because sudden death in general 
is of CVD origin [17]. CHD was defined as documented myocardial infarction and 
angina pectoris, with the aforementioned criteria. Fatal CHD cases were defined 
with ICD coded 410-414 (ischaemic heart disease). Follow-up time was calculated 
as the time between the date of the baseline examination and the date of the first 
event or January 1, 2000. 
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Statistical analysis 
 
Analyses were performed with SPSS 11.0.5 software. Subjects were categorized 
according to ALT tertiles. Differences between tertiles were tested with analysis of 
variance (ANOVA) for continuous variables and by the χ-square test for proportions. 
Hazard ratios and 95% confidence intervals of baseline ALT for all-cause mortality, 
incident CVD and CHD events were estimated from multivariable Cox proportional 
hazard analysis. The first models were adjusted for age and sex only. In the 
subsequent models we added the possible mediating or confounding factors one 
by one. In the final models, beside adjustments for age, sex, alcohol-intake, 
smoking and physical activity, we corrected for the traditional CVD risk factors, i.e. 
glucose tolerance status, systolic blood pressure, HbA1c, LDL-cholesterol, BMI  
(Table 2, Model 2) as well as for the components of the metabolic syndrome, as 
defined by the Adult Treatment Panel III (NCEP) (Table 2, Model 3), respectively. 
Two-sided P values < 0.05 were considered to indicate statistical significance.  
 
RESULTS 
 
Baseline characteristics of the participants 
 
The mean age of the 1439 participants (651 men and 788 women) was 60.9 (7.2) 
years. Table 8.1 shows the baseline characteristics of the participants divided into 
ALT tertiles. Subjects in the highest ALT tertile had a higher BMI, as well as waist 
and hip circumference. Also, they had higher fasting and 2 hour post-load plasma 
glucose levels, fasting insulin levels, total cholesterol concentrations, and higher 
blood pressure. LDL-cholesterol tended to be different across the tertiles, whereas 
HbA1c was similar in all tertiles. The highest ALT tertile consisted of a higher 
number of subjects with impaired glucose metabolism and DM2.  
 
Association of ALT and all-cause mortality, CVD and CHD events 
 
During the 10-year follow-up, 174 of the total of 1439 subjects died, 355 CVD 
events occurred of which 75 where fatal and 129 CHD events occurred of which 16 
were fatal. Table 8.2 shows the hazard ratios of the third relative to the first ALT 
tertile for all-cause mortality, CVD and CHD events. The age and sex adjusted risk 
for all-cause mortality, CVD events and CHD events were 1.30 (0.92-1.83), 1.40 
(1.09-1.81) and 2.04 (1.35-3.10), respectively, for the subjects in the upper ALT 
tertile compared to those in the first tertile. The association between ALT and all-
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cause mortality was not statistically significant and the association could be 
explained by the traditional CVD risk factors and/or the components of the 
metabolic syndrome (Table 8.2, Model 2 and Model 3). The significant association 
of ALT with CVD events disappeared after adjustment for the classical CVD risk 
factors and/or the components of the metabolic syndrome (Table 8.2, Model 2 and 
3). Only the association of ALT and CHD events remained statistically significant 
after adjustment for CVD risk factors as well as for the features of the metabolic 
syndrome. The association of ALT and CHD events was explained by BMI, waist and 
to a lesser extent by total cholesterol and triglycerides. Fasting insulin and HOMA-
IR did not substantially alter any of the associations presented (Table 8.2). 
Additional adjustment for baseline HDL in model 2 and additional adjustment for 
baseline LDL in model 3 (both HDL and LDL in one model) did not change the 
presented associations of ALT with CHD (data not shown). 
 
ALT and CHD events: the effect of gender, alcohol intake and diabetes 
 
In order to establish the robustness of the observed associations, we performed 
additional analyses, focusing on the role of gender, alcohol intake and DM2. 
Stratified analysis for men and women separately yielded similar results (data not 
shown). Since DM2 carries a greater risk of CHD and CVD, and its association with 
elevated ALT, we subsequently excluded the 119 DM2 subjects from the analysis, 
which resulted in an attenuation of the association of ALT with CHD events. After 
adjustment for traditional CVD risk factors,  the association became borderline 
significant (HR 1.65 [0.97-2.79]), whereas it remained significant after adjustment 
for the components of the metabolic syndrome (HR 1.78 [1.05-3.04]).  
In order to detail the effect of alcohol on the association of ALT with CHD-events, 
we excluded 232 subjects (77 women and 155 men) who had an average daily 
alcohol intake of more than 20 g. Exclusion of these subjects attenuated the 
association, however, ALT remained a predictor for CHD after adjustment for 
classical CVD risk factors (HR 1.72 [1.02-2.90]) and for the components of the 
metabolic syndrome (HR 1.67 [0.99-2.80]). 
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Table 8.1. Baseline characteristics of the participants (N=1439) stratified by ALT 
tertiles*  
Variable Alanine aminotransferase activity (U/L) 
Mean (SD), median (interquartile 
range), or percentage  
1 
N=551 
2 
N=420 
3 
N=468 
P  
ALT (U/L)† 12 (1-14) 17 (15-20) 26 (21-143)  
Age (years) 62.9 (7.4) 60.7 (7.1) 59.7 (6.8) <0.001 
Male (%) 30.9 48.6 59.2 <0.001 
Body mass index (kg/m2) 25.7 (3.4) 26.1 (3.2) 27.4 (3.3) <0.001 
Waist (cm) 87.0 (10.1) 89.6 (10.3) 94.2 (10.1) <0.001 
Hip (cm)  101.3 (6.7) 100.9 (6.2) 102.9 (6.4) <0.001 
Fasting glucose (mmol/l) 5.5 (1.1) 5.7 (1.4) 5.9 (1.5) <0.001 
2h post-load glucose (mmol/l) 5.6 (2.3) 5.8 (3.0) 6.5 (3.4) <0.001 
Fasting insulin  (pmol/l) 79.8 (48.2) 82.6 (49.9) 96.1 (58.0) <0.001 
HbA1c (%) 5.4 (0.7) 5.5 (0.8) 5.5 (0.9) 0.15 
Impaired glucose metabolism (%) 12.0 15.0 21.6 <0.001 
Type 2 diabetes mellitus (%) 6.0 7.6 8.2 0.03 
Plasma lipids (mmol/l)     
       Total-cholesterol 6.6 (1.1) 6.5 (1.1) 6.7 (1.2) <0.001 
       LDL-cholesterol 4.6 (1.0) 4.5 (1.0) 4.7 (1.1) 0.051 
       HDL-cholesterol 1.38 (0.36) 1.38 (0.37) 1.30 (0.36) <0.001 
       Triglycerides 1.4 (0.9) 1.4 (0.7) 1.8 (1.1) <0.001 
Systolic BP (mmHg) 133 (20) 134 (20) 137 (20) <0.001 
Diastolic BP (mmHg) 80 (11) 82 (10) 84 (10) <0.01 
Smoking, current (%) 35.2 27.9 26.3 <0.001 
Alcohol intake (g/day) 2.2 (0-10) 5.0 (0-15) 10 (2-17) <0.01 
*Abbreviations: ALT, alanine aminotransferase; SD, standard deviation; BP, blood pressure; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein   
†median (minimum-maximum value) 
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Table 8.2. Hazard ratios of the second and third compared to the first tertile of ALT 
in relation to all-cause mortality, CVD and CHD events* 
Model  All-cause 
mortality 
CVD-events CHD-events 
  HR (95%CI) HR (95%CI)  HR (95%CI)  
Events Tertile 174 355 129 
Model 1† 2nd 0.74 (0.49-1.10) 1.02 (0.78-1.33) 0.94 (0.57-1.53) 
 3rd 1.30 (0.92-1.83) 1.40 (1.09-1.81) 2.04 (1.35-3.10) 
Model 1 + alcohol-intake 2nd 0.74 (0.50-1.10) 1.02 (0.78-1.33) 0.93 (0.57-1.52) 
 3rd 1.30 (0.92-1.84) 1.39 (1.08-1.80) 2.03 (1.38-3.09) 
Model 1 + BMI 2nd 0.72 (0.48-1.08) 0.98 (0.75-1.28) 0.90 (0.55-1.47) 
 3rd 1.23 (0.85-1.76) 1.27 (0.98-1.65) 1.82 (1.18-2.81) 
Model 1 + waist 2nd 0.70 (0.47-1.05) 0.96 (0.73-1.26) 0.89 (0.55-1.46) 
 3rd 1.15 (0.80-1.65) 1.24 (0.96-1.62) 1.80 (1.17-2.77) 
Model 1 + triglycerides 2nd 0.73 (0.49-1.09) 1.02 (0.78-1.33) 0.97 (0.57-1.53) 
 3rd 1.24 (0.87-1.75) 1.34 (1.04-1.74) 1.97 (1.25-2.99) 
Model 1 + total cholesterol 2nd 0.74 (0.49-1.09) 1.02 (0.78-1.32) 0.92 (0.57-1.51) 
 3rd 1.27 (0.89-1.80) 1.36 (1.05-1.75) 1.89 (1.25-2.88) 
Model 1 + fasting glucose 2nd 0.67 (0.45-1.01) 0.96 (0.74-1.26) 0.92 (0.56-1.51) 
 3rd 1.21 (0.79-1.60) 1.25 (0.97-1.62) 1.98 (1.30-3.02) 
Model 1 + fasting insulin 2nd 0.72 (0.48-1.07) 1.03 (0.79-1.34) 0.95 (0.58-1.56) 
 3rd 1.29 (0.91-1.83) 1.41 (1.09-1.82) 2.06 (1.35-3.14) 
Model 1 + HOMA-IR 2nd 0.71 (0.47-1.05) 1.01 (0.78-1.32) 0.95 (0.58-1.56) 
 3rd  1.20 (0.85-1.72) 1.34 (1.03-1.74) 2.02 (1.32-3.10) 
Model 2‡ 2nd 0.75 (0.50-1.12) 0.99 (0.76-1.30) 0.89 (0.54-1.47) 
 3rd 1.21 (0.83-1.76) 1.25 (0.96-1.64) 1.75 (1.12-2.73) 
Model 3§ 2nd 0.71 (0.48-1.06) 0.99 (0.76-1.20) 0.93 (0.57-1.52) 
 3rd 1.10 (0.77-1.61) 1.22 (0.94-1.60) 1.88 (1.21-2.92) 
*Abbreviations: ALT, alanine aminotransferase; CVD, cardiovascular disease; CHD, coronary heart disease; HR, 
hazard ratio; CI, confidence interval; BMI, body mass index;  HOMA-IR, homeostasis model assessment for 
insulin resistance   
†Model 1: adjusted for age and sex  
‡Model 2: adjusted for age, sex, alcohol-intake, smoking, physical activity, glucose tolerance status, systolic 
blood pressure, HbA1c, LDL-cholesterol, BMI 
§Model 3: adjusted for age, sex, alcohol-intake, smoking, physical activity, waist, triglycerides, systolic blood 
pressure, fasting glucose, HDL-cholesterol 
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DISCUSSION 
 
The main novel finding of this population-based study with well-documented 
characterization and follow-up of the participants, was a significant prospective 
association of ALT with CHD events, independent of the traditional CVD risk 
factors, such as systolic blood pressure, HbA1c, LDL-cholesterol and BMI, and 
independent of the components of the NCEP-defined metabolic syndrome. In 
addition we confirmed the cross-sectional association of ALT, a marker of NAFLD, 
with components of the MetS, including measures of obesity, fasting glucose and 
lipids. No significant associations were found between ALT and CVD events or all-
cause mortality, the latter observation is in accordance with a previous study that 
found no significant association of ALT with all-cause mortality [18]. The reason 
that we did not demonstrate a significant association of ALT and CVD events may 
be explained by that fact that the assessment of non-fatal incident CVD may be 
more subject to non-differential misclassification than non-fatal incident CHD 
events, thus leading to an underestimation of the true associations. Our study is, to 
our best knowledge, the first to demonstrate a prospective relation of ALT with 
CHD events and extends the results from cross-sectional studies demonstrating 
correlations of ALT with CHD risk factors, including the components of the MetS 
[9,19]. Bruckert et al found that elevated ALT was associated with CHD risk factors, 
including elevated blood pressure, total cholesterol and triglyceride concentrations 
in 8,501 hyperlipidemic subjects [19]. We recently reported a positive association 
between ALT and endothelial dysfunction measured as brachial flow mediated 
vasodilatation. This association was independent of whole-body insulin sensitivity, 
indicating that other mechanisms besides insulin resistance, such as inflammation 
and/or oxidative stress might contribute to this association [9]. This is in 
accordance with the data from our present study, demonstrating that adjustment 
with HOMA-IR did not change the age and sex adjusted models to a significant 
extent. It should be noted that, although HOMA-IR is a validated surrogate measure 
for whole-body insulin sensitivity, it may not be a specific marker of hepatic insulin 
resistance. Targher et al showed that healthy male volunteers with ultrasound 
documented NAFLD had an increased cIMT relative to those without NAFLD [20]. 
Since this relation was largely explained by the amount of visceral abdominal fat, 
adipose-tissue derived adipocytokines were implicated as a link between fatty liver 
and atherosclerosis.  
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Taken together, three mechanisms, which all seem interrelated, may explain the 
association between ALT and the risk of coronary atherosclerosis. First, NALFD, 
often represented by its marker ALT, are linked with both hepatic and systemic 
insulin resistance and various components of the MetS [7,9]. As shown in recent 
reports form different populations, adults with the MetS are at increased risk of 
CHD, CVD and all-cause mortality [8,21]. Interestingly, however, adjustment for the 
components of the MetS did not blunt the association of ALT and CHD, indicating 
other contributing mechanisms. In addition, NAFLD is often referred to as the 
hepatic component of the MetS, and adjustment for the (other) components of the 
MetS may lead to an over adjustment in the association of ALT and CHD, since it is 
not yet fully clear whether the other components are cause, consequence or 
intermediate factors in the pathophysiology of NAFLD and CHD. Second, the low-
grade systemic and hepatic inflammatory state may link elevated ALT to a high risk 
of CHD. In the normal liver, the production of cytokines is absent or minimal 
(insignificant), however, various stimuli such as reactive oxygen species, may 
induce  the production of cytokines, such as tumour-necrosis factor-alpha and 
interleukin-6 [22], leading to inflammation and fibrosis. In addition to hepatic low-
grade inflammation, adipose tissue compartments, both in healthy and in obese 
subjects are a major source of these cytokines. These cytokines may further 
amplify the inflammatory cascade by stimulating hepatic CRP production. A recent 
study demonstrated higher CRP levels in subjects with elevated ALT compared to 
subjects with normal ALT, even after adjustment for major confounding factors 
[23]. Indeed, CRP may be important in linking NAFLD to atherosclerosis since an 
elevated plasma CRP level is by now established as an independent risk factor of 
CHD and CVD events [24,25]. Third, elevation of ALT in response to fatty 
infiltration of the liver may similarly reflect excessive fat deposition in other organs 
such as the myocardium and the skeletal muscle. In these non-adipose tissues, 
intracellular triglyceride overload increases the pool of long-chain acyl Co-A, thus 
providing abundant substrate for non-oxidative metabolic pathways and the 
formation of toxic metabolites and also causing mitochondrial dysfunction and 
subsequent production of reactive oxygen species and ultimately leading to organ 
dysfunction and cell apoptosis [26].  
 
A number of potential limitations of this study should be considered. The 
population consisted of Caucasian individuals aged 50 to 75, and caution should 
be exercised to generalize our findings to other populations. We excluded subjects 
with missing information on nonfatal disease because they did not give permission 
to access their hospital records. To study the possibility of selection bias, we 
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repeated the analyses for all-cause mortality using the data from the entire original 
Hoorn Study cohort, without prevalent CVD/CHD (n=2007), and the  estimates were 
almost identical (data not shown). We used, similar to others, ALT levels as a 
marker of NAFLD instead of imaging or biopsies, the latter being regarded as the 
gold standard. Since serum ALT shows a strong correlation with biopsy proven fatty 
liver disease in patients and with liver triglyceride content, measured by MRI/MRS 
[27,28], its use as a marker of NAFLD in epidemiological studies seems 
appropriate. Although we addressed alcohol as an important confounder in our 
study, we could not account for other factors that might have caused a rise in ALT, 
such as viral hepatitis infections or hepatotoxic drugs. We did not assess the 
association of other liver enzymes such as AST and gamma-glutamyl transferase 
with outcome, as data on these markers were not available in the Hoorn Study 
cohort. Finally, we did not measure CRP at baseline in the Hoorn Study, since low 
grade inflammation may be a contributing mechanism in the association of ALT 
and CHD, future studies should address this issue. 
 
The results of the present study show that ALT predicts CHD events, independent 
of traditional CVD risk factors and the components of the metabolic syndrome. 
Further studies are warranted to confirm these findings and to elucidate the 
pathophysiological mechanisms. 
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ABSTRACT 
Aims To study the association between alanine aminotransferase (ALT) and the 6-
year risk of the metabolic syndrome in a population-based study in Caucasian men 
and women. 
 
Methods The association of ALT with the 6-year risk of the metabolic syndrome in 
1,097 subjects, aged 50-75 years, was assessed in the Hoorn Study with logistic 
regression analysis. Subjects with the metabolic syndrome at baseline, defined 
according to the Adult Treatment Panel III of the National Cholesterol Education 
Program, were excluded.  
 
Results After 6.4 (range: 4.4-8.1) years of follow-up, 226 subjects (20.6%) had 
developed the metabolic syndrome. The odds ratio (95% confidence interval) for 
developing the metabolic syndrome, adjusted for age, sex, alcohol-intake and 
follow-up duration was 2.25 (1.50-3.37) for subjects in the upper tertile compared 
to those in the lower tertile of ALT. This association persisted after additional 
adjustment for all the baseline metabolic syndrome features [1.62 (1.02-2.58)]. 
Among the individual components of the metabolic syndrome, ALT was significantly 
associated only with fasting plasma glucose at follow-up.  
 
Conclusions These data suggest that ALT is associated with risk of the metabolic 
syndrome in a general population of middle-aged Caucasian men and women, 
further strengthening the role of ALT as an indicator for future metabolic 
derangement. These findings warrant further studies to elucidate the role of non-
adipose tissue fat accumulation in the pathogenesis of metabolic syndrome related 
complications.
ALANINE AMINOTRANSFERASE AND THE METABOLIC SYNDROME 
 
145 
INTRODUCTION 
 
The metabolic syndrome, characterised by abdominal obesity, hyperglycaemia, 
hypertension and dyslipidaemia, confers a high  risk for the development of type 2 
diabetes mellitus (DM2) [1,2] and cardiovascular disease (CVD) [3]. Individuals with 
DM2 or the metabolic syndrome have a higher prevalence of elevated liver 
enzymes, including alanine aminotransferase (ALT) [4,5]. Several cross-sectional 
studies have demonstrated associations of ALT with individual components of the 
metabolic syndrome, including obesity and dyslipidaemia [6,7].  
 
To date, a limited number of studies have addressed the prospective relation of 
liver enzymes with the future risk of the metabolic syndrome. Nakanishi et al found 
that of the liver enzymes studied, ALT was associated with risk of metabolic 
syndrome, but this study was limited to middle-aged Japanese men and used body 
mass index (BMI) instead of waist circumference to define the metabolic syndrome 
[8]. Hanley et al studied the relation of four different liver enzymes (including ALT) 
with the development of the metabolic syndrome in a multi-ethnic cohort and 
demonstrated that ALT was positively associated with risk of the metabolic 
syndrome [9]. In a Japanese cohort of male and female health care employees, 
Suzuki et al studies the sequential order of elevated transaminases (ALT and 
aspartate aminotransferase) with feature of the metabolic syndrome, and found 
that elevated transaminases are preceded by weight gain, while the other feature 
are followed by elevated transaminases [10]. To date, no study has assessed the 
prospective relation of ALT and the metabolic syndrome in a population-based 
study in Caucasian men and women. 
 
In the present study, we addressed the prospective association of ALT with the 6-
year risk of the metabolic syndrome, defined according to the Adult Treatment 
Panel III of the National Cholesterol Education Program, and with the individual 
components of the metabolic syndrome in a population-based study of glucose 
tolerance and related complications in Caucasian men and women aged 50-75 
years at baseline. 
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MATERIALS AND METHODS 
 
Study population and follow-up 
 
The subjects were participants in the Hoorn Study, a prospective population-based 
cohort study of glucose metabolism and diabetes complications [11]. In brief, in 
1989, a random sample of all man and women aged 50 to75 was taken from the 
municipal registry of the town of Hoorn in The Netherlands. Of the 3,552 
individuals who where invited to take part in the study, 2,540 agreed to participate 
(71%). Baseline data were collected from October 1989 through February 1992. 
After excluding non-Caucasians (n=56) the study cohort consisted of 2,484 men 
and women. Between January 1996 and December 1998, 2,086 participants were 
invited to take part in a follow-up examination, the other members of the original 
study population were not invited because of logistical reasons (n=140), or because 
they died (n=150) or had moved out of Hoorn (n=108). A total of 1,513 subjects 
(72.5%) took part in the follow-up measurements [12]. Metabolic syndrome at 
baseline and at follow-up was defined according to the Adult Treatment Panel III of 
the National Cholesterol Education Program, i.e. three or more of the following: 
fasting glucose ≥ 6.1 mmol/l, HDL cholesterol <1.0 mmol/l (men) or <1.3 mmol/l 
(women), triglycerides  ≥ 1.7 mmol/l, waist-circumference ≥ 102 cm (men) or ≥ 88 
cm (women) and hypertension ≥130/85 mmHg [13]. For the present study, subjects 
with the metabolic syndrome and/or DM2 at baseline were excluded (n=329). 
Furthermore subjects with missing data on alcohol intake, missing data on ALT 
enzyme activity, insulin, smoking status and physical activity at baseline were also 
excluded (n=22). Finally, subjects with missing data to define the metabolic 
syndrome at follow-up (n=63) and subjects with ALT levels > 2.5 times of the upper 
level of the reference value (n=2) were also excluded, the latter to reduce 
confounding due to subjects with ALT elevation caused by viral or toxic agents, 
resulting in 1,097 evaluable subjects. The Ethical Review Committee of VU 
University Medical Centre approved the Hoorn Study and written informed consent 
was obtained from all participants. 
 
Measurements  
 
Fasting blood samples were collected after an overnight fast from 20.00 hours the 
evening before. Serum ALT enzyme activity was measured according to the 1985 
method of the International Federation of Clinical Chemistry [14]. Glucose was 
measured in plasma with the glucose dehydrogenase method (Merck, Darmstadt, 
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Germany) at the baseline measurement and with the hexokinase method 
(Boehringer Mannheim, Germany) at the follow-up measurement. Immuno-specific 
insulin was measured in serum with a double-antibody RIA (antibody SP21, Linco 
Research, St. Louis, USA). Triglycerides, total and HDL-cholesterol were determined 
in serum by enzymatic techniques (Boehringer Mannheim, Germany). Systolic and 
diastolic blood pressure was measured twice on the right arm with a random-zero 
sphygmomanometer (Hawksley-Gelman, Lancing, UK) and the average of both 
measurements was used for the analyses. Information on alcohol intake was 
assessed by a validated semi-quantitative food frequency questionnaire [15]. 
Subjects were asked whether they drink alcohol and if so, how many glasses of 
alcoholic drinks they consumed in a week. This information was converted to 
alcohol intake in grams/day with the computerised version of the Dutch Food 
Composition Table. Physical activity was assessed as described previously [11]. 
Weight and height were measured in subjects wearing light clothes only, and the 
BMI was calculated as weight divided by height squared (kg/m2). Waist and hip 
circumference were measured according to a standardised method [16]. Smoking 
status was assessed by questionnaire. 
 
Statistical analysis 
 
Data are presented as mean (SD) or as median (interquartile range) for variables 
with a skewed distribution according to tertiles of ALT. For the prospective data, 
logistic regression analyses were performed to calculate the odds ratios (ORs) and 
the 95% confidence intervals (95% CIs) for the metabolic syndrome. The upper 
tertile of ALT was compared with the lower tertiles of ALT. The first model was 
adjusted for age, sex, alcohol-intake and follow-up duration, because follow-up 
differed between subjects. In the final model, additional adjustments were made 
for the individual components of the metabolic syndrome criteria entered as 
continuous variables. To assess the prospective relation of ALT with the individual 
components of the metabolic syndrome, we used multivariate linear regression 
models. In these models the individual metabolic syndrome component at follow-
up was entered as the outcome variable and ALT as the determinant. These models 
were adjusted for age, sex and follow-up-duration and subsequently adjusted for 
the metabolic syndrome component at baseline. These associations were expressed 
as standardised betas with the 95% CI. A standardised beta of 0.5 means that if the 
independent variable increases by 1 SD, the dependent variable increases by 0.5 
SD. Variables with a skewed distribution were entered in the models after 
logarithmic transformation. The statistical analyses were performed with SPSS for 
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Windows version 11.0.5. A two-sided P-value<0.05 was considered to indicate 
statistical significance. Effect-modification by age and sex were tested by entering 
interaction terms (age times ALT-tertile or sex times ALT-tertile) into the models. 
We choose a two-sided P-value<0.1 to indicate effect-modification. 
 
RESULTS 
 
Baseline  characteristics  
 
The mean age of the 1,097 participants (465 men and 632 women) was 60.0 (SD 
6.7) years. Table 9.1 shows the baseline characteristics of the participants stratified 
by ALT divided into tertiles. Subjects in the upper tertile were younger, more likely 
to be male, had higher fasting glucose and cholesterol levels, lower HDL-
cholesterol levels and a higher blood pressure, compared to those in the lower 
tertile. A borderline significant trend was observed for fasting triglyceride levels. 
 
Risk for development of the metabolic syndrome 
 
Table 9.2 shows the odds ratio of development of the metabolic syndrome among 
1,097 men and women who were free of the metabolic syndrome at baseline after a 
mean of 6.4 (range: 4.4-8.1) years of follow-up with ALT divided into tertiles. Of 
these, 226 (20.6%) subjects developed metabolic syndrome at follow-up. In the 
model adjusted for age, sex and follow-up duration and alcohol-intake, subjects in 
the upper tertile had an odds ratio of 2.25 (95%CI: 1.50-3.37) compared to those in 
the lower tertile. The subsequent models in which components of the metabolic 
syndrome were entered as continuous variables showed that this relation was most 
strongly attenuated by waist, followed by glucose and to a lesser extent by blood 
pressure, but the associations remained statistically significant (OR: 1.62 [1.02-
2.58]). Lifestyle factors, including physical activity and smoking, nor fasting insulin 
affected the relation to a significant extent. No effect modification for sex or age 
was observed (both P > 0.1). To further address the effect of alcohol-intake as a 
major potential confounder, we excluded subjects (n=152) with an alcohol-intake of 
more than 20 grams per day. However, this only lead to a small attenuation of  
model 1 [2.10 (1.36-2.54)]. The models in which the components of the metabolic 
syndrome were entered as dichotomised variables (according to the Adult 
Treatment Panel III of the National Cholesterol Education Program) did not 
materially change the associations presented in Model 1 (data not shown), the OR 
of Model 2 was slightly higher (OR: 2.02 [1.31-3.12]) 
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The analyses assessing the relation of ALT with the individual components of the 
metabolic syndrome showed that ALT was associated with all the components at 
follow-up except for HDL-cholesterol. After adjustment for the baseline values of 
the individual components, ALT was significantly associated with glucose only 
(Table 9.3). 
 
Table 9.1. Baseline characteristics of the participants (n=1,097) stratified by ALT 
tertiles  
Variable Alanine aminotransferase activity (U/L) 
 Tertile 1 Tertile 2 Tertile 3 Ptrend* 
N 329 418 350  
ALT (U/L) 10.4 (2.1) 15.6 (1.54) 27.3 (10.1)  
Age (years) 60.9 (6.9) 60.4 (6.8) 58.6 (6.3) <0.001 
Male (%) 27.1 41.9 57.4 <0.001 
Body mass index (kg/m2) 25.2 (2.9) 25.5 (2.7) 26.6 (3.0) <0.001 
Waist (cm) 84.5 (9.5) 87.4 (8.7) 91.0 (8.8) <0.001 
Fasting glucose (mmol/l) 5.2 (0.5) 5.3 (0.5) 5.4 (0.5) <0.001 
Plasma lipids (mmol/l)     
       Total-cholesterol 6.5 (1.1) 6.5 (1.0) 6.6 (1.1) 0.016 
       HDL-cholesterol 1.42 (0.35) 1.41 (0.36) 1.38 (0.39) 0.020 
       Triglycerides 1.2 (0.9-1.5) 1.2 (0.9-1.5) 1.3 (1.0-1.6) 0.054 
Systolic BP (mmHg) 127 (18) 130 (17) 131 (18) <0.001 
Diastolic BP (mmHg) 78 (10) 79 (9) 82 (9) <0.001 
Abbreviations: ALT, alanine aminotransferase; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-
density lipoprotein 
Data are means (SD) or median (interquartile range) for variables with a skewed distribution;  
*Tested for trend with regression analyses adjusted for age and sex 
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Table 9.2 The associations of ALT with development of the metabolic syndrome 
(N=1,097)  
 ALT enzyme activity 
Model Tertile 1 Tertile 2 Tertile 3  
N 329 418 350  
Model 1 1 1.43 (0.96-2.13) 2.25 (1.50-3.37)  
Model 1 +  waist 1 1.30 (0.89-1.95) 1.70 (1.11-2.58)  
Model 1 +  glucose 1 1.34 (0.89-2.01) 2.01 (1.33-3.03)  
Model 1 + HDL-cholesterol 1 1.55 (1.03-2.32) 2.60 (1.72-3.95)  
Model 1 + triglycerides 1 1.54 (1.03-2.35) 2.18 (1.43-3.33)  
Model 1 + systolic BP 1 1.39 (0.93-2.08) 2.08 (1.38-3.14)  
Model 1 + diastolic BP 1 1.41 (0.95-2.10) 2.11 (1.40-3.18)  
Model 1 + life style factors 1 1.45 (0.97-2.18) 2.29 (1.51-3.48)  
Model 1 + insulin 1 1.46 (0.97-2.20) 2.19 (1.44-3.35)  
Model 2  1 1.40 (0.90-2.18) 1.62 (1.02-2.58)  
*Model 1 adjusted for age, sex, alcohol-intake and follow-up duration; Model 2: Model 1 + adjusted for waist, 
glucose, HDL-cholesterol, triglycerides and systolic and diastolic blood pressure 
Life style factors: smoking and physical activity 
 
Table 9.3. Multivariate linear regression analysis of ALT with the 
individual metabolic syndrome components at follow-up* 
 Standardized betas (95%CI) 
Metabolic syndrome 
component at follow-up 
Model 1 Model 2 
Fasting glucose 0.19 (0.13-0.25) 0.13  (0.07;0.18) 
Waist circumference 0.17 (0.11-0.22) 0.004 (-0.03;0.04) 
Triglycerides 0.10 (0.03;0.16) 0.05 (-0.001;0.10) 
Diastolic blood pressure 0.10 (0.04;0.17) 0.03 (-0.02;0.09) 
Systolic blood pressure 0.09 (0.03;0;15) 0.03 (-0.02;0.08) 
HDL-cholesterol 0.03 (-0.03;0.09) -0.02 (-0.05;0.02) 
Models 1 and 2 adjusted for age, sex, alcohol-intake and follow-up duration,  
Model 2 additionally adjusted for the baseline value of the individual component. 
*Standardized betas indicate SD difference per 1 SD ALT at baseline 
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DISCUSSION 
 
The main finding of this study is that in an elderly population of non-diabetic 
Caucasian men and women free of the metabolic syndrome at baseline, ALT was 
associated with an increased risk of conversion to the metabolic syndrome. This 
association was independent of age, sex, alcohol-intake, follow-up duration and the 
baseline metabolic syndrome components. In the prospective analyses of the 
individual components of the metabolic syndrome, ALT was significantly associated 
with fasting glucose levels and to a lesser extent with HDL-cholesterol, triglyceride 
levels and elevated blood pressure and waist circumference. 
 
The findings of the present study are in accordance with the two previous studies, 
predominantly performed in Asian [8] and African American and Hispanic [9] 
populations, that addressed the relation of liver enzymes including ALT with future 
risk of the metabolic syndrome. Correction of all the baseline metabolic syndrome 
criteria may result in over-correction, implying that the models in the present study 
may underestimate the true associations. Other risk factors for the development of 
the metabolic syndrome have been studied. These factors included C-reactive 
protein (CRP) [17], physical inactivity [18], pro-insulin [19] and the individual 
components themselves [19]. In the present study, physical activity did not affect 
the associations. Unfortunately, pro-insulin and CRP levels were not available at 
baseline in the Hoorn study cohort and consequently the effect of these mediating 
or confounding variables could not be studied. The chronological ordering of 
elevated transaminases (ALT and AST)  in relation to components of the metabolic 
syndrome was studied by Suzuki and et al, they reported, that weight gain, low 
HDL-cholesterol and hypertrglyceridemia preceded transaminase elevation, follow 
by hypertension and glucose intolerance [10]. Our study was not designed to study 
the chronological ordering of ALT with the individual components of the metabolic 
syndrome, however, our results do support some of the findings by Suzuki et al 
that elevated ALT precedes components of the metabolic syndrome. Indeed, 
glucose at follow-up adjusted for baseline glucose values was the strongest 
component associated with elevated ALT. The mechanisms underlying the observed 
association between ALT (and other liver enzymes) and the metabolic syndrome are 
not yet fully understood. ALT is most strongly associated with liver fat 
accumulation measured by proton-magnetic-resonance spectroscopy [20], 
reflecting fat deposition in the liver, which is regarded as a feature of the metabolic 
syndrome [21,22]. This hepatic fat deposition, as reflected by slightly elevated ALT 
levels, may lead to early hepatic and systemic insulin resistance [23,24]. Indeed, an 
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earlier study demonstrated that hepatic fat content measured by proton 
spectroscopy is associated with insulin resistance, independent of obesity [25]. In 
addition, hepatic fat content was related to a decreased suppression of insulin-
mediated hepatic glucose output, which is in line with the observation of the 
present study that ALT is positively associated to fasting glucose levels in the 
prospective analysis. High ALT levels might also reflect hepatic and systemic 
inflammation, and the interplay of visceral adipose tissue, stimulating hepatic CRP 
production which may contribute to further metabolic derangement. The results of 
the present study show that subjects with slightly elevated ALT have a higher risk 
of developing the metabolic syndrome.  A number of potential limitations of this 
study should be considered. The population consisted of Caucasian individuals 
aged 50 to 75, and caution should be exercised to generalise our findings to other 
populations. Although, we addressed alcohol as a confounder in our study, we 
could not account for other factors that might have caused a rise in ALT, such as 
viral hepatitis infections or hepatotoxic drugs. To overcome this limitation to some 
extend, subjects with an ALT level of 2.5 times the upper level of the reference 
value were excluded. In about on third of hepatitis C infections, a condition 
associated with an increased risk for development of diabetes, subjects may have 
normal ALT levels [26,27]. However, the effect of hepatitis C with regard to our 
results may be very limited, as the prevalence of hepatitis C infection in the Dutch 
general population is very low [28]. In addition, the association of other liver 
enzymes such as asparatate aminotransferase and gamma-glutamyltransferase with 
risk of developing the metabolic syndrome were not assessed. A previous study, 
however, found ALT most strongly correlated to hepatic fat accumulation [20]. In 
the Hoorn study, no diagnostic work-up was performed to assess the cause of 
elevated ALT, however all relevant baseline data was send to the individual’s 
general practitioner with an advice to perform a further diagnostic work-up 
according to prevailing guidelines.  
 
Despite the above mentioned limitations, the findings obtained in a population-
based study of elderly Caucasian men and women support the conclusion that ALT 
is positively associated with the metabolic syndrome and further studies are 
needed to elucidate and understand the pathophysiological mechanisms. 
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We read with great interest the article by Nannipieri et al. [1], which reported no 
association between aspartate aminotransferase, alanine aminotransferase (ALT), or 
alkaline phosphatase and the 7-year incidence of impaired glucose tolerance and 
type 2 diabetes. Interestingly, γ-glutamyltransferase was, but ALT was not, a 
significant predictor of impaired glucose tolerance or type 2 diabetes. This is, as 
the authors stated, in contrast to previously published papers that found significant 
prospective associations of ALT with incident type 2 diabetes after adjustment for 
obesity, insulin sensitivity, or inflammation (C-reactive protein) [2–4]. We studied 
the baseline ALT enzyme activity in relation to 6-year incident type 2 diabetes in 
the Hoorn Study, a population-based cohort study of glucose tolerance among 
Caucasian men and women [5]. Glucose tolerance was assessed by oral glucose 
tolerance test at baseline and after 6.4 years of follow-up. The study methods were 
similar to the Mexico City Diabetes Study described by Nannipieri et al. [1], with the 
exception that the participants of the Hoorn Study were 15 years older at baseline 
(5). Of the 1,289 subjects free of type 2 diabetes at baseline, 123 developed type 2 
diabetes during follow-up. We found that ALT was a significant predictor of type 2 
diabetes only in the models adjusted for age, sex, and follow-up duration, with an 
odds ratio of 2.18 (95% CI 1.29–3.69) for subjects in the upper tertile versus those 
in the lower tertile. However, after additional adjustment for waist circumference, 
BMI, alcohol consumption, fasting plasma insulin levels, and 2-h postload glucose 
levels, the association attenuated and lost significance (1.18 [0.66–2.11]). The 
other liver enzymes were not determined in the Hoorn Study. Thus, in accordance 
with the report by Nannipieri et al. [1], but in contrast to the findings by others, we 
found that ALT was not an independent predictor of incident type 2 diabetes in the 
Hoorn study. We think it is important to report these findings, since we cannot 
exclude the possibility of publication bias leading to overrepresentation of studies 
showing an independent relationship between liver enzymes and risk of type 2 
diabetes. The observed association between ALT and incident type 2 diabetes in 
several published reports may be explained by the fact that these studies were 
performed in selected populations, i.e., in high-risk populations and may not be 
representative for the general population. An alternative explanation is that the 
applied models overadjust for potential mediating variables such as insulin and 2-h 
glucose, factors that might be directly related to liver fat. To increase the insight 
into the role of liver fat in the pathophysiology of the metabolic syndrome and type 
2 diabetes, further studies are needed to assess the underlying mechanisms. The 
role of oxidative stress, as hypothesized by Nannipieri et al. [1], as well as the 
contribution of inflammation should be explored in large-scaled prospective 
studies.  
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STUDY DESIGN AND STUDY POPULATIONS 
 
In this thesis both cross-sectional and prospective studies were used to assess the 
association of determinants with outcome measures. In cross-sectional studies, the 
determinants of interest and one or more outcome variables are measured at the 
same time. Thus, causal inference remains hypothetical, but nevertheless, these 
studies may contribute to a better insight in pathogenic processes. A causal 
relationship implies that the putative cause precedes the effect. In a prospective 
study design, determinants are measured before onset of the outcome, allowing 
assessment of the temporal relationship between determinant and outcome 
measure. However, merely a temporal relationship does not necessarily imply a 
causal relationship between the studied variables. More requirements, as proposed 
by Hill, need to be fulfilled to establish a true causal relationship between exposure 
or determinant and the outcome [1]. Although neither cross-sectional nor 
prospective studies can provide formal prove for a causal relation, the prospective 
study design is generally considered to be more informative. 
 
In Chapters 2 to 5 (determinants of postprandial metabolic changes and responses 
in relation to cardiovascular disease [CVD] risk) and Chapter 7 (ALT in relation to 
endothelial dysfunction and insulin sensitivity), cross-sectional study designs were 
used. In Chapters 8 and 9, a prospective study design was used to assess the 
relation of ALT as the determinant of interest with outcome. As pointed out before, 
a significant prospective association does not necessarily imply causality, but 
provides a stronger insight in the possible pathogenic mechanisms.  
 
Selection bias may affect the internal validity of the study, such that a distortion of 
the estimate of the association between determinant and outcome can occur, 
resulting in different estimates for participants and non-participants. In Chapters 2 
to 5, data from the Hoorn Prandial study was used [2]. The relative paucity of data 
in women and the disproportionately high relative risk of CVD in especially post-
menopausal women [3,4], prompted us to perform the study in women only. 
Moreover, postmenopausal women have higher postprandial triglyceride 
concentrations compared to pre-menopausal women [5]. The participants of the 
Hoorn Prandial study were randomly selected from the municipal registry of the city 
of Hoorn and from the registry from the Diabetes Care System in Hoorn. In these 
studies selection bias may indeed have occurred, since only 24% of the invited 
individuals were willing to participate in the study [2], possibly resulting in a 
relatively healthy selection of women with DM2 and controls. On the other hand, 
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the possibility of participation of relatively unhealthy control subjects (participating 
in the study as a health check-up) cannot be ruled out. In Chapter 7, the 
participants were recruited from shared care projects in Amsterdam and Hoorn, 
and through newspaper advertisements. Those who participated were willing to 
undergo the extensive study protocol. This may have resulted in a selection of 
participants who were relatively healthier than those who were unwilling to 
participate (volunteer bias). For Chapters 8 and 9, data from the Hoorn Study were 
used. Participants in this study were randomly selected from the municipal registry 
from the city of Hoorn and a relatively large number of the invited persons 
participated in the baseline (71.5% of those invited) and follow-up examinations 
(72.5% of those invited) [6,7], this may considered to be a representative sample of 
the general population. In Chapter 8, we excluded individuals with missing 
information on non-fatal disease because they did not give permission to access 
their hospital records. We have studied the possibility of selection bias and 
repeated the analyses for all-cause mortality using the data from the entire original 
Hoorn study cohort, without prevalent CVD and coronary heart disease, which 
yielded almost identical estimates.  
 
DETERMINANTS OF INTEREST  
 
In Chapter 2, we studied the associations of clinical and biochemical variables with 
fasting and postprandial glucose and triglycerides. The clinical and biochemical 
variables included anthropometric measures, laboratory analyses and information 
on physical activity and alcohol-intake assessed by questionnaires. Anthropometric 
measurements were determined in duplicate according to a predefined protocol. 
Medical history, medication, (former) smoking and alcohol use were assessed by 
questionnaires [8] and physical activity was assessed by the Short Questionnaire to 
Assess Health-enhancing physical activity of which reproducibility and relative 
validity were described previously [9]. The inter-assay coefficients of variation of 
the laboratory analyses were <7%.  
 
In Chapters 3 to 5, we measured fasting and postprandial glucose and triglyceride 
responses following two consecutive fat-rich or carbohydrate-rich meals and 
expressed these postprandial changes as incremental and/or total area under the 
curve [10]. Most postprandial studies applied a single fat-rich or carbohydrate-rich 
meal (e.g. [11-14]). However, glucose excursions following a first meal have been 
shown to influence the responses after a second meal [15], and type and amount of 
carbohydrate at breakfast have been shown to influence glucose, insulin and free 
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fatty acid (FFA) responses to a subsequent lunch [16]. We assumed that the test-
meal induced responses reflect “real-life” postprandial metabolic changes that have 
caused or are in part responsible for clinical or biochemical changes, i.e. structural 
and functional vascular changes in the past. However, it is important to notice that 
these postprandial responses may have been affected by life-style and/or 
medication interventions. This might be especially true in patients with DM2. In 
addition, these interventions may also have affected outcome measures. We applied 
two consecutive meals with different meal composition. The carbohydrate-rich meal 
consisted of 4 g fat, 162 g carbohydrates and 22 g of proteins and the fat-rich meal 
consisted of 50 g fat, 56 g carbohydrates and 28 g proteins. The fat-rich meal 
should be considered as a mixed meal because it contained carbohydrates, through 
which beta-cell stimulation and insulin secretion will be induced, which may have 
resulted in a lower postprandial triglyceride response [17], and possibly an 
underestimation of the presented associations.  
 
In Chapters 7 to 9, we used the enzyme activity of the liver enzyme alanine 
aminotransferase (ALT) as a marker for non-alcoholic fatty liver disease (NAFLD). 
The use of surrogate markers has been widely adopted in clinical and 
epidemiological research [18], and a number of them have been validated against 
the so-called “gold standard”, a diagnostic test, accepted as the most valid test to 
diagnose the disease or condition of interest. In the case of NAFLD, direct 
measurement of hepatic fat by means of liver biopsies, is regarded as the “gold 
standard” [19,20]. However, in epidemiological and clinical studies the use of this 
technique is limited, because of the elaborate and invasive nature and associated 
risks. Non-invasive imaging techniques, such as ultrasound, computed tomography 
and proton magnetic resonance spectroscopy (1H-MRS), have been used instead of 
biopsies [21,22]. Ultrasound examination of the liver can be used to indicate the 
presence or absence of fatty infiltration of the liver. However, at present, this 
technique at its best can provide only semi-quantitative data with regard to NAFLD. 
1H-MRS has been validated against direct determination of triglyceride content in 
human liver biopsies [23], and may be used for clinical purposes, but has limited 
applicability in larger populations, because of logistics and high costs. In 
epidemiological studies, ALT has been used as a surrogate marker for liver fat 
accumulation and to indicate the presence of NAFLD [24]. Westerbacka and 
colleagues assessed the correlation of ALT with hepatic triglyceride content by 1H-
MRS and found a modest, but significant correlation (r=0.5) [25]. In most studies in 
patients with biopsy proven NAFLD, ALT was higher compared to healthy controls, 
although one study reported on NAFLD patients with “normal” ALT levels (i.e. below 
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the laboratory reference range) [26]. Studies assessing the specificity and 
sensitivity of ALT as a marker of NAFLD are limited. The sensitivity and specificity 
of ALT in the diagnosis of NAFLD are low and depend on the cut-off value used 
[27]. Therefore, lower cut-off values than the current upper limit of the laboratory 
reference range have been proposed [28], but, since cut-off values depend on the 
assay used, this proposal has been questioned by others [29,30]. In the studies 
presented in this thesis, we chose not to define a cut-off value to delineate the 
presence or absence of NAFLD. Instead we modeled ALT as a continuous variable or 
divided into tertiles. In order to avoid confounding by other factors that might 
cause ALT elevation, a detailed history on alcohol intake is mandatory to exclude 
those patients with ALT elevation caused by alcohol-abuse, and to address alcohol-
intake as a possible confounder or effect-modifier. With these limitations in mind, 
we considered ALT to be an acceptable marker for NAFLD in epidemiological 
studies. However, we cannot rule out the possibility of non-differential 
misclassification, as ALT is not always elevated in patients with NAFLD. 
Furthermore, ALT may be elevated due to causes other than NAFLD. Unfortunately, 
no information on viral and autoimmune liver disease and hepatotoxic medication 
that might have caused ALT elevation in the presented studies was available, and 
therefore we cannot rule out the possibility of non-differential misclassification. 
Because non-differential misclassification may lead to an underestimation of the 
true estimate, our reported estimates may be regarded as conservative. As we [24] 
and others [31] have argued, measurement of ALT enzyme activity in fresh samples 
(non-frozen) is of utmost importance to avoid loss of enzyme activity after repeated 
freezing and thawing, which may further contribute to information bias (non-
differential misclassification). In the studies presented in this thesis in which ALT 
enzyme activity was assessed, measurements were performed in previously non-
frozen blood samples. The interassay coefficient of variation of the ALT assay was 
2.3%.  
 
OUTCOME VARIABLES 
 
Fasting and postprandial triglyceride and glucose concentrations after two 
consecutive fat-rich and carbohydrate-rich meals were used as outcome variables in 
Chapter 2 in order to study a number of determinants of these responses. 
Triglycerides and glucose were assessed by precise and validated methods, with 
interassay coefficients of variation of 2.2% and 1.3%, respectively. In Chapter 3, the 
intima-media thickness of the carotid artery (cIMT) was used as outcome variable. It 
is a well-established and widely applied marker of sub-clinical atherosclerosis in 
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epidemiological studies [32]. cIMT was measured by a single observer with an intra-
observer coefficient of variation of 5.2%. Markers of fasting and postprandial 
glycoxidative and lipoxidative stress were assessed in Chapter 4. Oxidized LDL was 
measured with a validated commercially available competitive ELISA with inter-assay 
and intra-assay coefficients of variation of 7.8% and 4.8%, respectively. Unbound 
CML and CEL were measured in EDTA-plasma by high-performance liquid 
chromatography with stable-isotope-dilution tandem mass spectrometric detection 
(LC-MS/MS) using a procedure developed for the analysis of protein-bound CML and 
CEL [33], with intra-assay and inter-assay coefficients of variation for CML of 3% and 
4%, respectively and for CEL 5% and 9%, respectively. 3DG was measured with a 
newly developed LC-MS/MS method after pre-column derivatization according to a 
published procedure [34]. Intra-assay and inter-assay coefficients of variation for 
3DG were 8% and 12%, respectively. Myeloperoxidase was determined in duplicate 
by a commercially available sandwich ELISA in EDTA-plasma. The intra-assay and 
inter-assay coefficients of variation were 3.3% and 5.0%, respectively (Chapter 5). In 
Chapter 7, brachial artery, endothelium-dependent flow-mediated vasodilatation 
(FMD) and whole body insulin sensitivity (M/I-value) as assessed with the 
euglycemic hyperinsulinemic clamp technique, were used as outcome variables. 
Important limitations for the FMD technique are the need for ultrasonographic 
expertise and the significant day-to-day [35,36], intra and inter-observer, and 
diurnal variability [37]. The intra-observer coefficient of variation of the FMD 
measurements in Chapter 7 was 10.1% [38]. We used the euglycemic 
hyperinsulinemic clamp technique, which is regarded as the “gold standard” for 
measuring insulin sensitivity. However, this technique provides information on 
whole body insulin sensitivity instead of the more relevant hepatic insulin 
sensitivity with respect to NAFLD. 
 
CONFOUNDING AND EFFECT MODIFICATION 
 
In epidemiological studies it is common to adjust for putative confounding 
variables and to present the estimates both before and after adjustment. A 
confounder is related to both exposure and outcome, and should not be involved 
as an intermediate variable. However, how to select potential confounders? This is 
still debated. This can be illustrated in Chapter 8.2 in which we could not 
demonstrate an independent association of ALT with incident DM2. We argued that 
the applied models might have over-adjusted for potential mediating variables such 
as insulin and 2-hour glucose. However, due to uncertainty of the pathogenic 
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processes involved, a clear distinction between confounding and mediating 
variables is not always possible. In addition, unmeasured confounding variables 
may also play an important role. In our studies in which ALT was used as a 
determinant, we could not rule out the effect of other causes besides alcohol that 
might have resulted in elevated ALT activity. However, for example, the prevalence 
of viral infections in the general population is relatively low [39], and therefore 
probably did not contribute to bias of the estimates. In the studies presented in 
this thesis, the analyses were adjusted for the appropriate confounding variables. 
 
Effect modification is present if the magnitude of an association of a determinant 
and an outcome is not uniform across a third variable. The higher relative CVD risk 
and the paucity of studies in postmenopausal women, prompted us to perform the 
postprandial studies (Chapter 2 to 5) in postmenopausal women only, which limits 
the external validity, but yields a relatively homogeneous group. We presented the 
analyses separately for women with NGM and DM2 to account for possible effect-
modification by DM2-status. In addition, we considered women with DM2 who used 
statin medication as a separate study group, as statin medication is known to 
influence lipid metabolism [40] and cIMT [41]. In Chapters 7 to 9 we addressed the 
possibility of effect-modification by sex and when applicable by DM2-status. 
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INTRODUCTION 
 
Already in 1979, Zilversmit postulated that atherogenesis might be a postprandial 
phenomenon [1]. Indeed, a number of studies suggested that postprandial or post-
load glucose and postprandial triglyceride concentrations are much stronger 
associated with some CVD risk factors and mortality than the respective fasting 
values [2-8]. There is, however, still debate as to whether postprandial glucose is 
causally related to CVD risk factors or merely a risk marker [9,10], i.e. reflecting the 
underlying metabolic abnormalities in for example lipid metabolism. To date, most 
studies used a single, often artificially composed liquid fat and/or carbohydrate 
load to assess postprandial responses. However, in normal daily life, the metabolic 
alterations following breakfast will affect the responses after lunch, thus potentially 
resulting in a cumulative effect of breakfast on the plasma glucose and 
triglycerides following lunch [11], especially in insulin resistant patients with type 2 
diabetes mellitus (DM2). The main objective of the first part of this thesis was to 
assess the relative contributions and elaborate on the potential mechanisms of 
postprandial glucose and postprandial triglyceride levels following two consecutive 
(breakfast and lunch) fat-rich or carbohydrate-rich meals to CVD risk in 
postmenopausal women with DM2 and in women with normal glucose metabolism 
(NGM). 
 
DETERMINANTS OF POSTPRANDIAL GLUCOSE AND TRIGLYCERIDES 
 
In Chapter 2, we have shown that the determinants of postprandial glucose and 
triglyceride responses differ. Fasting triglycerides were the main determinant of 
postprandial triglycerides, whereas postprandial glucose was determined by other 
factors than fasting glucose values. Although women with DM2 had higher total 
postprandial triglyceride responses (total area under the curve) as compared to 
women with NGM, we found no significant differences in postprandial increase in 
triglyceride concentrations (incremental area under the curve) between DM2 and 
NGM. We expected a greater increase in postprandial triglyceride concentrations in 
women with DM2, especially following the second meal (lunch). The relatively low 
triglyceride response in women with DM2 might be the result of the meal-
composition. The applied fat-rich meal should be considered as a mixed-meal, 
because of the substantial amount of carbohydrates. The resulting insulin response 
suppresses the VLDL-secretion by the liver, which in turn attenuates the 
postprandial triglyceride response. Furthermore, the women with DM2 included in 
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our study were in relatively good glycemic control, possibly contributing to an 
ameliorated response of the liver to the meal-induced insulin response. Finally, we 
measured up to 8 hours after the first meal was given (4 hours after the second 
meal). It may be conceivable that differences in postprandial triglyceride 
metabolism become evident only after a longer study period (i.e. 24 hours), due to 
differences in clearance between NGM and DM2 [12]. These explanations are 
speculative, as we did not measure the triglyceride kinetics in our studies. 
 
POSTPRANDIAL GLUCOSE AND TRIGLYCERIDE RESPONSES IN 
RELATION TO CVD RISK 
 
In the Hoorn Prandial study we addressed the question whether postprandial 
glucose or postprandial triglyceride concentrations were more closely related to 
CVD risk. In Chapter 3, we showed that postprandial glucose, and not the 
triglyceride concentrations, are associated with carotid intima-media thickness 
(cIMT) in women with NGM. The association between postprandial glucose and cIMT 
was found for the meals, irrespective of their composition. We also showed that 
measuring glucose 2 hours after the first meal was enough to assess the 
association between postprandial glucose and cIMT. In contrast, plasma glucose 
measured two hours after a 75-g oral glucose tolerance test (OGTT), was not as 
strongly associated with cIMT in women with NGM. This could not be attributed to 
limited precision of the single glucose measurement after the OGTT, because we 
found that a single 2-hour glucose measurement following a meal, although 
borderline significant, also was associated with cIMT. Based on this observation we 
concluded that postprandial glucose concentrations following a meal may provide 
additional clinical information above and beyond the 2-hour post-load glucose 
following an OGTT.  
 
In women with DM2, an association of cIMT was found with fasting glucose but not 
with postprandial glucose concentrations. A possible explanation for the lack of an 
association of postprandial glucose concentrations with cIMT in DM2, may be the 
fact that women with DM2 were treated with blood glucose lowering medication. 
These variably affect postprandial glucose, dependent on the mode of action of the 
agents. In addition, some blood glucose lowering agents and life-style interventions 
have been shown to retard IMT progression [13-15].  
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Based on previously published papers, we would have expected an association 
between postprandial triglycerides and cIMT, not only in patients with DM2 [3,7], 
but also in healthy subjects [8,16]. However, no such associations between were 
found in the study described in Chapter 3. In the Atherosclerosis Risk in 
Communities (ARIC) Study, postprandial triglyceride levels were associated with 
early atherosclerosis, but only in non-obese subjects [16]. The ARIC investigators 
suggested that this association might be explained by high levels of atherogenic 
triglyceride-rich lipoprotein remnants in the postprandial state. These lipoprotein 
remnants were indeed related to cIMT, independent of postprandial triglycerides 
[17]. Since we did not measure lipoprotein remnant particles in the present study, 
the question regarding the presence or absence of an association between 
postprandial lipids and cIMT in our study cannot be conclusively answered. It 
should furthermore be considered that gender-specific studies on the relation 
between postprandial triglycerides and CVD risk are scarce. The above-mentioned 
ARIC Study reported an association between postprandial triglycerides and cIMT in 
both men and women [16], whereas in another study the association was only 
present in men and not in women [18].  
 
MECHANISMS LINKING POSTPRANDIAL DYSMETABOLISM TO CVD 
 
Glycoxidative and lipoxidative stress, AGE-formation and inflammation are 
implicated as potential mechanisms that may link postprandial dysmetabolism to 
CVD risk [19-22]. In chapter 4, we studied acute changes in markers of 
glycoxidative and lipoxidative stress, including oxidized low-density-lipoprotein 
(oxLDL), Nε-(carboxyethyl)-lysine (CEL), Nε-(carboxymethyl)-lysine (CML) and 3-
deoxyglucosone (3DG), following two consecutive fat-rich or carbohydrate-rich 
meals. We found that oxLDL, 3DG and CML increased in the postprandial state. The 
fasting concentrations of 3DG, oxLDL and CML in women with DM2 were 
comparable with the postprandial concentrations of these markers in women with 
NGM (Chapter 4). These finding extend a previous study from our group, 
describing an increase in oxLDL and malondialdehyde in healthy young men 
following 2 consecutive fat-rich mixed meals [23]. The increased postprandial 
concentrations of oxLDL and 3DG may contribute to functional and structural 
vascular changes which may contribute to the increased CVD risk. Indeed, the 
postprandial increase in oxidative stress was associated with an impaired 
postprandial flow-mediated vasodilatation in healthy young men in the 
aforementioned study [23]. Future studies should address the relation of 
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postprandial oxidative stress markers with vascular (dys)function in patients with 
DM2.  
 
Postprandial dysmetabolism may affect leukocyte recruitment and/or activation. In 
turn, myeloperoxidase (MPO), which is expressed in leukocytes and released upon 
activation, has been associated with CVD [24-26]. In Chapter 5, we hypothesized 
that MPO would increase in the postprandial state, due to postprandial leukocyte 
recruitment and/or activation, especially in individuals with DM2. However, in 
contrast to our hypothesis, MPO decreased in NGM (both meal types) and in DM2 
(fat-rich meals). Moreover, despite an increase of leukocytes following the fat-rich 
meals in both NGM and DM2, no postprandial MPO increase was observed. The 
mechanism by which a postprandial increase in number of leukocytes contributes 
to CVD risk remains unclear. One study has reported that the postprandial increase 
in number of leukocytes was associated with an impaired flow-mediated 
vasodilatation [27].    
 
CONCLUSIONS 
 
The association of postprandial glucose with cIMT in women with NGM was 
stronger than that of postprandial triglycerides. The association between 
postprandial glucose and cIMT in women with NGM suggests that postprandial 
glucose, in the normal range, is a marker or a risk factor of CVD. Possible 
mechanisms that may contribute to the association between postprandial glucose 
and CVD risk may include generation of postprandial oxidative stress. Future 
studies should address the widely debated question whether lowering postprandial 
glucose and oxidative stress may lower CVD risk.   
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INTRODUCTION 
 
Non-alcoholic fatty liver disease (NAFLD) is characterized by a wide spectrum of 
liver abnormalities ranging from liver steatosis to the more severe non-alcoholic 
steatohepatitis (NASH), resembling alcohol-induced liver disease. By definition 
NAFLD develops in subjects who are not heavy alcohol consumers and who have 
negative tests for viral and autoimmune liver diseases. It usually has a benign 
clinical course, but it may progress to NASH, fibrosis, cirrhosis and rarely, to 
hepatocellular carcinoma [1,2]. In recent years, NAFLD has gained appreciation 
because of its relationship with insulin resistance, metabolic syndrome and type 2 
diabetes mellitus (DM2). Currently, NAFLD is considered by some authors to be the 
hepatic component of the metabolic syndrome [3,4], and evidence is accumulating 
that patients with NAFLD are at increased risk of developing cardiovascular disease 
(CVD).  
 
NAFLD IN RELATION TO THE METABOLIC SYNDROME AND DM2 
The putative role of the liver in the pathogenesis of DM2 has gained much interest 
and several cross-sectional studies have demonstrated that NAFLD is related to 
features of the metabolic syndrome and DM2 [5-7]. In the analysis of the third 
National Health and Nutrition Examination Survey (NHANES III) up to 31% of the 
elevated alanine aminotransferase (ALT) activity could be explained by high alcohol 
consumption, hepatitis B or C infection and/or high transferrin saturation, whereas 
in the remaining 69%, the elevated ALT activity was significantly associated with 
higher body mass index (BMI), waist circumference, triglycerides, fasting insulin 
and lower high density lipoprotein (HDL) cholesterol [5]. Several studies have 
addressed the prospective relation of ALT and the metabolic syndrome and DM2 
[8,9]. In the Hoorn Study, a population-based cohort study among elderly Caucasian 
men and women, we found that ALT was associated with the development of the 
metabolic syndrome after 6 years of follow-up (Chapter 9). In patients with DM2, 
elevated serum ALT enzyme activity is more frequently observed than in the 
general population [10,11]. In addition, some [12-16], but not all studies [8,17-19] 
(including the study presented in Chapter 9), have demonstrated independent and 
significant associations of ALT with future DM2. The observed association between 
ALT and incident DM2 in the mentioned studies may be explained by the fact that 
they were performed in high-risk populations that may not be representative for 
the general population. Overall, these studies show that patients with NAFLD are at 
increased risk for developing DM2 and the metabolic syndrome, suggesting that 
the increased CVD risk may be mediated via components of the metabolic 
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syndrome and DM2. Since the pathophysiology linking NAFLD with either the 
metabolic syndrome and/or diabetes has not been clarified, it is difficult to make 
the distinction between confounding and mediating variables in the 
epidemiological analyses. 
 
NAFLD AND INCREASED CVD RISK 
 
Several cross-sectional studies have demonstrated an increase in carotid artery 
intima-media thickness (cIMT) in patients with NAFLD [34-36]. However, in these 
studies diagnosis of NAFLD was based on evaluation of liver enzymes or on 
ultrasound evaluation but not confirmed by liver biopsy, which is regarded as the 
“gold standard” in the diagnosis of NAFLD [20]. In a recent study, Targher and 
colleagues have demonstrated that patients with biopsy proven NAFLD have a 
significantly higher cIMT compared to age-, sex- and BMI matched healthy controls. 
Moreover, they demonstrated that the histologically assessed NAFLD predicted 
cIMT, independent of classical risk factors, including insulin resistance and 
components of the metabolic syndrome [21]. In well-controlled DM2 patients, we 
have shown that slightly elevated ALT, as a surrogate marker of NAFLD, is 
associated with a decreased brachial artery flow-mediated vasodilatation and an 
impaired whole-body insulin sensitivity (Chapter 7). In line with the observation in 
patients with DM2, it was shown that non-diabetic patients with NAFLD have a 
decreased brachial artery flow-mediated vasodilatation compared to matched 
healthy controls, independent of other risk factors, including insulin resistance and 
components of the metabolic syndrome [22]. Ioanou and colleagues studied the 
association of ALT and the calculated 10-year risk of coronary heart disease as 
estimated with the Framingham risk score (FRS). Subjects with elevated ALT values 
had a significantly higher FRS compared to those with normal ALT values, 
indicating a higher CVD risk in patients with NAFLD [23]. Only a limited number of 
studies have addressed the prospective relation of ALT with CVD and mortality. In 
the Hoorn Study, a population-based cohort of Caucasian men and women aged 50 
to 75 years, we studied the association of ALT at baseline with all-cause mortality, 
and incident cardiovascular and coronary heart disease events (CVD and CHD, 
respectively) and found a significant association of ALT with incident CHD after 
adjustment for components of the metabolic syndrome and traditional CVD risk 
factors (Chapter 8). We found no independent associations of ALT with CVD events 
and all-cause mortality. The latter result was in line with a previous study by Arndt 
and colleagues who studied the association of ALT with all-cause mortality in 8,043 
male construction workers and found no significant association [24]. In contrast, a 
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recent study by Nakamura and co-workers found a positive association of ALT with 
all-cause mortality in Japanese men and women, but only for those with a body 
mass index below the median (22.7 kg/m2) [25].  
 
MECHANISMS LINKING NAFLD TO INCREASED CVD RISK 
 
The increased CVD risk associated with NAFLD might be explained by the close 
relation of NAFLD with components of the metabolic syndrome and DM2, although 
recent studies support the notion that NAFLD in itself might contribute to the 
increased CVD risk [21,22]. However, the mechanisms for this putative relationship 
are not clear. Several of the following, probably highly interrelated, factors 
contribute to the enhanced risk of DM2 and metabolic syndrome in persons with 
NAFLD.  
 
Oxidative stress and inflammation 
 
Hepatic steatosis, promoted by an insulin resistance mediated elevated flux of free 
fatty acids (FFA), may worsen to further liver injury as a consequence of oxidative 
stress [26] (Figure 10.1). However, the underlying factors that promote disease 
progression to cirrhosis are not understood. Enhanced FFA oxidation increases the 
formation of oxygen radicals, in turn leading to lipid peroxidation, mitochondrial 
dysfunction and cell damage with subsequent release of cytokines, including tumor 
necrosis factor-α (TNF-α), interleukin-6 (IL-6) and C-reactive protein (CRP). Indeed, 
Kerner and colleagues found an association of ALT with CRP [27]. In contrast, 
Haukeland and coworkers studied the role of systemic inflammation in individuals 
with NAFLD and NASH compared to healthy controls and demonstrated that IL-6, 
but not CRP, after adjustment for BMI, age and sex, was elevated in NAFLD 
compared to controls and TNF-α was higher in NASH as compared to NAFLD [28]. 
Of interest, a study by Targher and coworkers demonstrated that CRP was elevated 
in individuals with NAFLD, but this association was largely explained by the amount 
of visceral fat [29]. 
 
Adiponectin, leptin and resistin  
 
Decreased adiponectin levels, may represent another mechanism linking NAFLD to 
CVD. Patients with NAFLD have lower levels of adiponectin compared to healthy 
controls, independent of components of the metabolic syndrome [28,30,31]. This 
observation may be relevant, as some studies have shown that lower levels of 
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adiponectin are associated with CVD [32]. Leptin is a cytokine hormone mainly 
produced by adipocytes, that regulates food intake and fat metabolism through 
actions on the central nervous system. It has been suggested that leptin may act as 
one of the proinflammatory regulators in the progression of NAFLD to NASH by up-
regulation of transforming growth factor β [33]. However, a recent study found no 
association of leptin with liver disease severity [34]. Resistin is a protein expressed 
in adipose tissue and related to insulin resistance in mice [35]. Recently, a 
relationship between resistin and NAFLD and NASH was demonstrated in humans, 
with higher plasma resistin levels in individuals with NASH [34]. 
 
insulin resistance
↑ lipolysis
obesity
↑ portal FFA
↑ FFA
mitochondrial 
dysfunction
↑ TG
VLDL
assembly/secretion
oxidative 
stress
impaired 
hepatic
Insulin 
signaling
↑ hepatic glucose
↑ de novo
lipogenesis
TG-rich VLDL
glucose
hyperglycemia
[↑ALT]
ALT
hepatocyte
damage
cytokines
adipokines
inflammatory
cytokines
(e.g. CRP)
 
 
Figure 10.1. Overview of mechanisms involved in the development of non-alcoholic fatty liver disease (NAFLD) 
and the contribution of NAFLD to cardiometabolic risk. NAFLD is characterized by an increased uptake of free 
fatty acids (FFA) by the liver, an increased de novo lipogenesis, impaired β-oxidation caused by mitochondrial 
dysfunction and an insufficient assembly and secretion of very-low-density lipoproteins (VLDL). The impaired 
mitochondrial β-oxidation enhances formation of reactive oxygen species causing hepatocyte damage and up-
regulation of pro-inflammatory cytokines. Oversupply of FFA may lead to excess TG storage and hepatic insulin 
resistance due to ser-phosphorylation of components of the insulin-signaling cascade. Hepatic insulin 
resistance and increased FFA supply will increase gluconeogenesis, collectively leading to an increased hepatic 
glucose output. Alanine aminotransferase (ALT) is released upon hepatocyte damage and possibly up-regulated 
by the hepatic insulin resistant state. 
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Postprandial dysmetabolism 
 
Studies comparing the postprandial response of triglycerides and FFAs to a fat-rich 
meal in non-diabetic subjects with biopsy proven NASH to controls, showed that 
patients with NASH had significantly higher postprandial triglyceride levels than 
healthy controls [36,37]. Another study demonstrated that patients with ultrasound 
diagnosed NAFLD with an abnormal ALT and or AST had higher glucose levels after 
a 75-g oral glucose tolerance test than those with normal ALT and AST [38]. Toledo 
and colleagues observed that in obese patients with DM2, increased hepatic 
steatosis, as quantified by computed tomography scanning, was positively 
correlated with serum triglycerides and inversely with HDL-cholesterol. No 
difference in LDL-cholesterol and apolipoprotein B100 was observed relative to the 
degree of hepatic steatosis. However, the LDL particle size was smaller in the group 
with severe hepatic steatosis. These observations indicate that hepatic steatosis 
may contribute to the increased CVD risk in these patients by increasing 
triglyceride enrichment of VLDL particles, lowering HDL-cholesterol and by 
increasing the number of small, dense LDL-particles. The relationship of hepatic 
steatosis with serum triglycerides was stronger in subjects with a minor degree of 
hepatic steatosis and weaker in those with a more severe degree of hepatic 
steatosis, which may, as the authors suggested, indicate that the incorporation of 
triglycerides into VLDL has a limited capacity [39]. In the Hoorn Prandial study, we 
found no significant association between ALT and postprandial glucose and 
triglycerides (Chapter 2), in contracts to a recent study form our group, in which 
we found a significant association between liver fat (quantified by proton-magnetic-
resonance-spectroscopy) and postprandial triglycerides (Tushuizen et al, 
unpublished data). These observations suggest that the latter method may be a 
better indicator of liver fat in the associations of liver fat with postprandial 
dysmetabolic changes than ALT.  
 
CONCLUSIONS 
 
Evidence is accumulating that NAFLD is associated with cardiovascular risk factors 
and markers of sub-clinical atherosclerosis, but also to overt CVD events. This 
increased risk for CVD necessitates the evaluation and treatment of these patients. 
Long-term outcome studies need to establish the benefit of treatment of NAFLD on 
the reduction and prevention of diabetes and CVD risk.  
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SUMMARY 
 
Chapter 1 starts with a brief outline about diabetes and the metabolic syndrome in 
relation to cardiovascular disease (CVD) risk in patients with type 2 diabetes 
mellitus (DM2) and introduces some new putative CVD risk determinants that may 
explain the excess CVD risk in patients with DM2.  
 
In Chapter 2, we describe the determinants of postprandial triglyceride and 
glucose concentrations following two consecutive (breakfast and lunch) fat-rich and 
carbohydrate-rich meals in post-menopausal women with normal glucose 
metabolism (NGM) and in women with DM2 who were part of the Hoorn Prandial 
Study. The postprandial increment in triglycerides did not differ between women 
with NGM and DM2, whereas fasting triglycerides and the total triglyceride 
response was higher in DM2. Fasting triglyceride concentration, HbA1c, total 
cholesterol, and, inversely, high density lipoprotein (HDL) cholesterol were 
independently associated with the postprandial increment in triglycerides in women 
with NGM. In women with DM2, the fasting triglyceride concentration was the only 
determinant of the postprandial increment in triglycerides. In women with NGM, 
age and fasting triglycerides were independently associated with postprandial 
increment in glucose. In women with DM2, HbA1c was independently associated 
with the postprandial increment in glucose, and in women on statin therapy 
physical activity was an additional determinant. We concluded that the postprandial 
increment in triglycerides did not differ between post-menopausal women with 
NGM and well-controlled DM2. Furthermore, fasting triglyceride levels were a 
strong predictor of the postprandial increment in triglycerides, whereas the 
postprandial increment in glucose was especially determined by variables other 
than fasting glucose.  
 
The study in Chapter 3 compared the associations of postprandial glucose and 
postprandial triglycerides with carotid intima media thickness (cIMT) after two 
consecutive fat-rich or carbohydrate rich meals in women with NGM and DM2. In 
women with NGM, an increase of 1.0 mmol/l in plasma glucose following the fat-
rich meals and an increase of 1.8 mmol/l in plasma glucose concentration 
following the carbohydrate meals were associated with a 50 µm larger cIMT. No 
association between postprandial glucose and cIMT was found in women with DM2. 
Postprandial triglycerides were not associated with cIMT. The association between 
postprandial glucose and cIMT in women with NGM suggests that postprandial 
glucose in the normal range is a marker or a risk factor for atherosclerosis.  
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In the next chapter (Chapter 4), we addressed possible mechanisms that link 
postprandial dysmetabolism to CVD risk. The influence of two consecutive meals  
(breakfast and lunch) with different composition (both fat-rich or carbohydrate-rich) 
on acute changes in various markers of glycoxidative and lipoxidative stress, 
including oxidized low-density-lipoprotein (oxLDL), Nε-(carboxyethyl)-lysine (CEL), 
Nε-(carboxymethyl)-lysine (CML) and 3-deoxyglucosone (3DG) were studied in a 
sub-sample of the Hoorn Prandial Study (27 with NGM and 26 with DM2). We found 
significant elevations of oxLDL, 3DG and CML during the postprandial period in 
post-menopausal women with DM2 and NGM. The fasting values of oxLDL, 3DG 
and CML in women with DM2 were of similar magnitude as the postprandial values 
in women with NGM. The elevations of oxLDL were closely correlated with changes 
in postprandial triglycerides, whereas 3DG alterations were correlated with changes 
in postprandial glucose following the fat-rich meals. CML and CEL correlated to with 
neither postprandial glucose nor triglyceride changes. These results suggest that 
exaggerated glycoxidative and lipoxidative stress, due to postprandial 
dysmetabolism, may contribute to the increased CVD risk in DM2. 
 
In Chapter 5 we studied the 8-hour time course of myeloperoxidase (MPO) 
following two consecutive (breakfast and lunch) fat-rich and carbohydrate rich-
meals in postmenopausal women with NGM and in women with DM2. MPO is 
abundantly expressed in leukocytes, and released upon activation in the 
extracellular space. MPO has been associated with CVD and endothelial 
dysfunction. Postprandial leukocyte recruitment and activation with subsequent 
MPO release may contribute to atherosclerosis and CVD. We hypothesized that 
plasma MPO would increase in the postprandial state, due to leukocyte recruitment 
and/or activation, especially in individuals with DM2. Baseline MPO was not 
significantly different between NGM and DM2. Baseline MPO was weakly associated 
with leukocytes and inversely associated with HDL-cholesterol. In the postprandial 
phase, in contrast to our hypothesized increase, MPO decreased in NGM (both meal 
types) and in DM2 (fat-rich meals). Based on these results we concluded that our 
findings provide no support to our initial hypothesis that meal induced release of 
MPO might be a mechanism that contributes to CVD risk in DM2. 
 
Chapter 6 reviews the applicability of alanine aminotransferase (ALT) as a marker 
of non-alcoholic fatty liver disease (NAFLD) and provides an overview of the 
epidemiological studies that assessed the associations between ALT and the 
metabolic syndrome, DM2 and CVD. We concluded that in epidemiological studies, 
ALT is an adequate marker of NAFLD, provided that alcohol-intake as a 
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confounding or effect-modifying variable is considered, and provided that other 
more rare causes of ALT elevation are excluded. 
  
In a cross-sectional study in 64 normotriglyceridemic patients with DM2, we 
studied the relation of ALT with endothelial function, measured as flow-mediated 
vasodilatation (FMD), and with insulin sensitivity (M/I-value) (Chapter 7). We found 
that ALT was significantly, albeit weakly, associated with FMD and M/I-value, 
independent of obesity. Moreover, the relation of ALT with FMD was independent of 
insulin sensitivity. These findings suggest that in DM2, elevated ALT is associated 
with a more unfavorable CVD risk profile.  
 
In the study described in Chapter 8 we used data from the Hoorn Study to assess 
the prospective relation of ALT with all-cause mortality, CVD and coronary heart 
disease (CHD) events in a population-based cohort of elderly Caucasian men and 
women. We demonstrated that individuals with ALT levels in the upper tertile, had a 
significantly higher risk for CHD events that those in the lower tertile, after 
adjustment for components of the metabolic syndrome and traditional risk factors. 
No significant associations were found between ALT and all-cause mortality and 
CVD events, after applying the same adjustment. This study shows that individuals 
with even slightly elevated ALT levels are at an increased risk for CHD events. The 
pathogenic mechanisms underlying this association are not incompletely 
understood and require further study.  
 
In Chapter 9, we studied the prospective relation of ALT with incident metabolic 
syndrome and DM2. We found that higher ALT levels were related to conversion to 
the metabolic syndrome, after adjustment for confounding factors including 
alcohol-intake, age and the individual components of the metabolic syndrome. 
However, in contrast to previous reports, we could not demonstrate an 
independent prospective relation between ALT and the risk of DM2. These results 
suggest that the increased CVD risk might be mediated by metabolic derangements 
that differ from those that result in hyperglycemia (Chapter 9). 
 
The last chapter (Chapter 10) discusses the methodological and pathophysiological 
aspects of the studies presented in this thesis. 
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SAMENVATTING  VOOR NIET INGEWIJDEN 
 
Het aantal gevallen van “ouderdomssuikerziekte” (type 2 diabetes mellitus) neemt 
in de Westerse wereld snel toe als gevolg van veranderingen in leefstijl (verhoogde 
consumptie van vet- en energierijke voeding en verminderde lichaamsbeweging), 
en als gevolg van de vergrijzing van de bevolking. Mensen met type 2 diabetes 
mellitus hebben een verhoogd risico op het krijgen van hart- en vaatziekten. Dit 
verhoogde risico kan voor een deel verklaard worden door reeds bekende 
risicofactoren voor hart- en vaatziekten, zoals hoge bloeddruk (hypertensie), roken, 
afwijkende vetspiegels in het bloed (een verhoogd LDL-cholesterol (het “slechte” 
cholesterol), laag HDL cholesterol (goede cholesterol) en verhoogde hoeveelheden 
triglyceriden), alsook hoge  glucose (suiker) concentraties in het bloed. Met name 
bij vrouwen na de menopauze (overgang) is het risico op hart- en vaatziekten hoger 
dan bij vrouwen vóór de menopauze. Na de overgang stijgt de hoeveelheid 
triglyceriden en daalt de hoeveelheid HDL-cholesterol in het bloed. Dit heeft ons 
aangespoord de effecten van maaltijden te bestuderen bij vrouwen na menopauze. 
 
Het is al langer bekend dat glucose en triglyceriden, en verbindingen die hieruit 
gevormd kunnen worden, schadelijk kunnen zijn voor de bloedvaten en daardoor 
kunnen bijdragen aan het ontwikkelen van hart- en vaatziekten. Ruim een kwart 
eeuw geleden is geopperd dat verstoringen in de vet- en glucosestofwisseling die 
optreden na een maaltijd mogelijk kunnen bijdragen aan het verhoogde risico op 
hart- en vaatziekten. Na het eten van een maaltijd stijgen de triglyceriden- en 
glucoseconcentraties in het bloed. De triglyceriden en de glucose worden gebruikt 
als bouwstoffen of als brandstoffen voor het lichaam. De mate waarin deze stoffen 
worden verwerkt en opgeslagen verschilt tussen gezonde mensen en mensen met 
type diabetes mellitus. De lever speelt hierbij een belangrijke rol. Een verhoogde 
hoeveelheid vet in de lever (steatose), een aandoening die vaker voorkomt bij 
mensen met diabetes en overgewicht, kan deze processen verstoren, alsook het 
risico op hart- en vaatziekten verhogen. Het hormoon insuline speelt een 
belangrijke rol bij het verwerken van de triglyceriden en de glucose. Bij mensen 
met type 2 diabetes mellitus werkt het insuline minder goed waardoor de 
triglyceriden en de glucose trager worden opgenomen en verwerkt. De vraag is 
welke stof schadelijker is voor de vaatwand: de glucose of de triglyceriden?  
De onderzoeken die in dit proefschrift beschreven zijn, proberen antwoord te 
geven op de volgende vragen: 1a) hoe is het beloop van glucose en triglyceriden in 
het bloed na twee vetrijke en twee koolhydraatrijke maaltijden, 1b) wat is de 
relatieve bijdrage van glucose en triglyceriden in relatie tot hart- en vaatziekten en 
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1c) welke mechanismen kunnen het verhoogde risico op hart- en vaatzieken 
verklaren bij patiënten met type 2 diabetes mellitus; 2a) hebben mensen met 
leververvetting een verhoogde kans op het risico van hart- en vaatzieken en 2b) wat 
zijn de mogelijke mechanismen waardoor dit verklaard kan worden? 
 
In Hoofdstuk 1 geven we een korte beschrijving van type 2 diabetes mellitus en 
het metabool syndroom (cluster van risicofactoren samenhangend met 
overgewicht). Daarnaast geven we een kort overzicht van bekende en nieuwe 
determinanten voor hart- en vaatziekten bij mensen met type 2 diabetes mellitus. 
Tenslotte beschrijft dit hoofdstuk de vraagstellingen en de opbouw van dit 
proefschrift.  
 
Hoofdstuk 2 beschrijft het beloop van glucose en triglyceriden in het bloed na 
twee vetrijke dan wel koolhydraatrijke maaltijden in post-menopauzale vrouwen 
met en zonder type 2 diabetes mellitus. Ongeveer de helft van de vrouwen met 
type 2 diabetes mellitus werd behandeld met cholesterolverlagende medicatie 
(statines) en gezien het mogelijke effect op de vetstofwisseling werden de 
resultaten voor deze vrouwen afzonderlijk gepresenteerd. Bij vrouwen met diabetes 
(met en zonder statines) waren de hoeveelheid triglyceriden en glucose hoger dan 
bij de gezonde vrouwen. We vonden echter geen verschil in de toename van 
triglyceriden na de vetrijke maaltijden tussen de vrouwen met diabetes en de 
gezonde vrouwen. Bij de gezonde vrouwen werd een verband gezien tussen de 
stijging van de triglyceriden concentratie na de vetrijke maaltijden en de nuchtere 
triglyceriden waarde, het totaal cholesterol, het HbA1c (afspiegeling van de 
gemiddelde hoeveelheid glucose in het bloed gedurende 6-8 weken) en het HDL-
cholesterol. Bij vrouwen met diabetes was de nuchtere triglyceride waarde de 
belangrijkste bepalende factor voor de triglyceride waarden na beide vetrijke 
maaltijden. De glucosewaarde na de koolhydraatrijke maaltijden werd bij de 
gezonde vrouwen voornamelijk bepaald door leeftijd en de nuchtere 
triglyceridenwaarde en in de vrouwen met diabetes door HbA1c. 
 
Het onderzoek naar het mogelijke verband tussen de bijdrage van de nuchtere en 
post-prandiale (na de maaltijd) glucose en triglyceridenconcentraties en 
manifestaties van hart- en vaatziekten is beschreven in Hoofdstuk 3. De dikte van 
de vaatwand (intima-media dikte) van de halsslagader gemeten met een 
echotechniek werd gebruikt als maat voor het risico op hart- en vaatziekten. We 
vonden dat postprandiale glucosewaarden gerelateerd was aan de intima-media 
dikte bij de gezonde vrouwen en niet bij de vouwen met type 2 diabetes mellitus. 
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De postprandiale triglyceridenconcentraties waren niet gerelateerd aan de intima-
media dikte. We concludeerden dat de glucosespiegel na de maaltijd een indicator 
kan zijn voor hart- en vaatziekten bij vrouwen zonder type 2 diabetes mellitus.  
 
In Hoofdstuk 4 bestudeerden we het effect van twee vetrijke en van twee 
koolhydraatrijke maaltijden op de vorming van geoxideerde LDL-cholesterol 
deeltjes (oxLDL), de reactieve suikerverbinding 3-deoxyglucoson (3DG) en twee 
verschillende versuikerde eiwitverbindingen (de zogenaamde ‘advanced glycation 
end-products’ CML en CEL). Van deze verschillende verbindingen wordt 
verondersteld dat ze mogelijk een relatie hebben met hart- en vaatziekten. Over de 
vorming van deze verbindingen na de maaltijd is weinig bekend. We vonden dat de 
nuchtere waarden van oxLDL, 3DG en CML hoger waren bij de vrouwen met type 2 
diabetes mellitus dan bij de gezonde vrouwen. De nuchter waarden van deze 
verbindingen bij vrouwen met type 2 diabetes waren vergelijkbaar met de 
postprandiale waarden bij de gezonde vrouwen.  Het oxLDL correleerde met de 
hoeveelheid postprandiale triglyceriden na de vetrijke maaltijden en het 3DG 
correleerde met hoeveel postprandiale glucose na de vetrijke maaltijd. We 
concludeerden dat oxLDL, 3DG en CML mogelijk kunnen bijdragen aan het 
voorhoogde risico op hart- en vaatziekten. 
 
In Hoofdstuk 5 besschrijven we het effect van twee koolhydraatrijke en twee 
vetrijke maaltijden op de vorming van myeloperoxidase. Dit is een enzym dat in 
witte bloed cellen (leukocyten) wordt gemaakt en dat betrokken is bij de afweer van 
infecties. Een aantal studies hebben een relatie laten zien met hart- en vaatzieken. 
We onderzochten of dit enzym toe neemt na de maaltijden en in het bijzonder bij 
de vrouwen met type 2 diabetes mellitus. Tot onze verbazing zagen we, ondanks 
de stijging van de leukocyten, geen toename, maar juist een afname van het enzym 
na beide maaltijdtypen. Dit gebeurde zowel bij de gezonde vrouwen als bij de 
vrouwen met type 2 diabetes mellitus. We concludeerden dat myeloperoxidase na 
de maaltijd geen belangrijk factor is in relatie tot hart- en vaatziekten.  
 
Hoofdstuk 6 introduceert de niet-alcoholische leververvetting, een vorm van 
leververvetting die optreedt bij mensen die niet of matig alcohol nuttigen. Deze 
vorm wordt vaak gezien bij mensen met overgewicht en type 2 diabetes mellitus. In 
de onderzoeken die in dit proefschrift beschreven zijn, wordt het leverenzym 
alanine aminotransferase (ALAT) gebruikt als indicator voor leververvetting. Dit 
hoofdstuk beschrijft de toepasbaarheid van ALAT in relatie tot leververvetting. 
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In Hoofdstuk 7 vonden we dat bij goed ingestelde patiënten met type 2 diabetes 
mellitus, een hoge ALAT waarde in het bloed, als marker voor leververvetting, 
samenhangt met een verminderde endotheel-afhankelijke vaatverwijding (geeft een 
indruk over de werking van het endotheel, de “binnenbekleding” van de bloedvaten) 
en een verminderde insulinegevoeligheid. Deze bevinding suggereert dat mensen 
met leververvetting een verhoogde kans hebben op hart- en vaatziekten. Alanine 
aminotransferase, endotheel-afhankelijke vaatverwijding en de insuline 
gevoeligheid zijn echter op één moment gemeten, waardoor er geen uitspraak 
gedaan kan worden over oorzaak en gevolg.  
 
De vraag of een verhoogde ALAT waarde gepaard gaat met het optreden van hart- 
en vaatzieken wordt beantwoord in Hoofdstuk 8. In de Hoorn Studie (een 
bevolkingsonderzoek van mannen en vrouwen tussen 50 en 75 jaar) vonden wij dat 
een hoge ALAT waarde, als marker voor leververvetting, samenhangt met het 
optreden van kransslagaderaandoeningen (coronaire hartziekten) gedurende een 
vervolgperiode van 11 jaar. Deze relatie kon niet verklaard worden door reeds 
bekende risicofactoren. Onze conclusie was dan ook dat mensen met 
leververvetting een verhoogd risico hebben op coronaire hartziekten.  
 
Hoofdstuk 9 beschrijft de rol van ALAT als voorspeller (na 6 jaar) voor het 
optreden van type 2 diabetes mellitus en het metabool syndroom in de Hoorn 
Studie. We vonden dat ALAT type 2 diabetes voorspelt, maar deze relatie kon deels 
verklaard worden door reeds bekende risicofactoren voor diabetes mellitus, zoals 
een licht verhoogde hoeveelheid glucose in het bloed en het hebben van 
overgewicht. ALAT voorspelde wel het optreden van het metabool syndroom.  
 
In het laatste hoofdstuk (Hoofdstuk 10) worden de bevindingen van dit 
proefschrift bediscussieerd, de relevantie voor de klinische praktijk beschreven en 
worden suggesties gedaan voor verder onderzoek op dit gebied.  
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